



XCyting
FISH Probes

2021/22

CATALOG

Dear Customer,

The sudden appearance of the Severe Acute Respiratory Syndrome Coronavirus-2 at the end of 2019 presented us all with unprecedented challenges. Even under these difficult conditions, all of us have made FISH diagnostics possible. Our team is very proud that we have again succeeded in enhancing our already comprehensive portfolio of DNA FISH probes with the creation of several interesting products in the field of hematology-oncology.

The COVID-19 outbreak has led to global efforts to understand the mechanisms of the virus-induced disease and to find effective countermeasures. In this context, MetaSystems Probes has joined forces with RNA-FISH specialist PixelBiotech for the development of highly sensitive and specific SARS-CoV-2 probes, as well as other COVID-19 related probe products.

As a result of this fruitful collaboration, we are adding a completely new "XCyting" product range to this edition of the MetaSystems Probes Catalog - our XRNA probes. We are very excited to break new ground in the field of RNA FISH and are looking forward to supporting your activities in this area with the same high-quality products that you have come to expect from MetaSystems.

Innovative development always requires close interaction between manufacturer and customer. With this in mind, we thank you for your contributions and your loyalty.

Please visit our webpage, <https://metasystems-probes.com>, to be continuously updated with our latest developments.

Altussheim, Germany, December 2020










Disclaimer

All MetaSystems Human FISH probe products are classified as IVD products in the EU according to the In-Vitro Diagnostic Medical Device Directive 98/79/EC and CE labeled, unless otherwise indicated in the product description. This information is valid until May 2022.

Note

Some products may not be available in all markets.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Further information is available on request. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale.

	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175



XL

XCyting Locus-Specific Probes
... for Hematology / Oncology

7



XA

XCyting Locus-Specific Probes
... for Aneuploidy Detection

109



Microdeletion Probes

XCyting Locus-Specific Probes
... for Detection of Microdeletions

121



XCE

XCyting Centromere
Enumeration Probes

129



XCP

XCyting Chromosome Paints

135



XCyte mFISH

XCyting Multicolor
FISH Probes

141



XCyte mBAND

XCyting Multicolor
Banding Probes

145



Non-Human

Paints and mFISH Kits
... for Mouse, Rat and CHO

149



XRNA

XCyting RNA FISH Probes

155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XL ABL2 BA

XL ABL2 BA consists of an orange-labeled probe hybridizing proximal to the breakpoint in the ABL2 gene region at 1q25.2 and a green-labeled probe hybridizing distal to the break point in the ABL2 gene region at 1q25.2.

Acute lymphoblastic leukemia (ALL) is a rare disease with approximately 1:100,000 new diagnoses per year. Around 3-5% of pediatric ALL and 25% of adult ALL are characterized by t(9;22), resulting in the BCR-ABL1 fusion gene, a constitutively active tyrosine kinase. Furthermore, BCR-ABL1 is genetically characterizing chronic myelogenous leukemia. Tyrosine kinase inhibitor treatment of BCR-ABL1-positive cases, which initially have a poor prognosis, dramatically improves the outcome. A novel high risk subtype called BCR-ABL1-like ALL or Philadelphia-like ALL was discovered based on similar gene expression profiles to BCR-ABL1-positive ALL and is characterized by aberrations resulting in activation of tyrosine kinase signaling pathways. Prominent genes in the JAK/STAT activating group are CRLF2, EPOR and JAK2, while members of the ABL-class fusions are ABL1, ABL2, CSF1R and PDGFRB. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia specifies B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like as a provisional entity.

The ABL2 gene has been initially identified as a novel fusion partner of ETV6. ABL2 belongs to the Abelson family of non-receptor tyrosine kinases and is highly similar to ABL1. t(1;12)(q25;p13) results in a chimeric ETV6-ABL2 protein with a constitutive active tyrosine kinase.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.



Literature

- Iijima et al (2000) Blood 95:2126-2131
- Arber et al (2016) Blood 127:2391-2405
- Tasian et al (2017) Blood 130:2064-2072

Order No:
D-6021-100-OG


Size: 100 µl

XCytting Locus-Specific Probes
Deletion Probe **XL**

XL 1p36/1q25 del

XL 1p36/1q25 del consists of an orange-labeled probe hybridizing to the CHD5 gene region at 1p36.3 and a green-labeled probe hybridizing to the ABL2 gene region at 1q25.2.

The 2016 'World Health Organization Classification of Tumors of the Central Nervous System' (WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord starting in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 1p can be detected in about 67% of oligodendroglial tumors and has also been identified in neuroblastomas and other tumor entities. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion generally have a good prognosis. Co-deletion of 1p/19q also has predictive character, the molecular status of 1p/19q is relevant for therapy decisions.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

- Reifenberger et al (1994) Am J Pathol 145:1175-1190
- Louis et al (2016) Acta Neuropathol 131:803-820
- Staedtke et al (2016) Trends Cancer 2:338-349

XL CDKN2C/CKS1B

XL CDKN2C/CKS1B consists of a green-labeled probe hybridizing to the CDKN2C (p18) gene region at 1p32.3 and an orange-labeled probe hybridizing to the CKS1B gene region at 1q21-22.

Multiple myeloma (MM) is a plasma cell malignancy characterized by very complex cytogenetic and molecular genetic aberrations. Hyperdiploid karyotypes are characterized mainly by trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19, and 21, non-hyperdiploid karyotypes typically have translocations involving the IGH locus at 14q32. The most frequent deletions are 13q, 17p and 1p32.

Deletions of chromosome 1p have been described in 7-15% of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. Gain of 1q is one of the most recurrent chromosomal aberrations in MM. Amplification and overexpression of the CKS1B gene in chromosome band 1q21 has been associated with an aggressive clinical course in MM.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

Two green (2G) and three orange (3O) signals resulting from gain of one orange signal.



Aberrant Cell (typical results)

One green (1G) and two orange (2O) signals resulting from loss of one green signal.



Literature

- Hanamura et al (2006) Blood 108:1724-1732
- Leone et al (2008) Clin Cancer Res 14:6033-6041
- Jian et al (2016) Medicine 95:1-7

Order No:
D-5116-100-OG

Size: **100 µl**


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL 2p11 IGK BA


XL 2p11 IGK BA probe consists of an orange-labeled probe hybridizing to the 'IGKV distal' region at 2p11.2, and a green-labeled probe hybridizing distal to the 'IGKV proximal', IGKJ and IGKC region at 2p11.2.

The immunoglobulin (IG) genes for the kappa light chain at 2p11 (IGK), the lambda light chain at 22q11 (IGL) and the heavy chain at 14q32 (IGH) are recurrently involved in the development of non-Hodgkin lymphomas (NHL). By far most frequently involved is IGH with more than 30 partner genes, less frequently IGK and IGL. IG-translocations are leading to juxtaposition of proto-oncogenes with IG enhancer sequences resulting in overexpression of the respective oncogene. Chromosomal translocations involving MYC at 8q24 and IG genes frequently occur in Burkitt lymphoma (BL). BL is a rare but fast growing type of NHL which is rapidly fatal if left untreated. About 75% of BL patients are carrying the MYC rearrangement t(8;14) while the remainder show a translocation between MYC and IGK or IGL. MYC-IG rearrangements are also involved in other B-cell malignancies such as atypical Burkitt/Burkitt-like lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and multiple myeloma. Besides 8q24 (MYC), other translocation partners for IGK, such as chromosomal regions 1p13, 3q27 (BCL6), 7q21, 16q24 and 18q21 (BCL2), are known.

FISH break apart assays are valuable tools for the detection of IG light chain rearrangements independent of the translocation partner. Furthermore, double translocations have been described which are difficult to detect by PCR-based methods.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.

Literature

- Martin-Subero et al (2002) Int J Cancer 98:470-474
- Einerson et al (2006) Leukemia 10:1790-1799
- Fujimoto et al (2008) Eur J Haematol 80:143-150

XL ALK BA

XL ALK BA consists of an orange-labeled probe hybridizing to a region within the ALK gene at 2p23 and a green-labeled probe hybridizing distal to the ALK gene region at 2p23.

The EML4/ALK fusion gene is responsible for approximately 3-5% of non-small-cell lung cancer (NSCLC). The vast majority of cases are adenocarcinomas. Two other fusion partners of ALK have been reported in lung cancer - TFG and KIF5B. Up to 12 other translocation partners have been described in anaplastic large-cell lymphomas (ALCL), renal cancer, esophageal squamous cell, colon, and breast carcinoma. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase which was discovered in anaplastic large-cell lymphoma (ALCL).

The formation of a fusion protein with a partner through chromosomal translocations is the most common mechanism of ALK overexpression and ALK kinase domain activation. The ALK inhibitor crizotinib has increased the significance of detecting ALK rearrangements in lung cancer and ALCL.

Expected Patterns

Normal Cell

Two green-orange colocalization/fusion signals (2GO).




Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Kutok et al (2002) J Clin Oncol 20:3691-3702
- Perner et al (2008) Neoplasia 10:298-302
- Shaw et al (2009) J Clin Oncol 27:4247-4253

Order No:
D-6031-100-OG

Size: 100 µl


XCytting Locus-Specific Probes
Amplification Probe **XL**

XL MYCN amp

XL MYCN amp consists of a green-labeled probe hybridizing to the MYCN gene region at 2p24 and an orange-labeled probe hybridizing to the NMI gene region at 2q23.

The MYCN gene is a member of the MYC transcription factor family consisting of c-MYC, MYCN and MYCL. It is crucial for embryonic development, especially in the nervous system. The expression is tightly regulated in a spatial and timely manner and high levels are found in the developing brain, retina, neuroepithelial cells, lung and kidney. MYCN expression is associated with the maintenance of self-renewal capacity and the pluripotent status of stem cells. Dysregulation of MYCN contributes to the development of different kinds of childhood tumors including neuroblastoma, medulloblastoma, rhabdomyosarcoma and Wilms tumor. MYCN is also involved in the development of some adulthood neoplasms such as prostate and lung cancer.


Neuroblastoma is the most common extracranial solid tumor in infants. About 6% of all cancers in children are caused by neuroblastomas and 20-25% of neuroblastoma patients are showing an amplification of the MYCN gene. MYCN amplification is an important prognostic marker for risk stratification in neuroblastoma. Generally, patients with MYCN amplification have a poor prognosis. FISH is a valuable tool for the analysis of the MYCN amplification status. It detects MYCN amplification on single-cell level and allows the correlation with morphological cell features.




Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two orange (2O), one green (1G) and green signal clusters resulting from an amplification of the green signal (homogeneously staining region).



Aberrant Cell (typical results)
Two orange (2O) and multiple green (mG) signals resulting from amplification of the green signal (double minutes).

Literature

- Theissen et al (2009) Clin Cancer Res 15:2085-2090
- Huang and Weiss (2013) Cold Spring Harb Perspect Med 2013;3(10):a014415
- Ruiz-Pérez et al (2017) Genes 8(4):113

XL BCL6 BA

XL BCL6 BA consists of a green-labeled probe hybridizing proximal to the BCL6 gene region at 3q27 and an orange-labeled probe hybridizing distal to the BCL6 gene region at 3q27-28.

Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBL) represent the two most common entities of non-Hodgkin lymphoma (NHL) worldwide with up to 22% and 31% of tumors, respectively. FLs have been classically associated with the translocation t(14;18)(q32;q21) in 70% to 95% of reported tumors, whereas translocations involving the BCL6 proto-oncogene locus in chromosomal band 3q27 are encountered in 6% to 14%. In DLBLs, a BCL6 translocation can be found in up to 40% of cases, while BCL2 translocations occur in 20% to 30%.

The relatively wide separation of the probe binding sites allows for the detection of translocations in the MBR (major breakpoint cluster region) as well as in the ABR (alternative breakpoint cluster region).

Expected Patterns


Normal Cell

Two green-orange (2GO) fusion signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the BCL6 locus.



Literature

- Butler et al (2002) Cancer Res 62:4089-4094
- Katzenberger et al (2004) Am J Pathol 165:481-490
- Iqbal et al (2007) Leukemia 21:2332-2343

Order No:
D-5059-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL MECOM 3q26


XL MECOM 3q26 consists of an orange-labeled probe hybridizing proximal to the MECOM gene region at 3q26.2 and a green-labeled probe hybridizing distal to the MECOM gene region also spanning a distal part of the gene region at 3q26.2.

Myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

Chromosomal translocations involving the EVI1 locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. Two common recurrent rearrangements affect the 3q26 locus. One is the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which EVI1 overexpression is caused by juxtaposition of the EVI1 gene to enhancer elements of the Ribophorin gene at 3q21. EVI1 activation is also observed in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) and is due to generation of the fusion genes ETV6/EVI1 and RUNX1/EVI1, respectively.




Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.



Aberrant Cell (typical results)
Two green-orange colocalization/fusion signals (2GO) and one separate green (1G) signal indicating a chromosome break at a more distal region of the locus covered by the green probe.

Literature

- Lugthart et al (2008) Blood 111:4329-4337
- De Melo et al (2008) Leukemia 22:434-437
- De Braekeleer et al (2011) Anticancer Res 31:3441-3448

XL t(3;3) GATA2/MECOM DF

XL t(3;3) GATA2/MECOM DF consists of a green-labeled probe hybridizing to the GATA2 gene region at 3q21 and an orange-labeled probe hybridizing to the MECOM gene region at 3q26.2.

The chromosomal aberrations inv(3)(q21q26.2) and t(3;3)(q21;q26.2) characterize a distinct entity within patients with acute myeloid leukemia (AML). Their incidence in AML is about 1-2.5% and patients have an unfavorable prognosis and low response to chemotherapy.

Inv(3)/t(3;3) juxtapose the GATA2 enhancer with the MECOM locus which results in overexpression of EVI1. The EVI1 gene is located in 3q26 and is involved in hematopoietic stem cell maintenance. EVI1 is, together with MDS1, located in the 'MDS1 and EVI1 complex locus' (MECOM) and is the major player in this subtype of AML.

Furthermore, structural rearrangements caused by inv(3)/t(3;3) result in reduced GATA2 expression which may contribute to the oncogenic potential of this aberration. GATA2 is located in chromosomal region 3q21 and is involved in development and proliferation of hematopoietic stem cells. Several other recurrent 3q26 rearrangements such as t(3;21)(q26;q22), t(3;12)(q26;p13) and t(2;3)(p15-23;q26) are known and many more rearrangements may occur.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from an inversion or reciprocal translocation with breakpoints in the respective loci.




Aberrant Cell (typical results)

Two green (2G) and three orange (3O) signals resulting from a translocation with breakpoints in the orange labeled gene region and another unknown chromosome.



Aberrant Cell (typical results)

A deletion of the labeled region in the long arm of chromosome 3 results in the signal pattern one green (1G) and one orange (1O) signal.



Literature

- Gröschel et al (2014) Cell 157:369-381
- De Braekeleer et al (2015) Fut Oncol 11:1675-1686
- Arber et al (2016) Blood 19:2391-2405

Order No:
D-5063-100-TC

Size: 100 µl


XCyting Locus-Specific Probes
Translocation/Deletion Probe

XL


XL 4q12

XL 4q12 consists of a green-labeled probe hybridizing proximal to the FIP1L1 gene region at 4q12, an orange-labeled probe hybridizing to the CHIC2 gene region at 4q12 and an aqua-labeled probe hybridizing to the PDGFRA gene region at 4q12.


The category 'myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1/JAK2' of the revised 4th edition of the WHO classification defines three particular groups with rearrangements in PDGFRA, PDGFRB or FGFR1 and a provisional entity with PCM1/JAK2 rearrangement. The clinical manifestations within this category are numerous and heterogeneous and include myeloproliferative neoplasms, myelodysplastic syndromes as well as de novo or secondary mixed phenotype acute leukemia and lymphomas. Neoplasms with eosinophilia are associated with dysregulated tyrosine kinases, usually as a result of gene fusions. It is of great importance to identify the genes involved because aberrant tyrosine kinases react with varying sensitivity to tyrosine kinase inhibitors. Patients with PDGFRA and PDGFRB rearrangements are responsive to imatinib whereas FGFR1-related diseases are non-responsive. PDGFRA rearrangements are usually associated with chronic eosinophilic leukemia (CEL). The most frequent PDGFRA-related aberration is the interstitial deletion of the CHIC2 gene with breakpoints in the FIP1L1 and PDGFRA genes. The deletion of a fragment of about 800kb is resulting in the FIP1L1-PDGFRB fusion gene, a constitutively activated tyrosine kinase transforming hematopoietic cells. In FISH assays, the detection of CHIC2 deletion at 4q12 is a surrogate for the direct detection of the FIP1L1-PDGFRB fusion gene. Translocations with other partner genes, resulting in aberrant tyrosine kinase activity, are known. Involvement of PDGFRA can be detected by break apart FISH strategies.



Expected Patterns



Normal Cell
Two blue-green-orange fusion signals (2BGO).



Aberrant Cell (typical results)
One blue-green-orange (1BGO) and one blue-green (1BG) fusion signal, indicating a deletion of CHIC2.

Literature

- Cools et al (2003) N Engl J Med 348:1201-1214
- Pardanani et al (2003) Blood 102:3093-3096
- Swerdlow et al (2017) WHO classification of tumors of haematopoietic and lymphoid tissues (revised 4th edition)

XL 4q12 DC

XL 4q12 DC consists of a green-labeled probe hybridizing proximal to the FIP1L1 gene region at 4q12, an orange-labeled probe hybridizing to the CHIC2 gene region at 4q12 and another green-labeled probe hybridizing to the PDGFRA gene region at 4q12.

The category 'myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1/JAK2' of the revised 4th edition of the WHO classification defines three particular groups with rearrangements in PDGFRA, PDGFRB or FGFR1 and a provisional entity with PCM1/JAK2 rearrangement. The clinical manifestations within this category are numerous and heterogeneous and include myeloproliferative neoplasms, myelodysplastic syndromes as well as de novo or secondary mixed phenotype acute leukemias and lymphomas. Neoplasms with eosinophilia are associated with dysregulated tyrosine kinases, usually as a result of gene fusions. It is of great importance to identify the genes involved because aberrant tyrosine kinases react to tyrosine kinase inhibitors with varying sensitivity. Patients with PDGFRA and PDGFRB rearrangements are responsive to imatinib, whereas FGFR1-related diseases are non-responsive. PDGFRA rearrangements are usually associated with chronic eosinophilic leukemia (CEL). The most frequent PDGFRA-related aberration is the interstitial deletion of the CHIC2 gene with breakpoints in the FIP1L1 and PDGFRA genes. The deletion of a fragment of about 800kb is resulting in the FIP1L1-PDGFR fusion gene, a constitutively activated tyrosine kinase transforming hematopoietic cells. In FISH assays, the detection of CHIC2 deletion at 4q12 is a surrogate for the direct detection of the FIP1L1-PDGFR fusion gene. Translocations with other partner genes, resulting in aberrant tyrosine kinase activity, are known. Involvement of PDGFRA can be detected by FISH using break apart strategies.

Expected Patterns

Normal Cell

Two green-orange colocalization/fusion signals (2GO).




Aberrant Cell (typical results)

One green-orange (1GO) colocalization/fusion signal and one green (1G) signal resulting from the loss of one orange signal.



Aberrant Cell (typical results)

One green (1G) and two green-orange colocalization/fusion (2GO) signals resulting from a translocation between the green labeled PDGFRA gene region and an unknown chromosome.



Literature

- Cools et al (2003) N Engl J Med 348:1201-1214
- Pardanani et al (2003) Blood 102:3093-3096
- Swerdlow et al (2017) WHO classification of tumors of haematopoietic and lymphoid tissues (revised 4th edition)

Order No:
D-5137-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Break Apart Probe **XL**


XL PDGFRA BA

XL PDGFRA BA consists of a green-labeled probe hybridizing proximal to the PDGFRA gene region at 4q12 and an orange-labeled probe hybridizing distal to the PDGFRA gene region at 4q12.


The category 'myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1/JAK2' of the revised 4th edition of the WHO classification defines three particular groups with rearrangements in PDGFRA, PDGFRB or FGFR1 and a provisional entity with PCM1/JAK2 rearrangement. The clinical manifestations within this category are numerous and heterogeneous and include myeloproliferative neoplasms, myelodysplastic syndromes as well as de novo or secondary mixed phenotype acute leukemia and lymphomas. Neoplasms with eosinophilia are associated with dysregulated tyrosine kinases, usually as a result of gene fusions. It is of great importance to identify the genes involved because aberrant tyrosine kinases react to tyrosine kinase inhibitors with varying sensitivity. Patients with PDGFRA and PDGFRB rearrangements are responsive to imatinib whereas FGFR1-related diseases are non-responsive. PDGFRA rearrangements are usually associated with chronic eosinophilic leukemia (CEL).

The most frequent PDGFRA-related aberration is the interstitial deletion of the CHIC2 gene with breakpoints in the FIP1L1 and PDGFRA genes. The deletion of a fragment of about 800kb results in the FIP1L1-PDGFRA fusion gene, a constitutively activated tyrosine kinase transforming hematopoietic cells.

In FISH assays, the detection of CHIC2 deletion at 4q12 is a surrogate for the direct detection of the FIP1L1-PDGFRA fusion gene. Translocations with other partner genes, resulting in aberrant tyrosine kinase activity, are known. Involvement of PDGFRA can be detected by FISH break apart strategies.




Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus.



Aberrant Cell (typical results)
One green-orange (1GO) colocalization/fusion signal and one orange (1O) signal resulting from the loss of one green signal.

Literature

- Cools et al (2003) N Engl J Med 348:1201-1214
- Pardanani et al (2003) Blood 102:3093-3096
- Swerdlow et al (2017) WHO classification of tumors of haematopoietic and lymphoid tissues (revised 4th edition)

XL TET2

XL TET2 consists of an orange-labeled probe hybridizing to the TET2 gene region at 4q24 and a green-labeled probe hybridizing to 4q12.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

A minimally deleted region on chromosome 4q24 is described in subgroups of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). The region encompasses the TET2 gene. The frequency of TET2 mutations in unselected patients was 19% (15 of 81 patients) with myelodysplastic syndromes, 12% (24 of 198 patients) with myeloproliferative disorders, 24% (5 of 21 patients) with secondary AML, and 22% (2 of 9 patients) with chronic myelomonocytic leukemia.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal, indicating a deletion of TET2 (4q24).



Literature

- Jankowska et al (2009) Blood 113:6403-6410
- Delhommeau et al (2009) N Engl J Med 360:2289-2301
- Flach et al (2010) Haematologica 95:518-519

Order No:
D-5131-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe

XL

XL t(4;11) AFF1/KMT2A DF

XL t(4;11) AFF1/KMT2A DF consists of an orange-labeled probe hybridizing to the AFF1 gene region at 4q21.3-22 and a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3.

Chromosomal rearrangements of the KMT2A (lysine methyltransferase 2A) gene, formerly MLL (mixed lineage leukemia), are associated with various hematological disorders. Most patients suffer from acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), while only a minority develops mixed lineage leukemia (MLL). Several chromosomal aberrations involving the KMT2A gene have been identified. However, the majority of leukemias result from translocations leading to KMT2A fusions. More than 90 KMT2A translocation partner genes fused to the 5' - KMT2A portion have been identified. The most common translocation partners in KMT2A associated leukemia are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN, described here in the order of their frequency. The fusion of KMT2A and AFF1 (AF4/FMR2 family member 1) is the most frequent KMT2A translocation observed in ALL cases. About 60% of ALL patients carrying KMT2A rearrangements are characterized by the KMT2A-AFF1 fusion gene. Infant patients mainly have breakpoints in intron 11 of KMT2A, whereas adult patients have a tendency for breakpoints within intron 9. Oncogenic KMT2A-AFF1 fusions have been implicated in the DOT1L and SEC transcriptional complexes. AFF1 plays an important role in the regulation of RNA polymerase II-dependent transcription, elongation and chromatin remodeling mediated by histone methylation. AFF1 is the docking platform for several components of the DOT1L complex consisting of DOT1L, a H3K79 methyltransferase, MLLT3, MLLT1, and MLLT10, whose genes are also common translocation partners of KMT2A. Mouse studies revealed increased and extended histone methylation signatures in the presence of KMT2A-AFF1 and reciprocal AFF1-KMT2A fusions. DOT1L inhibitors are promising candidates for clinical treatment which are currently being evaluated.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.

Literature

- De Braekeleer et al (2011) Mol Oncol 5:555-563
- Meyer et al (2013) Leukemia 27:2165-2176
- Burns et al (2018) Hematology (7th ed) Ch 64: Pathobiology of acute lymphoblastic leukemia:1005-1019.e11

XL t(4;14) FGFR3/IGH DF

XL t(4;14) FGFR3/IGH DF consists of an orange-labeled probe hybridizing to the FGFR3 gene region at 4p16.3 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunoglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depend on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.

The recurrent translocation t(4;14)(p16;q32) is juxtaposing FGFR3 with the 3' alpha IgH enhancer on der(14), whereas expression of NSD2 is controlled by the E_μ enhancer on der(4). FGFR3 overexpression is detectable in about 70% of t(4;14) positive MM patients, suggesting that FGFR3 dysregulation is not the crucial oncogenic event. The poor outcome of patients lacking FGFR3 expression due to the loss of der(14) is supporting this conclusion. Transcripts from the NSD2 locus on the other hand are found to be overexpressed in all t(4;14) positive MM cases, suggesting that this gene region plays a major role in the manifestation of MM.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Literature

- Chesi et al (1998) Blood 92:3025-3034
- Keats et al (2005) Blood 15:4060-4069
- Rajan and Rajkumar (2015) Blood Cancer J 5:e365

Order No:
D-5104-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL 5q32 PDGFRB BA


XL 5q32 PDGFRB BA consists of an orange-labeled probe hybridizing proximal to the PDGFRB gene region at 5q32 and a green-labeled probe hybridizing distal to the PDGFRB gene region at 5q32-33.1.

The updated (2016) World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues indicates the category myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1, or with PCM1-JAK2.

Myeloid neoplasms (MPNs) with rearrangement of PDGFRB are phenotypically and genotypically diverse. The fusion genes involving PDGFRB described to date have been associated with cytogenetically detectable translocations. MPNs associated with rearrangement of PDGFRB are responsive to imatinib.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.

Literature

- Wlodarska et al (1997) Blood 89:1716-1722
- Apperley et al (2002) N Engl J Med 347:481-487
- Wilkinson et al (2003) Blood 102:4187-4190

XL TLX3 BA

XL TLX3 BA consists of an orange-labeled probe hybridizing proximal to the TLX3 gene region at 5q35.1 and a green-labeled probe hybridizing distal to the TLX3 gene region at 5q35.1.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer type. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and quickly progressing type of ALL affecting T-lymphocytes. Genomic data suggests that more than 10 functional aberrations are contributing to the development of this disease. T-ALL cases can be grouped by distinct genetic profiles and the aberrant expression of a characteristic transcription factor. Major subgroups are characterized by ectopic expression of TAL1, TLX1, TLX3, HOXA9/10, LMO2 or NKX2-1 and others as a result of chromosomal rearrangements or mutations. About 20% of childhood T-ALL cases are characterized by aberrant expression of TLX3 as a result of t(5;14)(q35;q32). This cryptic translocation juxtaposes TLX3, normally not expressed in T-cells, with the BCL11B gene, which is active in T-cells, resulting in ectopic expression of TLX3.

Fluorescence in situ hybridization is a valuable method for the detection of t(5;14)(q35;q32) since cryptic translocations may escape during classical cytogenetic analysis. Furthermore, the broad range of breakpoints in the chromosomal region 14q32 makes the development of efficient PCR-based methods difficult.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Literature

- Van Zutven et al (2004) Haematologica 89:671-678
- Su et al (2006) Blood 108:4198-4201
- Girardi et al (2017) Blood 129:11113-1123

Order No:
D-5042-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL 5q31/5q33

XL 5q31/5q33 consists of an orange-labeled probe hybridizing to the EGR1 gene region at 5q31.2 and a green-labeled probe hybridizing to the RPS14 gene region at 5q32-33.1.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

The 5q syndrome is defined as a primary MDS with del(5q) as the sole karyotypic abnormality. Two different critical regions are described; one is located at 5q31 and contains the EGR1 and CDC25C genes; a more distal region at 5q32-q33 contains RPS14 which has been identified as a causal gene for the 5q syndrome.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal, indicating a deletion in 5q31.2.



Aberrant Cell (typical results)
One green (1G) and two orange (2O) signals, indicating a deletion in 5q33.



Aberrant Cell (typical results)
One green (1G) and one orange (1O) signal, indicating deletions of both loci in 5q31.2 and 5q33.

Literature

- Horrigan et al (2000) Blood 95:2372-2377
- Wei et al (2009) Proc Natl Acad Sci USA 106:12974-12979
- Boulwood et al (2010) Blood 16:5803-5811

XL del(5)(q31)

XL del(5)(q31) consists of a green-labeled probe hybridizing to a region at 5p15.2-15.3 and an orange-labeled probe hybridizing to the EGR1 gene region at 5q31.2.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3,3).

5q syndrome is defined as primary MDS with del(5q) as the sole karyotypic abnormality. Two different critical regions are described, one is located at 5q31 and contains the EGR1 and CDC25C genes. A more distal region at 5q32-q33 containing RPS14 has been identified as a causal region for 5q syndrome.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Horrigan et al (2000) Blood 95:2372-2377
- Ebert et al (2008) Nature 451:335-339
- Mallo et al (2008) Heamatologica 93:1001-1007

Order No:
D-5091-100-OG

Size: **100 µl**


XCytting Locus-Specific Probes
Deletion Probe **XL**

XL del(5)(q33)

XL del(5)(q33) consists of a green-labeled probe hybridizing to a region at 5p15.2-15.3 and an orange-labeled probe hybridizing to the RPS14 locus at 5q32-33.1.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3,3).

5q syndrome is defined as primary MDS with del(5q) as the sole karyotypic abnormality. Two different critical regions are described, one is located at 5q31 and contains the EGR1 and CDC25C genes. A more distal region at 5q32-q33 containing RPS14 has been identified as a causal region for 5q syndrome.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

- Horrigan et al (2000) Blood 95:2372-2377
- Boulwood et al (2002) Blood 99:4638-4641
- Ebert et al (2008) Nature 451:335-339

XL 5q31/5q33/5p15

XL 5q31/5q33/5p15 consists of an aqua-labeled probe hybridizing to a region at 5p15.2-15.3, an orange-labeled probe hybridizing to the EGR1 gene region at 5q31.2 and a green-labeled probe hybridizing to the RPS14 gene region at 5q32-33.1.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3,3).

5q syndrome is defined as a primary MDS with del(5q) as the sole karyotypic abnormality. Two different critical regions are described, one is located at 5q31 and contains the EGR1 and CDC25C genes. A more distal region at 5q32-q33 containing RPS14 has been identified as a causal region for 5q syndrome.

Expected Patterns

Normal Cell

Two green (2G), two orange (2O) and two blue (2B) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two blue (2B) signals, indicating a large 5q deletion including 5q31 and 5q33.



Aberrant Cell (typical results)


Two green (2G), one orange (1O), and two blue (2B) signals, indicating a deletion in 5q31.

One green (1G), two orange (2O), and two blue (2B) signals, indicating a deletion in 5q33 only.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one blue (1B) signal indicating a monosomy 5.



Literature

- Horrigan et al (2009) Blood 95:2372-2377
- Wei et al (2009) PNAS 106:12974-12979
- Boulwood et al (2010) Blood 16:5803-5811

Order No:
D-5095-100-TC

Size: 100 µl


XCyting Locus-Specific Probes
Enumeration Probe **XL**

XL 5p15/9q22/15q22 Hyperdiploidy

XL 5p15/9q22/15q22 Hyperdiploidy consists of a green-labeled probe hybridizing to a region at 5p15.2-15.3, an aqua-labeled probe hybridizing to a region at 9q22.3-31 and an orange-labeled probe hybridizing to the SMAD6 gene region at 15q22.3.

In multiple myeloma (MM) pathogenesis, hyperdiploidy and non-hyperdiploidy are recognized as two major cytogenetic pathways. The hyperdiploid group is characterized by gains of the odd chromosomes 3, 5, 7, 9, 11, 15, 19, and 21. Hyperdiploidy has been internationally defined and requires trisomy for at least 2 of the 3 chromosomes 5, 9, and 15.

Patients with hyperdiploid MM, which can be observed in 50-60% of MM patients, tend to have a better prognosis than those with a non-hyperdiploid subtype.



Expected Patterns



Normal Cell
Two green (2G), two blue (2B), and two orange (2O) signals.



Aberrant Cell (typical results)
Three green (3G), two blue (2B), and three orange (3O) signals, indicating hyperdiploidy.



Aberrant Cell (typical results)
Two green (2G), three blue (3B), and three orange (3O) signals, indicating hyperdiploidy.



Aberrant Cell (typical results)
Three green (3G), three blue (3B), and two orange (2O) signals, indicating hyperdiploidy.

Literature

- Willeme et al (2005) Leukemia 19:275-278
- Kumar et al (2009) Mayo Clin Proc 84:1095-1110
- Bochtler et al (2011) Blood 117:3809-3815

XL 6q21/6q23

XL 6q21/6q23 consists of a green-labeled probe hybridizing to the SEC63 gene region at 6q21 and an orange-labeled probe hybridizing to the MYB gene region at 6q23.3.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

Deletions involving the long arm of chromosome 6 (6q) are among the most common structural aberrations leading to a loss of chromosomal material in lymphoproliferative disorders and non-Hodgkin lymphoma (NHL). Two distinct regions, one at 6q21-22.1, the other at 6q23.3-25, have been found as minimal deleted regions in 6q- patients. A 6q deletion has also been found in a variety of other human malignancies, including breast carcinoma, malignant melanoma, renal cell carcinoma, salivary gland adenocarcinoma, ovarian carcinoma, acute lymphoblastic leukemia, and nodal NHL.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal, indicating a deletion in 6q23 (MYB).




Aberrant Cell (typical results)

One green (1G) and two orange (2O) signals, indicating a deletion in 6q21.



Aberrant Cell (typical results)

One green (1G) and one orange (1O) signal, indicating deletions of both loci in 6q21 and 6q23.



Literature

- Stilgenbauer et al (1999) *Leukemia* 13:1331-1334
- Zhang et al (2000) *Genes Chrom Canc* 27:52-58
- Starostik et al (2000) *Blood* 95:1180-1187

Order No:
D-5088-100-TC

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL 6q21/6q23/6cen

XL 6q21/6q23/6cen consists of a green-labeled probe hybridizing to the SEC63 gene region at 6q21, an orange-labeled probe hybridizing to the MYB gene region at 6q23.3 and an aqua-labeled probe hybridizing to the centromere of chromosome 6.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) is heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

Deletions involving the long arm of chromosome 6 (6q) are among the most common structural aberrations leading to a loss of chromosomal material in lymphoproliferative disorders and non-Hodgkin lymphoma (NHL). Two distinct regions, one at 6q21-22.1, the other at 6q23.3-25, have been found as minimal deleted regions in 6q- patients. A 6q deletion has been found in a variety of other human malignancies as well, including breast carcinoma, malignant melanoma, renal cell carcinoma, salivary gland adenocarcinoma, ovarian carcinoma, acute lymphoblastic leukemia, and nodal NHL.



Expected Patterns



Normal Cell
Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two blue (2B) signals, indicating a large 6q deletion including 6q21 and 6q23.



Aberrant Cell (typical results)
Two green (2G), one orange (1O), and two blue (2B) signals, indicating a deletion in 6q23.



Aberrant Cell (typical results)
One green (1G), two orange (2O), and two blue (2B) signals, indicating a deletion in 6q21.

Literature

- Stilgenbauer et al (1999) *Leukemia* 13:1331-1334
- Zhang et al (2000) *Genes Chrom Canc* 27:52-58
- Starostik et al (2000) *Blood* 95:1180-1187

XL IRF4 BA

XL IRF4 BA consists of a green-labeled probe hybridizing proximal to the IRF4 gene region at 6p25 and an orange-labeled probe hybridizing distal to the IRF4 gene region at 6p25.

The updated (2016) revision of the World Health Organization (WHO) classification of tumors of lymphoid neoplasms considers the large B-cell lymphoma with IRF4 rearrangement as a new provisional entity. Head and neck regions including the Waldeyer ring are particularly affected. Chromosomal translocations involving the IRF4 gene and the immunoglobulin loci IGH, IGL and IGK (IG) result in dysregulation of IRF4 expression; other translocation partners may occur. Since t(6;14)(p25;q32) is cytogenetically cryptic, FISH is a valuable tool in detecting this recurrent aberration. IG/IRF4 positive lymphomas normally lack t(14;18), which is observed in about 85% of adult patients with follicular lymphoma, and are commonly associated with young age and a good course. IRF4 rearrangements have also been identified in peripheral T-cell lymphomas (PTCL). PTCL are defined as a diverse group of aggressive lymphomas of mature-stage T-cells accounting for about 10% of non-Hodgkin lymphomas. Recent data suggests that IRF4 translocations detected by FISH have a predictive value for primary cutaneous CD30(+) anaplastic large cell lymphoma.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Literature

- Feldman et al (2009) Leukemia 23:574-580
- Salaverria et al (2011) Blood 7:139-147
- Kiran et al (2013) Leukemia Research 37:396-400

Order No:
D-6029-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL ROS1-GOPC BA


XL ROS1-GOPC BA consists of a green-labeled probe hybridizing proximal to the ROS1 gene region at 6q22.1 and an orange-labeled probe hybridizing distal to the ROS1 gene region at 6q22.1.

Translocations involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs). Chromosomal rearrangements involving the ROS1 gene were originally described in glioblastomas, where ROS1 is fused to the GOPC gene by an interstitial deletion.

Fusions of ROS1 with other genes lead to constitutive kinase activity and are associated with *in vitro* sensitivity to tyrosine kinase inhibitors such as crizotinib.




Expected Patterns



Normal Cell
Two green-orange (2GO) fusion signals representing the two normal ROS1-GOPC loci.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the ROS1-GOPC locus.



Aberrant Cell (typical results)
One green (1G) and one green-orange (1GO) fusion signal, indicating a rearrangement of ROS1 by a deletion between ROS1 and GOPC.

Literature

- Charest et al (2003) Genes Chrom Cancer 37:58-71
- Takeuchi et al (2011) Nat Med 18:378-381
- Bergethon et al (2012) J Clin Oncol 30:863-870

XL t(6;9) DEK/NUP214

XL t(6;9) DEK/NUP214 consists of a green-labeled probe hybridizing to the DEK gene region at 6p22.3 and an orange-labeled probe hybridizing to the NUP214 gene region at 9q34.1.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myelogenous leukemia (AML) with recurrent genetic abnormalities. Three new cytogenetically defined entities were recently incorporated: AML with t(6;9)(p23;q34) DEK/NUP214; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1/EVI1 and AML (megakaryoblastic) with t(1;22)(p13;q13) RBM15/MKL1, a rare leukemia most commonly occurring in infants.

The t(6;9)(p23;q34) DEK/NUP214 fusion occurs with an incidence of 1–5% in adult patients with AML. This translocation tends to occur in younger adults and is associated with an unfavorable prognosis at diagnosis. Although the t(6;9) is usually the sole cytogenetic aberration at diagnosis, additional karyotypic abnormalities are frequently identified during disease progression.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange fusion signals (2GO).



v10.1

Literature

- Shearer et al (2005) Leukemia 19:126-131
- Doehner et al (2010) Blood 115:453-474
- Sandahl et al (2014) Haematologica 99:865-872

Order No:
D-5132-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe

XL

XL t(6;11) AFDN/KMT2A DF

XL t(6;11) AFDN/KMT2A DF consists of an orange-labeled probe hybridizing to the AFDN gene region at 6q27 and a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3.

Chromosomal rearrangements of the KMT2A (lysine methyltransferase 2A) gene, formerly MLL (mixed lineage leukemia), are associated with various hematological disorders. Most patients suffer from acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), while only a minority develops mixed lineage leukemia (MLL). Several chromosomal aberrations involving the KMT2A gene have been identified. However, the majority of leukemias result from translocations leading to KMT2A fusions. More than 90 KMT2A translocation partner genes fused to the 5' - KMT2A portion have been identified. The most common translocation partners in KMT2A associated leukemia are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN, described here in the order of their frequency. The AFDN (afadin) gene, formerly known as MLLT4 and AF6, is located on chromosome 6 (6q27). KMT2A-AFDN fusions result from translocations of the type t(6;11)(q27;q23). The most frequent breakpoint in the KMT2A gene leading to this translocation is positioned in intron 9. The majority of ALL patients have breakpoints in exon 1 or 2 of the AFDN gene. Intriguingly, T-cell ALL patients show a significantly higher percentage of KMT2A-AFDN and KMT2A-MLLT1 fusions than other ALL subgroup patients. However, within the cohort of patients with KMT2A-AFDN rearrangements, unusual KMT2A breakpoints in intron 21 and 23 have been detected, in a minority of cases. One cellular consequence of the KMT2A-AFDN fusion is an increased and extended DOT1L mediated H3K79 methylation signature, which is also being observed in the presence of KMT2A-AFF1, AFF1-KMT2A, KMT2A-MLLT3, KMT2A-MLLT1, and KMT2A-MLLT10 fusions. Therefore, DOT1L inhibitors are promising candidates for clinical treatment which are currently being evaluated.



Literature

- De Braekeleer et al (2011) Mol Oncol 5:555-563
- Meyer et al (2013) Leukemia 27:2165-2176
- Meyer et al (2017) Leukemia 32:273-284

XL t(6;14) CCND3/IGH DF

XL t(6;14) CCND3/IGH DF consists of an orange-labeled probe hybridizing to the CCND3 gene region at 6p21.1 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunoglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depend on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.

Cyclins of the D-family are essential for the transition from G1- to S-Phase during the cell cycle. t(6;14)(p21;q32) moves the cyclin D3 gene in proximity to 3' IGH enhancer sequences and is associated with cyclin D3 overexpression. The chromosomal translocation has been reported as a rare and recurrent event not only in myeloma but also in other B-cell malignancies such as diffuse large B-cell lymphoma.

Expected Patterns



Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



v10.1

Literature

- Shaughnessy et al (2001) Blood 98:217-223
- Sonoki et al (2001) Blood 98:2837-2844
- Rajan and Rajkumar (2015) Blood Cancer J 5:e365

Order No:
D-5043-100-TC

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL 7q22/7q36

XL 7q22/7q36 consists of an orange-labeled probe hybridizing to the KMT2E gene region at 7q22, a green-labeled probe hybridizing to the CUL1/EZH2 gene region at 7q36 and an aqua-labeled probe hybridizing to the centromere of chromosome 7.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2017), recurrent cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

Loss of chromosome 7 (-7) or deletion of the long arm (7q-) are recurrent chromosome abnormalities in myeloid leukemias such as MDS or acute myeloid leukemia (AML). The association of -7/7q with myeloid leukemia suggests that certain regions contain tumor suppressor gene(s), whose loss of function contribute to leukemic transformation or tumor progression. Multiple critical regions have been identified: one in band 7q22 (including the KMT2E gene), the more telomeric region 7q31 and 7q35-q36 (including the EZH2 gene).



Expected Patterns



Normal Cell
Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell (typical results)
Two green (2G), one orange (1O), and two blue (2B) signals indicating the deletion of a 7q22 locus or one green (1G), two orange (2O), and two blue (2B) signals, indicating the deletion of a 7q36 locus.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two blue (2B) signals indicating the deletion of a 7q22 locus and of a 7q36 locus.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and one blue (1B) signal indicating a monosomy 7.

Literature

- Le Beau et al (1996) Blood 88:1930-1935
- Emerling et al (2002) Oncogene 21:4849-4854
- De Weer et al (2010) PLoS One 13:e8676

XL del(7)(q22q31)

XL del(7)(q22q31) consists of an orange-labeled probe hybridizing to the KMT2E gene region at 7q22, a green-labeled probe hybridizing to the MET gene region at 7q31.2 and an aqua-labeled probe hybridizing to the centromere of chromosome 7.

Myelodysplastic syndromes (MDS) and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2017), recurrent cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

Loss of chromosome 7 (-7) or deletion of the long arm (7q-) are recurrent chromosome abnormalities in myeloid leukemias such as MDS or acute myeloid leukemia (AML). The association of -7/7q with myeloid leukemia suggests that certain regions contain tumor suppressor gene(s), whose loss of function contribute to leukemic transformation or tumor progression. Multiple critical regions have been identified: one in band 7q22 (including the KMT2E gene), the more telomeric region 7q31 and 7q35-q36 (including the EZH2 gene).

Expected Patterns

Normal Cell

Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell (typical results)

Two green (2G), one orange (1O), and 2 blue (2B) signals indicating the deletion of a 7q22 locus or one green (1G), two orange (2O), and 2 blue (2B) signals, indicating the deletion of a 7q31 locus.




Aberrant Cell (typical results)

One green (1G), one orange (1O), and two blue (2B) signals indicating the deletion of a 7q22 locus and of a 7q31 locus.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one blue (1B) signal indicating a monosomy 7.



v10.1

Literature

- Le Beau et al (1996) Blood 88:1930-1935
- Emerling et al (2002) Oncogene 21:4849-4854
- De Weer et al (2010) PLoS One 13:e8676

Order No:
D-6005-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Amplification Probe **XL**


XL EGFR amp

XL EGFR amp consists of an orange-labeled probe hybridizing to the EGFR gene region at 7p11.2 and a green-labeled probe hybridizing to the centromere of chromosome 7.

EGFR (epidermal growth factor receptor) gene amplification generally results in increased protein expression in breast carcinomas. About 6% of breast carcinomas show moderate to low-level EGFR amplification associated with genuine EGFR protein overexpression. Studies in non-small cell lung cancer (NSCLC) have shown that EGFR expression is associated with reduced survival, frequent lymph node metastasis, and poor chemosensitivity.

EGFR is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases which all play an important role in controlling normal cell growth, apoptosis, and other cellular functions. Mutations of EGFRs can lead to NSCLC, pancreatic cancer, breast cancer, colon cancer, and some other cancers.

New drugs such as gefitinib and erlotinib directly target the EGFR. EGFR-positive patients have shown a 60% response rate, which exceeds the response rate for conventional chemotherapy.




Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G), one orange (1O), and orange signal clusters, indicating amplification of EGFR (homogenous staining region = HSR).



Aberrant Cell (typical results)
Two green (2G) and multiple copies of orange signals indicating amplification of EGFR (double minutes = dm).

v10.1

Literature

- Okada et al (2003) Cancer Res 63:413-416
- Bhargava et al (2006) Mod Patho 18:1027-1033
- Sholl et al (2009) Cancer Res 69:8341-8348

XL t(7;12) MNX1/ETV6

XL t(7;12) MNX1/ETV6 consists of an orange-labeled probe hybridizing to the MNX1 gene region at 7q36 and a green-labeled probe hybridizing to the ETV6 gene region at 12p13.2.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

The t(7;12)(q36;p13) translocation is a recurrent chromosome abnormality which involves the ETV6 gene on chromosome 12 and has been identified in 20–30% of infant patients with AML. The detection of t(7;12) rearrangements relies on the use of fluorescence in situ hybridization (FISH) because this translocation is hardly visible by chromosome banding methods. The clinical outcome of t(7;12) patients is believed to be poor, therefore an early and accurate diagnosis is important in the clinical management and treatment.

Expected Patterns


Normal Cell

Two green (2G) and two orange signals (2O).



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange fusion signals (2GO).



Literature

- Ballabio et al (2009) Leukemia 23:1179-1182
- Naiel et al (2013) Cancers 5:281-295
- Owokaet al (2015) Hematol Leuk 3:1-4

Order No:
D-5041-100-OG

Size: 100 μ l


XCytting Locus-Specific Probes
Break Apart Probe **XL**

XL FGFR1


XL FGFR1 consists of a green-labeled probe hybridizing proximal to the FGFR1 gene region at 8p11.2 and an orange-labeled probe hybridizing distal to the FGFR1 gene region at 8p11.2.

In 2008, the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of these cases present as a myeloproliferative neoplasm, usually with eosinophilia.

The 8p11 myeloproliferative syndrome (MPD) also known as stem cell leukemia-lymphoma syndrome (SCLL) is associated with translocations disrupting FGFR1. Imatinib, which induces durable responses in MPDs with PDGFRA and PDGFRB fusion genes, is inactive in patients with FGFR1 translocations.



Expected Patterns



Normal Cell
Two green-orange fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange fusion signal (1GO), one green (1G), and one orange (1O) signal indicating a chromosome break in the FGFR1 locus.

Literature

- Cross et al (2002) Leukemia 16:1207-1212
- Walz et al (2005) Leukemia 19:1005-1009
- Chase et al (2007) Blood 110:3729-3734

XL MYC amp

XL MYC amp consists of an orange-labeled probe hybridizing to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing to the centromere of chromosome 8.

Amplification of MYC has been described in many types of tumor, including breast, cervical and colon cancers, as well as in squamous cell carcinomas of the head and neck, myeloma, non-Hodgkin lymphoma, gastric adenocarcinomas and ovarian cancer. MYC is the most frequently amplified oncogene and the elevated expression of its gene product correlates with tumor aggression and poor clinical outcome.

The proto-oncogene MYC, located at 8q24.1, encodes a nuclear phosphoprotein transcription factor which has an integral role in a variety of cellular processes, such as cell cycle progression, proliferation, metabolism, adhesion, differentiation, and apoptosis.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

Two green (2G), one orange (1O), and orange signal clusters, indicating amplification of MYC (homogenous staining region = HSR).



Aberrant Cell (typical results)

Two green (2G) and multiple copies of orange signals, indicating amplification of MYC (double minutes = dm).



Literature

- Rummukainen et al (2001) Mod Pathol 14:1030-1035
- Blancato et al (2004) Br J Cancer 90:1612-1619
- Singhi et al (2012) Mod Pathol 25:378-387

Order No:
D-6023-100-OG

Size: **100 µl**


XCytting Locus-Specific Probes
Break Apart Probe **XL**

XL MYC BA


XL MYC BA consists of an orange-labeled probe hybridizing proximal to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing distal to the MYC gene region at 8q24.21.

Translocations involving MYC are observed in diffuse large-B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other lymphomas. In Burkitt Lymphoma, the MYC gene, located at 8q24, is activated by a translocation next to an immunoglobulin constant gene. Most frequently, MYC is positioned near the immunoglobulin heavy-chain (IGH) constant region on chromosome 14q32. However, in some tumors MYC can also be positioned near the light-chain region on chromosome 2p11 (IGK) or 22q11 (IGL). In addition, other translocation partners have been identified (e.g. BCL11A, PAX5, ZCCHC7).

The XL MYC probe is designed as a break apart probe with two probes juxtaposed and differentially labeled. The proximal and distal regions are sufficiently large to achieve intense signals also on paraffin-embedded tissue sections. The wide gap between the orange and green part of this probe allows for the detection of the t(2;8) translocation as well as t(8;14) and t(8;22).



Expected Patterns



Normal Cell
Two green-orange (2GO) fusion signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the MYC locus.

Literature

- Hummel et al (2006) N Engl J Med 354:2419-2430
- Einerson et al (2006) Leukemia 20:1790-1799
- Bertrand et al (2007) Leukemia 21:515-523

XL MYC BA triple-color

XL MYC BA triple-color consists of an orange-labeled probe hybridizing proximal to the MYC gene region at 8q24.21, an aqua-labeled probe hybridizing to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing distal to the MYC gene region at 8q24.21.

Translocations involving MYC are observed in diffuse large-B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and other lymphomas. In Burkitt Lymphoma, the MYC gene, located at 8q24, is activated by a translocation next to an immunoglobulin constant gene. Most frequently, MYC is positioned near the immunoglobulin heavy-chain (IGH) constant region on chromosome 14q32. However, in some tumors MYC can also be positioned near the light-chain region on chromosome 2p11 (IGK) or 22q11 (IGL). In addition, other translocation partners have been identified (e.g. BCL11A, PAX5, ZCCHC7).

The XL MYC BA Triple-color probe is designed as a break apart probe with three probes juxtaposed and differentially labeled. In cases with 8q24 rearrangement, the co-localization patterns of orange-blue versus green-blue allows to distinguish different breakpoints in MYC translocations which can be an aid in diagnosis.

Expected Patterns

Normal Cell

Two blue-green-orange (2BGO) fusion signals.




Aberrant Cell (typical results)

One green-blue (1GB) signal and one separate orange (1O) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.



Aberrant Cell (typical results)

One orange-blue (1OB) signal and one separate green (1G) signal from the translocated chromosomes and one blue-green-orange (1BGO) fusion signal from the normal chromosome.



Literature

- Hummel et al (2006) N Engl J Med 354:2419-2430
- Einerson et al (2006) Leukemia 20:1790-1799
- Bertrand et al (2007) Leukemia 21:515-523

Order No:
D-5120-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe


XL

XL t(8;9) PCM1/JAK2 DF

XL t(8;9) PCM1/JAK2 DF consists of an orange-labeled probe hybridizing to the PCM1 gene region at 8p22 and a green-labeled probe hybridizing to the JAK2 gene region at 9p24.

Receptor tyrosine kinases as well as Janus kinases (JAKs) have multiple functions in the signal transmission of cytokines and growth factors. Furthermore, constitutively enhanced JAK phosphorylation levels play critical roles in chronic inflammatory processes and cancer development. Chromosomal rearrangements involving JAK2, leading to constitutive activation of the kinase, have been detected in several patients with myeloproliferative neoplasm (MPN) or myelodysplastic syndrome (MDS). While ETV6-JAK2 and BCR-JAK2 fusion genes, resulting from translocations of the type t(9;12)(p24;p13) and t(9;22)(p24;q11), respectively, have been reported only in a small number of patients, pericentriolar material 1 (PCM1)-JAK2 represents the most frequent JAK2 fusion gene. The responsible translocation generating the described fusion is t(8;9)(p22;p24.1). Multiple breakpoints have been identified.

In 2017, the WHO updated the category 'myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement' by adding a provisional entity, PCM1-JAK2. All mentioned neoplasms described in this category are associated with rearrangements or (rarely) mutations of four tyrosine kinases: PDGFRA, PDGFRB, FGFR1 or JAK2, respectively. As PCM1-JAK2 fusions are associated with a poor prognosis, only allogeneic hematopoietic stem cell transplantation is considered to be rather successful, although first small studies using the JAK2 inhibitor ruxolitinib as treatment for patients with PCM1-JAK2 positive chronic eosinophilic leukemia, not otherwise specified, have shown promising short term remission.



Literature

- Lierman et al (2012) Blood 120:1529-1531
- Rumi et al (2013) J Clin Oncol 31:e269-e271
- Reiter and Gotlib (2017) Blood 129:704-714

XL t(8;14) MYC/IGH DF

XL t(8;14) MYC/IGH DF consists of an orange-labeled probe hybridizing to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

Chromosomal translocations involving the IGH locus are recurrent in many types of lymphomas. Burkitt lymphoma (BL) is a rare, but fast growing type of non-Hodgkin lymphoma (NHL). The translocation between the MYC gene locus at 8q24 and the immunoglobulin genes (IG) for the kappa light chain at 2p12 (IGK), for the heavy chain at 14q32 (IGH) or for the lambda light chain at 22q11 (IGL), juxtapose the MYC gene to an IG enhancer, resulting in overexpression of MYC. About 80% of BL patients show the MYC rearrangement t(8;14)(q24;q32) while approximately 10% show a translocation between the MYC gene region and IGK or IGL. Additional breakpoints in BCL2, BCL6 and CCND1 are indicators for an aggressive course and short overall survival.

MYC translocations are also present in other types of lymphomas such as diffuse large B-cell lymphoma (DLBCL), which is difficult to distinguish from BL by morphology and immunophenotype alone. The use of different techniques including FISH, genomic and cytogenetic profiling can provide additional information.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Aberrant Cell (typical results)

Two green (2G) and three orange (3O) signals resulting from a translocation between the orange labeled and an unknown chromosome.



v10.1

Literature

- Siebert et al (1998) Blood 91:984-990
- Boerma et al (2009) Leukemia 23:225-234
- Nguyen et al (2017) Genes 8:1-23

Order No:
D-5125-100-TC

Size: 100 µl

XCyting Locus-Specific Probes
Translocation/Dual Fusion and
Amplification Probe


XL

XL t(8;14) MYC/IGH DF 8cen

XL t(8;14) MYC/IGH DF 8cen consists of an aqua-labeled probe hybridizing to the centromere of chromosome 8, an orange-labeled probe hybridizing to the MYC gene region at 8q24.21 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

Chromosomal translocations involving the IGH locus are recurrent in many types of lymphomas. Burkitt lymphoma (BL) is a rare, but fast growing type of non-Hodgkin lymphoma (NHL). The translocation between the MYC gene locus at 8q24 and the immunoglobulin genes (IG) for the kappa light chain at 2p12 (IGK), for the heavy chain at 14q32 (IGH) or for the lambda light chain at 22q11 (IGL), juxtapose the MYC gene to an IG enhancer, resulting in overexpression of MYC. About 80% of BL patients show the MYC rearrangement t(8;14)(q24;q32) while approximately 10% show a translocation between the MYC gene region and IGK or IGL. Additional breakpoints in BCL2, BCL6 and CCND1 are indicators for an aggressive course and short overall survival.

MYC translocations are also present in other types of lymphomas such as diffuse large B-cell lymphoma (DLBCL), which is difficult to distinguish from BL by morphology and immunophenotype alone. The use of different techniques including FISH, genomic and cytogenetic profiling can provide additional information.



Expected Patterns



Normal Cell
Two blue (2B), two green (2G), and two orange (2O) signals.



Aberrant Cell (typical results)
Two blue (2B), one green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Aberrant Cell (typical results)
Three blue (3B), two green (2G), and three orange (3O) signals resulting from a trisomy of the orange/blue labeled chromosome.



Aberrant Cell (typical results)
Two blue (2B), two green (2G), and three orange (3O) signals resulting from a reciprocal translocation between the orange labeled and an unknown chromosome.

Literature

- Siebert et al (1998) Blood 91:984-990
- Boerma et al (2009) Leukemia 23:225-234
- Nguyen et al (2017) Genes 8:1-23

XL t(8;21) plus

XL t(8;21) plus consists of a green-labeled probe hybridizing to the RUNX1T1 gene region at 8q21.3-22.1 and an orange-labeled probe hybridizing to the RUNX1 gene region at 21q22.1.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

t(8;21)(q21;q22) is the most common translocation in de novo AML occurring in up to 20% of adult and 40% of pediatric cases. The translocation fuses RUNX1 with RUNX1T1 to produce a RUNX1/RUNX1T1 fusion gene located on the derivative chromosome 8. For these patients, the prognosis after intensive chemotherapy is better than for the majority of AML patients. Small hidden interstitial insertions resulting in a RUNX1/RUNX1T1 rearrangement have been found, necessitating the use of a breakpoint spanning rather than a breakpoint flanking FISH probe.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



v10.1

Literature

- Zhang et al (2002) PNAS 99:3070-3075
- Gamedinger et al (2003) Gene Chromosome Canc 36:261-272
- Jang et al (2010) Ann Clin Lab Sci 40:80-84

Order No:
D-5148-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Break Apart Probe **XL**


XL ABL1 BA

XL ABL1 BA consists of a green-labeled probe hybridizing proximal to the ABL1 gene region at 9q34.1 and an orange-labeled probe hybridizing distal to the ABL1 gene region at 9q34.1.


Acute lymphoblastic leukemia (ALL) is the most common malignancy in children with a prevalence of approximately 1:1500. Children with Down syndrome have a 10- to 20-fold increased risk of developing acute leukemia (B-cell precursor-ALL, acute myeloid leukemia, and particularly acute megakaryoblastic leukemia).

In 2017, the WHO recognized BCR-ABL1-like ALL, a subtype of B-lymphoblastic leukemia/lymphoma, as a new entity. BCR-ABL1-like ALL, also known as Philadelphia chromosome (Ph)-like ALL, is found in 10-20% of childhood and in 20-30% of all adult B-cell dependent ALL cases. BCR-ABL1-like ALL is characterized by a gene expression profile sharing significant overlap with that of Ph-positive (Ph+) ALL. In contrast to Ph+ ALL, defined by the presence of the BCR-ABL1 fusion resulting from t(9;22)(q34;q11), BCR-ABL1-like cases include a variety of genomic alterations enhancing kinase and cytokine receptor signaling.

Prominent genes involved in the pathogenesis of BCR-ABL1-like ALL are CRLF2, EPOR, JAK2, ABL1, ABL2, CSF1R and PDGFRB. The already known heterogenous 5' fusion partners of ABL1 are CENPC, ETV6, FOXP1, LSM14A, NUP153, NUP214, RANBP2, R3SD1, SFPQ, SNX1, SNX2, SPTAN1 and ZMIZ1. The kinase domain of ABL1 is present in all identified chimeric fusion proteins.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.

Literature

- Tasian et al (2017) Blood 130:2064-2072
- Conant and Czuchlewski (2019) Int J Lab Hematol 41 Suppl 1:126-130
- Jain and Abraham (2019) Arch Pathol Lab Med:doi:10.5858/arpa.2019-0194-RA

XL CDKN2A

XL CDKN2A consists of an orange-labeled probe hybridizing to the CDKN2A (p16)/CDKN2B (p15) gene region at 9p21 and a green-labeled probe hybridizing to the centromere of chromosome 9.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer type. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and quickly progressing type of ALL affecting T-lymphocytes. Inactivation of the tumor suppressor genes CDKN2A/2B, located at chromosomal region 9p21, is a significant event in the development of T-ALL and other cancer types. Principally, loss of function might happen by deletion, methylation of promotor regions or mutations, whereas deletion of chromosomal region 9p21 seems to be the predominant mechanism. CDKN2A/2B deletions can be detected in about 60% of pediatric and about 50% of adult T-ALL cases. Most deletions are within the resolution of the FISH technique. Genetic alterations of the 9p21 locus result in loss of regulation of the cell cycle which is critical to cancer development.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal, indicating the deletion of the CDKN2A (p16) at 9p21.



Aberrant Cell (typical results)

Two green (2G) and no orange (no O) signal, indicating a homozygous deletion of the CDKN2A (p16) at 9p21.



Literature

- Novara et al (2009) Human Genet 126:511-520
- Sulong et al (2009) Blood 113:100-107
- Girardi et al (2017) Blood 129:1113-1123

Order No:
D-5118-100-OG


Size: 100 µl

XCyting Locus-Specific Probes
Deletion Probe **XL**

XL CDKN2A/9q22

XL CDKN2A/9q22 consists of an orange-labeled probe hybridizing to the CDKN2A(p16)/CDKN2B (p15) gene region at 9p21 and a green-labeled probe hybridizing to the CENPP gene region at 9q22.3.

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer type. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and quickly progressing type of ALL affecting T-lymphocytes. Inactivation of the tumor suppressor genes CDKN2A/2B, located at chromosomal region 9p21, is a significant event in the development of T-ALL and other cancer types. Principally, loss of function might happen by deletion, methylation of promotor regions or mutations, whereas deletion of chromosomal region 9p21 seems to be the predominant mechanism. CDKN2A/2B deletions can be detected in about 60% of pediatric and about 50% of adult T-ALL cases. Most deletions are within the resolution of the FISH technique. Genetic alterations of the 9p21 locus result in loss of regulation of the cell cycle which is critical to cancer development.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Aberrant Cell (typical results)
Two green (2G) and no orange (no O) signal resulting from homozygous deletion of the locus covered by the orange probe.

Literature

- Novara et al (2009) Human Genet 126:511-520
- Sulong et al (2009) Blood 113:100-107
- Girardi et al (2017) Blood 129:1113-1123

XL JAK2 BA

XL JAK2 BA consists of an orange-labeled probe hybridizing proximal to the JAK2 gene region at 9p24 and a green-labeled probe hybridizing distal to the JAK2 gene region at 9p24.

Patients with clinical characteristics of chronic myelogenous leukemia (CML) lacking a BCR/ABL fusion gene are usually referred to as having atypical CML. Most commonly, diverse tyrosine kinase genes such as the receptors FGFR1, PDGFRA, or PDGFRB are involved. In addition, the Janus (tyrosine) kinases (JAK) can be deregulated in leukemia/lymphoma by copy number alterations, mutations and chromosomal translocations.

Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities in myeloproliferative neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. In cell line models and primary patient material, it could be shown that treatment with ruxolitinib has significant activity against JAK2 activated by gene rearrangement and presents evidence for potential activity against cells with JAK2 amplification.

Expected Patterns


Normal Cell

Two green-orange fusion signals (2GO).



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the JAK2 locus.



Literature

- Bousquet et al (2005) *Oncogene* 24:7248-7252
- Chase et al (2012) *Haematologica* 93:404-408
- Ehrentraut et al (2013) *PLoSone* 8:e53767

Order No:
D-5133-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe


XL

XL t(9;11) MLLT3/KMT2A DF

XL t(9;11) MLLT3/KMT2A DF consists of an orange-labeled probe hybridizing to the MLLT3 gene region at 9p21 and a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3.

The KMT2A (formerly MLL) gene, located on chromosome 11q23, is rearranged in about 10% of all acute leukemia patients. Most of them suffer from acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), only a minority shows mixed lineage leukemia which has given the gene its original name 'MLL'. In infants, the incidence of KMT2A rearrangements in leukemia is 70-80%. KMT2A encodes a nuclear protein with methyltransferase activity and is part of multiprotein complexes involved in the regulation of target genes essential during early development and hematopoiesis. Today, more than 80 translocation partners of KMT2A have been identified. Translocations are resulting in in-frame fusions between the KMT2A part N-terminal to the breakpoint cluster region and the respective fusion partners. The most common translocation partners in KMT2A associated leukemia are, in the order of their prevalence, AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN.


KMT2A is involved in about 3-5% of adult de novo AML cases and the most common aberration in this subgroup is t(9;11) (p22;q23) involving the MLLT3 gene. Pediatric patients carrying this aberration do have a favorable outcome which is comparable to AML patients without KMT2A involvement. FISH is described as a reliable method for the identification of t(9;11).



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.

Literature

- Cavazzini et al (2006) Haematologica 91:381-385
- Meyer et al (2013) Leukemia 27:2165-2176
- Winters and Bernt (2017) Front Pediatr 5:doi:10.3389/fped.2017.00004

XL BCR/ABL1 plus

XL BCR/ABL1 plus consists of an orange-labeled probe hybridizing to the ABL1 gene region at 9q34.1 and a green-labeled probe hybridizing to the BCR gene region at 22q11.2.

Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22) (q34;q11), resulting in a BCR/ABL gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.

Expected Patterns



Normal Cell

Two green (2G) and two orange signals (2O).



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange fusion signals (2GO).



v10.1

Literature

- Dewald et al (1998) Blood 91:3357-3365
- Huntly et al (2003) Blood 102:1160-1168
- Primo et al (2003) Leukemia 17:1124-1129

Order No:
D-5082-100-TC

Size: 100 µl



XCyting Locus-Specific Probes
Deletion/Dual Fusion Probe **XL**

XL BCR/ABL1/ASS

XL BCR/ABL1/ASS consists of an aqua-labeled probe hybridizing to the ASS1 gene region at 9q34.1, an orange-labeled probe hybridizing to the ABL1 gene region at 9q34.1 and a green-labeled probe hybridizing to the BCR gene region at 22q11.2.

Chronic myelogenous leukemia (CML) is genetically characterized by the presence of the reciprocal translocation t(9;22) (q34;q11), resulting in a BCR/ABL1 gene fusion on the derivative chromosome 22, called the Philadelphia (Ph) chromosome. The same translocation can also be found in acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) with some variation in the breakpoint region. Glivec® (imatinib mesylate) treatment targeting the BCR/ABL1 active tyrosine kinase has become a major drug in treating CML, gastrointestinal stromal tumors, and other cancers.

Deletions at the t(9;22) breakpoint regions, found in 5% of CML patients with a Ph translocation, have been associated with resistance to treatment in patients receiving tyrosine kinase inhibitors.




v10.1


Expected Patterns



Normal Cell
Two blue-orange (2BO) fusion signals and two separate green signals (2G).



Aberrant Cell (typical results)
One blue-orange (1BO), one green (1G), one blue-green-orange (1BGO) and one green-orange (1GO) fusion signal.



Aberrant Cell (typical results)
One blue-orange (1BO), two green (2G), and one green-orange (1GO) fusion signal, indicating a deletion at 9q34 in addition to a t(9;22).

Literature

- Dewald et al (1998) Blood 91:3357-3365
- DeMelo et al (2008) Canc Genet Cytogenet 182:111-115
- Luatti et al (2012) Blood 120:761-767

XL t(10;11) MLLT10/KMT2A DF

XL t(10;11) MLLT10/KMT2A DF consists of an orange-labeled probe hybridizing to the MLLT10 gene region at 10p12.3 and a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3.

Chromosomal rearrangements of the KMT2A (lysine methyltransferase 2A) gene, formerly MLL (mixed lineage leukemia), are associated with various hematological disorders. Most patients suffer from acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), while only a minority develops mixed lineage leukemia (MLL). Several chromosomal aberrations involving the KMT2A gene have been identified. However, the majority of leukemias result from translocations leading to KMT2A fusions. More than 90 KMT2A translocation partner genes fused to the 5' - KMT2A portion have been identified. The most common translocation partners in KMT2A associated leukemia are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN, described here in the order of their frequency. MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor), previously known as AF10, is one of the most frequent fusion partners of KMT2A across all acute leukemia cases. KMT2A-MLLT10 fusions result from multiple breakpoints in both gene loci. The subsequent chromosomal rearrangements include reciprocal translocations, insertions, inversions, deletions and duplications. MLLT10 is a cofactor of the histone H3K79 methyltransferase DOT1L and mediates the interaction of AFF1, MLLT1 and MLLT3 with DOT1L. The consequence of the presence of KMT2A-AFF1, AFF1-KMT2A, KMT2A-MLLT3, KMT2A-MLLT1, and KMT2A-MLLT10 fusions is an increased and extended H3K79 methylation signature that is a requirement for the maintenance of RNA transcription. DOT1L inhibitors are promising candidates for clinical treatment which are currently being evaluated.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

Two green (2G), one orange (1O), and one green-orange colocalization/fusion signal (1GO).



Aberrant Cell (typical results)

Two green (2G), two orange (2O), and one green-orange colocalization/fusion signal (1GO).



Complex genomic rearrangements must occur to create an in-frame KMT2A/MLLT10 fusion gene. At least 3 chromosomal breaks are required to produce the pathogenic 5'KMT2A/3'MLLT10 fusion. The majority of cases show an abnormal karyotype; however, cryptic aberrations may occur.

Literature

- De Braekeleer et al (2011) Mol Oncol 5:555-563
- Meyer et al (2013) Leukemia 27:2165- 2176
- Peterson et al (2019) Genes Chromosomes Cancer 58:567-577

Order No:
D-5102-100-OG

Size: 100 µl


XCytting Locus-Specific Probes
Deletion Probe **XL**

XL ATM/11cen

XL ATM/11cen consists of an orange-labeled probe hybridizing to the ATM gene region at 11q22.3 and a green-labeled probe hybridizing to the centromere of chromosome 11.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

Chromosome 11q22.3-23.1 deletions involving the ataxia-telangiectasia mutated (ATM) locus are detected at diagnosis in 15-20% of cases of B-cell CLL and are associated with a more aggressive disease.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal indicating the deletion of ATM at 11q22.

Literature

- Doehner et al (1997) Blood 89:2516-2522
- Cuneo et al (2002) Haematologica 87:44-51
- Tsimberidou et al (2009) Cancer 115:373-380

XL CCND1

XL CCND1 consists of an orange-labeled probe hybridizing proximal to the MYEOV gene region at 11q13.3 and a green-labeled probe hybridizing to CCND1 and distal to the CCND1 gene region at 11q13.3.

The t(11;14)(q13;q32) chromosomal translocation is the hallmark of mantle cell lymphoma (MCL) and is found in approximately 30% of multiple myeloma (MM) tumors with a 14q32 translocation. Variant translocations can fuse CCND1 with other genes, such as IGH or IGL.

Expected Patterns


Normal Cell

Two green-orange (2GO) fusion signals representing the two normal CCND1 loci.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the CCND1 locus.



Literature

- Vandraager et al (1997) Blood 89:349-350
- Fonseca et al (2002) Blood 99:3735-3741
- Wlodarska et al (2004) Leukemia 18:1705-1710

Order No:
D-5090-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL KMT2A BA


XL KMT2A BA consists of an orange-labeled probe hybridizing proximal to the KMT2A gene region at 11q23.3 extending into the gene up to intron 24 and a green-labeled probe hybridizing distal to the KMT2A gene region at 11q23.3 extending into the gene up to intron 20 and thus overlapping each other for 3.4kb (GRCh37/hg19).

The KMT2A (formerly MLL) gene, located on chromosome 11q23, is rearranged in about 10% of all acute leukemia patients. Most of them suffer from acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). Only a minority shows mixed lineage leukemia which has given the gene its original name 'MLL'. In infants, the incidence of KMT2A rearrangements in leukemia is 70-80%. KMT2A encodes a nuclear protein with methyltransferase activity and is part of multiprotein complexes involved in the regulation of target genes essential during early development and hematopoiesis. Today, more than 80 translocation partners of KMT2A have been identified. Translocations are resulting in in-frame fusions between the KMT2A part N-terminal to the break point cluster region and the respective fusion partners. The most common translocation partners in KMT2A associated leukemia are, in the order of their prevalence, AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN. Fusion genes may also be the result of an insertion of genetic material including portions of KMT2A into other chromosomal locations. Some examples of fusion genes reported as a result of this mechanism are KMT2A-AFF1, KMT2A-MLLT3 and KMT2A-MLLT10.

The proven MetaSystems XL MLL plus D-5060-100-OG is designed to detect breaks in the KMT2A gene region. Featuring a new gene covering design, XL KMT2A BA D-5090-100-OG allows the detection of cryptic insertion of portions of KMT2A into other chromosomes as an added benefit, provided that the inserted DNA fragment is in the size range detectable by fluorescence microscopy.




Expected Patterns



Normal Cell
Two green-orange (2GO) colocalization/fusion signals.



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus. Translocations with breakpoints within the KMT2A breakpoint cluster region result in a small orange split signal remaining with the separated green signal. The residual orange signal is significantly smaller than the separated orange signal and might even be invisible.



Aberrant Cell (typical results)
Two green-orange colocalization/fusion signals (2GO) and one separate usually small orange (1O) signal indicating an insertion of the respective genomic region to an unknown chromosome.

Literature

- Soler et al (2008) Cancer Genet Cytogenet 183:53-59
- Meyer et al (2013) Leukemia 27:2165-2176
- Winters and Bernt (2017) Front Pediatr 5:4.doi:10.3389/fped.2017.00004

XL MLL plus

XL MLL plus consists of an orange-labeled probe hybridizing proximal to the KMT2A gene region at 11q23.3 and a green-labeled probe hybridizing distal to the KMT2A gene region at 11q23.3.

A number of recurrent chromosomal abnormalities have been shown to have prognostic significance in acute lymphoblastic leukemia (ALL), especially in B-precursor ALL. Some chromosomal abnormalities, such as high hyperdiploidy and the TEL-AML1 fusion, are associated with more favorable outcomes, while others, including the t(9;22), rearrangements of the KMT2A gene (chromosome 11q23), and intrachromosomal amplification of the AML1 gene (iAMP21), are associated with a poorer prognosis.

Chromosomal rearrangements involving the human KMT2A gene are recurrently associated with the disease phenotype of acute leukemias. The identification of KMT2A gene rearrangements is necessary for rapid clinical decisions resulting in specific therapy regimens. Amplification of KMT2A in myelodysplastic syndrome and acute myeloid leukemia has also been observed, and transcriptional similarities between KMT2A amplified and KMT2A rearranged leukemias were identified.

Expected Patterns


Normal Cell

Two green-orange (2GO) fusion signals representing the two normal KMT2A loci.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the KMT2A locus.



Literature

- Poppe et al (2004) Blood 103:229-235
- Meyer et al (2006) Leukemia 20:777-784
- Cavazzini et al (2006) Haematologica 91:381-385

Order No:
D-5077-100-OG

Size: 100 µl


XCytting Locus-Specific Probes
Break Apart Probe **XL**

XL NUP98


XL NUP98 consists of an orange-labeled probe hybridizing proximal to the NUP98 gene region at 11p15.4 and a green-labeled probe hybridizing distal to the NUP98 gene region at 11p15.4.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myelogenous leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

Translocations involving nucleoporin 98kD (NUP98) on chromosome 11p15 occur at relatively low frequency in AML, but can be missed with routine karyotyping. NUP98 is known to be fused to at least 28 different partner genes in patients with hematopoietic malignancies, including acute myeloid leukemia, chronic myeloid leukemia in blast crisis, myelodysplastic syndrome, acute lymphoblastic leukemia, and bilineage/biphenotypic leukemia.



Expected Patterns



Normal Cell
Two green-orange fusion signals (2GO).



Aberrant Cell (typical results)
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the NUP98 locus.

Literature

- Nebral et al (2005) Haematologica 90:746-752
- Romana et al (2006) Leukemia 20:696-706
- Gough et al (2011) Blood 118:6247-6257

XL t(11;14) MYEOV/IGH DF

XL t(11;14) MYEOV/IGH DF consists of an orange-labeled probe hybridizing to the MYEOV/CCND1 gene region at 11q13.3 and a green-labeled probe hybridizing to the IGH gene region at 14q32.3.

Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) with an aggressive clinical course. It is genetically characterized by t(11;14)(q13;q32) which is present in about 95% of MCL patients. By lower frequency, t(11;14) is also detectable in B-cell prolymphocytic leukemia, myelomas and chronic lymphocytic leukemia. The translocation induces overexpression of CCND1 which is normally not detected in B lymphocytes. CCND1 is a major player in cell cycle regulation and involved in the G1/S-phase transition. The oncogenic potential of CCND1 overexpression is related to its role in the cell cycle but also to other, non-cell cycle-related mechanisms such as increased genomic instability and cell survival. t(11;14) is considered as a primary event, often followed by secondary chromosome alterations.

In multiple myeloma (MM), t(11;14) is the most common translocation, detectable by FISH in about 15-20% of all MM patients. Conventional cytogenetics has a much lower sensitivity, detecting t(11;14) in about 5% of MM patients. MM t(11;14) patients do have a relatively favorable outcome compared to other recurrent IGH translocations.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Literature

- Fonesca et al (2002) Blood 99:3735-3741
- Bentz et al (2004) Canc Cytopath 102:124-131
- Jares et al (2012) J Clin Invest 122:3416-3423

Order No:
D-5046-100-OG

Size: 100 µl



XCytting Locus-Specific Probes
Deletion Probe **XL**

XL ATM/TP53

XL ATM/TP53 consists of a green-labeled probe hybridizing to the ATM gene region at 11q22.3 and an orange-labeled probe hybridizing to the TP53 gene region at 17p13.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

TP53 is a tumor suppressor gene which stops cell division when DNA damage is present. Loss of TP53 at 17p13 is a powerful predictor of resistance to therapy with purine analogues and alkylating agents, and of poor prognosis in CLL. Chromosome 11q22.3-23.1 deletions involving the ataxia telangiectasia mutated (ATM) locus are detected at diagnosis in 15 - 20% of cases of B-cell CLL and are associated with a more aggressive disease.



v10.1

Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G) and two orange (2O) signals indicating a deletion of an ATM locus.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal indicating a deletion of a TP53 locus.

Literature

- Doehner et al (2000) N Engl J Med 343:1910-1916
- Stilgenbauer et al (2002) Leukemia 16:993-1007
- Gunn et al (2008) J Mol Diagn 10:442-451

XL t(11;19) KMT2A/ELL DF

XL t(11;19) KMT2A/ELL DF consists of a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3 and an orange-labeled probe hybridizing to the ELL gene region at 19p13.1.

Chromosomal rearrangements of the KMT2A (lysine methyltransferase 2A) gene, formerly MLL (mixed lineage leukemia), are associated with various hematological disorders. Most patients suffer from acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), while only a minority develops mixed lineage leukemia (MLL). Several chromosomal aberrations involving the KMT2A gene have been identified. However, the majority of leukemias result from translocations leading to KMT2A fusions. More than 90 KMT2A translocation partner genes fused to the 5' - KMT2A portion have been identified. The most common translocation partners in KMT2A associated leukemia are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN, described here in the order of their frequency. Fusions between KMT2A and ELL (elongation factor for RNA polymerase II), caused by translocations of the type t(11;19)(q23;p13.1), belong to the most common KMT2A fusion genes in AML. Approximately 11% of AML patients carrying KMT2A rearrangements are characterized by the KMT2A-ELL fusion gene. The breakpoints within the KMT2A gene resulting in KMT2A-ELL fusions are found in intron 9 in the case of patients younger than one year and in intron 11 in the case of patients older than one year. This breakpoint distribution is unique among all KMT2A fusions. The outcome of patients with breakpoints in KMT2A intron 11 is worse compared to patients with upstream breakpoints. ELL is a component of the super elongation complex (SEC). Chimeric KMT2A-ELL fusion proteins have the ability to recruit SEC resulting in aberrant gene expression.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical result)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.



Note: In case of t(11;19) (q23.3;p13.3) with fusion of KMT2A and MLLT1, one orange and one green signal may appear fused on metaphase spreads due to the close proximity of ELL and MLLT1.



v10.1

Literature

- De Braekeleer et al (2011) Mol Oncol 5:555-563
- Meyer et al (2017) Leukemia 32:273-284
- Chan and Chen (2019) Front Cell Dev:doi:10.3389/fcell.2019.00081

Order No:
D-5136-100-OG

Size: 100 µl



XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe

XL

XL t(11;19) KMT2A/MLLT1 DF

XL t(11;19) KMT2A/MLLT1 DF consists of a green-labeled probe hybridizing to the KMT2A gene region at 11q23.3 and an orange-labeled probe hybridizing to the MLLT1 gene region at 19p13.3.

Chromosomal rearrangements of the KMT2A (lysine methyltransferase 2A) gene, formerly MLL (mixed lineage leukemia), are associated with various hematological disorders. Most patients suffer from acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), while only a minority develops mixed lineage leukemia (MLL). Several chromosomal aberrations involving the KMT2A gene have been identified. However, the majority of leukemias result from translocations leading to KMT2A fusions. More than 90 KMT2A translocation partner genes fused to the 5' - KMT2A portion have been identified. The most common translocation partners in KMT2A associated leukemia are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN, described here in the order of their frequency. MLLT1 (MLLT1 super elongation complex subunit), originally designated as ENL, is one of the most common KMT2A fusion partners. KMT2A-MLLT1 fusions result from translocations of the type t(11;19)(q23;p13.3). Most patients carrying a KMT2A-MLLT1 fusion have breakpoints in intron 11 of the KMT2A gene. KMT2A-MLLT1 fusions are prevalent in both AML and ALL. Multiple KMT2A translocation partner genes, including MLLT1, are organized within the DOT1L transcriptional complex. AFF1 serves as DOT1L complex docking platform for MLLT1 and MLLT3, while MLLT10 directly mediates this interaction. More precisely, the MLLT1 protein has been shown to interact with AFF1 via its C-terminus. Due to the close interaction of these KMT2A fusion partners with DOT1L, DOT1L inhibitors are considered as promising candidates for treatment of such leukemia cases.



v10.1

Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical result)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.

Note: In case of t(11;19) (q23.3;p13.1) with fusion of KMT2A and ELL, one orange and one green signal may appear fused on metaphase spreads due to the close proximity of ELL and MLLT1.

Literature

- Meyer et al (2005) Proc Natl Acad Sci USA 102:449-454
- De Braekeleer et al (2011) Mol Oncol 5:555-563
- Winters and Bernt (2017) Front Pediatr 5 (4):doi:10.3389/fped.2017.00004

XL CLL Probe Kit (XL DLEU/ LAMP/12cen + XL ATM/TP53)

XL CLL contains different probe mixes provided in separate test vials.


XL DLEU/LAMP/12cen consists of a green-labeled probe hybridizing to the centromere of chromosome 12, an orange-labeled probe hybridizing to the DLEU1/MIR15A/MIR16-1 gene region at 13q14.2 including D13S319 and an aqua-labeled probe hybridizing to the LAMP1 gene region at 13q34.

XL ATM/TP53 consists of a green-labeled probe hybridizing to the ATM gene region at 11q22.3 and an orange-labeled probe hybridizing to the TP53 gene region at 17p13.

The XL CLL Probe Kit is a combination of probes covering the most frequent chromosomal aberrations in chronic lymphocytic leukemia (CLL). For a more detailed description, please refer to product XL DLEU/LAMP/12cen (D-5055-100-TC) and XL ATM/TP53 (D-5046-100-OG).

Expected Patterns

Please refer to XL DLEU/
LAMP/12cen (D-5055-100-TC)
and XL ATM/TP53 (D-5046-
100-OG) for signal patterns.



Literature

- Doehner et al (2000) N Engl J Med 343:1910-1916
- DeWald et al (2003) Brit J Haem 121:287-295
- Nelson et al (2007) Am J Clin Pathol 128:323-332

Order No:
D-6032-100-OG


Size: 100 µl

XCyting Locus-Specific Probes
Break Apart Probe **XL**


XL DDIT3 BA

XL DDIT3 BA consists of an orange-labeled probe hybridizing proximal to the DDIT3 gene region at 12q13.3 and a green-labeled probe hybridizing distal to the DDIT3 gene region at 12q13.3-14.

Histological similarities and a subset of common immunohistochemical features make the diagnosis of soft tissue neoplasms challenging. Several entities characterizing reciprocal translocations have been identified and FISH based assays specific for the detection of these aberrations have become a valuable tool in diagnostics today. Myxoid/round cell liposarcoma (MRCLS) is the most common liposarcoma with an increased incidence in the extremities. Compared to other liposarcomas, MRCLS has a greater tendency for metastasis. It is characterized by the reciprocal translocation $t(12;16)(q13;p11)$ which is present in up to 95% of cases. The resulting FUS-DDIT3 fusion protein has oncogenic potential and interferes with adipogenic differentiation. A paralog of FUS with high sequence homology is the EWS RNA Binding Protein 1 (EWSR1). EWSR1 is an alternative translocation partner of DDIT3 and the resulting fusion protein EWSR1-DDIT3, originating from $t(12;22)(q13;q12)$, accounts for <5% of MRCLS cases. DDIT3 rearrangements are highly specific for MRCLS due to the presence of FUS-DDIT3 or EWSR1-DDIT3 fusion genes.



Expected Patterns



Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus.

Literature

- Cristina et al (2000) JMD 2:132-138
- Downs-Kelly et al (2008) Am J Surg Pathol 32:8-13
- Tanas et al (2009) Adv Anat Pathol 16:383-391

XL ETV6

XL ETV6 consists of an orange-labeled probe hybridizing proximal to the ETV6 gene region at 12p13.2 and a green-labeled probe hybridizing distal to the ETV6 gene region at 12p13.2.

The ETV6 gene, located on 12p13.2, is involved in numerous translocations found in myeloid and lymphoid malignancies. Two mechanisms are common: fusion to a tyrosine kinase resulting in a constitutively active tyrosine kinase and fusions to transcription factors driving aberrant expression of target genes. The frequent translocation t(12;21)(p13;q22) results in the formation of the chimeric transcription factor ETV6-RUNX1 which can be identified in about 25% of childhood B-cell acute lymphoblastic leukemia (B-ALL) cases. ETV6-RUNX1 causes expansion of B-cell precursors with impaired ability of differentiation to mature B-cells. Another important aberration is t(5;12)(q33;p13), found in chronic myelomonocytic leukemia (CML) and myeloproliferative diseases, resulting in the fusion of ETV6 with the receptor tyrosine kinase PDGFRB. The resulting oncogene is sensitive to the kinase inhibitor imatinib. t(7;12)(q36;p13) can be identified in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is resulting in the fusion gene MNX1-ETV6.

Besides hematological malignancies, ETV6 is also involved in the development of the pediatric congenital mesoblastic nephroma and fibrosarcoma. t(12;15)(p13;q25) fuses ETV6 to the tyrosin receptor kinase NTRK3 resulting in the ETV6-NTRK3 fusion gene, a constitutively active tyrosine kinase.

Expected Patterns


Normal Cell

Two green-orange (2GO) fusion signals representing the two normal ETV6 loci.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the ETV6 locus.



Literature

- Lierman and Cools (2007) Haematologica 92:145-147
- Adem et al (2001) Mod Pathol 14:1246-1251
- Naiel et al (2013) Cancers 5:281-295

Order No:
D-5047-100-OG


Size: 100 µl

XCytting Locus-Specific Probes
Amplification Probe **XL**

XL MDM2

XL MDM2 consists of an orange-labeled probe hybridizing to the MDM2 gene region at 12q15 and a green-labeled probe hybridizing to the centromere of chromosome 12.

The tumor suppressor gene TP53 is a key regulator in the cell cycle and is involved in apoptosis, genomic stability and angiogenesis. Inactivation of TP53 function prevents the antiproliferative effect and contributes to the development of many types of cancer. Several mechanisms of TP53 loss of function are known such as gene mutations, interaction of p53 with viral proteins and association of p53 with the MDM2 oncoprotein. MDM2 is an ubiquitin ligase negatively regulating p53. MDM2 is amplified in about 7% of all human cancers with the highest frequency of about 20% in soft tissue tumors. MDM2 might also have p53-independent transforming capabilities. Well-differentiated liposarcomas/atypical lipomatous tumors (WDL-ALT) and dedifferentiated liposarcomas are among the most common soft tissue tumors in adults. Both entities share the same genetic aberration, an amplification of the chromosomal region including MDM2. WDL-ALT and benign lipomatous tumors can be morphologically similar and a clear assignment based on histological features might be difficult. The analysis of the MDM2 amplification status by FISH is considered as a useful technique for the differential diagnosis of WDL-ALT and benign lipomatous tumors since benign lesions do not harbor MDM2 amplifications. Furthermore, MDM2 overexpression has been reported to be a potential cause of p53 dysfunction in chronic lymphoblastic leukemia.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and three orange (3O) signals, indicating a duplication of the MDM2 locus.

Literature

- Haidar et al (1997) Am J Hematol 54:189-195
- Momand et al (1998) Nucleic Acids Res 26:3453-3459
- Weaver et al (2008) Mod Pathol 21:943-949

XL t(12;21) ETV6/RUNX1 DF

XL t(12;21) ETV6/RUNX1 DF consists of a green-labeled probe hybridizing to the ETV6 gene region at 12p13.2 and an orange-labeled probe hybridizing to the RUNX1 gene region at 21q22.1.

Acute lymphoblastic leukemia (ALL) is a rapidly progressing cancer type characterized by the malignant transformation of lymphoid progenitor cells. It is the most common childhood cancer type and the second most common leukemia in adults. Treatment of children usually results in good prognosis whereas the outcome for adults is less optimistic. Most patients show a transformation of precursors of the B-cell type, but also the T-cell phenotype is frequently observed. The most common aberration in pediatric B-cell ALL is t(12;21)(p13;q22) with an incidence of about 25%, compared to <5% in adults. The result of this reciprocal translocation is an ETV6/RUNX1 fusion gene. Scientific data suggest that ETV6/RUNX1 is already established prenatally, but additional chromosomal aberrations are necessary for the development of ALL postnatally. The ETV6/RUNX1 fusion gene is transcriptionally active and is dysregulating a cascade of downstream genes. One study has shown, that all positive t(12;21) cases harbored the ETV6/RUNX1 fusion gene but not the reciprocal gene. This suggests, that ETV6/RUNX1 is involved in the manifestation of ALL, but not RUNX1/ETV6.

Since t(12;21) is not detectable by conventional cytogenetic methods, FISH is one of the methods of choice.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Aberrant Cell (typical results)

No green (no G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci and a deletion of the locus covered by the green probe. In t(12;21) cases the normal ETV6 at 12p13 is often deleted.



v10.1

Literature

- Romana et al (1995) Blood 85:3662-3670
- Al-Obaidi et al (2002) Leukemia 16:669-674
- Sun et al (2017) Oncotarget 8:35445-35459

Order No:
D-6034-100-OG


Size: 100 µl

XCytting Locus-Specific Probes
Break Apart Probe **XL**


XL FOXO1 BA

XL FOXO1 BA consists of a green-labeled probe hybridizing proximal to the FOXO1 gene region at 13q14.1 and an orange-labeled probe hybridizing distal to the FOXO1 gene region at 13q14.1.

Rhabdomyosarcoma (RMS) is a relatively rare cancer type but it is the most common soft tissue sarcoma in children and adolescents. The histopathological classification includes several subtypes: embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) are the most common variants, in the order of their occurrence. ARMS is associated with a worse outcome and is characterized by the two reciprocal translocations $t(2;13)(q35;q14)$ and $t(1;13)(p36;q14)$, affecting the FOXO1 gene region and PAX3 or PAX7 respectively, in about 80% of cases. The result is an in-frame fusion of the PAX DNA binding domain with the transcriptional active domain of FOXO1 generating a highly potent chimeric activator for PAX target genes. Patients harboring FOXO1-PAX3/7 fusions have an inferior event-free survival compared to patients without translocation, suggesting that the molecular status in RMS provides valuable prognostic information.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus.

Literature

- McManus et al (1996) J Pathol 178:410-414
- Barr (2001) Oncogene 20:5736-5746
- Skapek et al (2013) Pediatr Blood Cancer 60:1411-1417

XL DLEU/LAMP

XL DLEU/LAMP consists of an orange-labeled probe hybridizing to the DLEU1/MIR15A/MIR16-1 gene region at 13q14.2 including D13S319 and a green-labeled probe hybridizing to the LAMP1 gene region at 13q34.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13 and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

The most frequently deleted region in B-CLL is located in 13q14.3 distal to RB1. The minimal deleted region (MDR) is 350kb in size and includes the gene loci for the mi-RNAs 15 and 16. CLL with 13q deletion as the sole cytogenetic abnormality usually have a good prognosis.

Deletions of chromosomal region 13q14 have also been reported in a variety of human tumors, including other types of lymphoid tumors and myeloid leukemias, as well as prostate, head and neck, and non-small-cell lung cancers.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal, indicating the deletion of a 13q14.3 locus.




Aberrant Cell (typical results)

One green (1G) and two orange (2O) signals, indicating a deletion of the terminal region of the long arm of chromosome 13.



Aberrant Cell (typical results)

One green (1G) and one orange (1O) signal, indicating deletions of both loci in 13q14 and 13qter.



Literature

- Doehner et al (2000) N Engl J Med 343:1910-1916
- Calin et al (2002) Proc Natl Acad Sci USA 99:15524-15529
- Gunn et al (2008) J Mol Diagn 10:442-451

Order No:
D-5070-100-TC

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL RB1/DLEU/LAMP

XL RB1/DLEU/LAMP consists of a green-labeled probe hybridizing to the RB1 gene region at 13q14.2, an orange-labeled probe hybridizing to the DLEU1/MIR15A/MIR16-1 gene region at 13q14.2 including D13S319 and an aqua-labeled probe hybridizing to the LAMP1 gene region at 13q34.

In chronic lymphocytic leukemia (CLL), deletion at 13q14 with at least one allele occurs in more than 50% of cases. A minimal deleted region (MDR) of 350kb in size has been identified and is usually seen as an indicator for good prognosis. However, recent studies using high resolution arrays have shown, that the 13q14 deletion can vary in size and, if it is including the RB1 gene, may lead to a change in the prognosis of CLL patients. RB1 is a critical regulator of cell cycle progression and genomic stability and its loss could explain this change of interpretation in CLL.

Deletions of chromosome 13q14 have been reported in a variety of human tumors, including other types of lymphoid tumors and myeloid leukemias, as well as prostate, head and neck, and non-small-cell lung cancers.



Expected Patterns



Normal Cell
Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell
Two green (2G), one orange (1O), and two blue (2B) signals.



Aberrant Cell
One green (1G), one orange (1O), and two blue (2B) signals.



Aberrant Cell
One green (1G), one orange (1O), and one blue (1B) signal.

Literature

- Doehner et al (2000) N Engl J Med 34:1910-1916
- Ouillette et al (2008) Cancer Res 68:1012-1021
- Dal Bo et al (2011) Genes Chromosomes Cancer 50:633-643

XL DLEU/LAMP/12cen

XL DLEU/LAMP/12cen consists of a green-labeled probe hybridizing to the centromere of chromosome 12, an orange-labeled probe hybridizing to the DLEU1/MIR15A/MIR16-1 gene region at 13q14.2 including D13S319 and an aqua-labeled probe hybridizing to the LAMP1 gene region at 13q34.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15, and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

The most frequently deleted region in B-CLL is located in 13q14.3 distal to RB1. The minimal deleted region (MDR) is 350 kb in size and includes the gene loci for the mi-RNAs 15 and 16. CLL with 13q deletion as the sole cytogenetic abnormality usually have a good prognosis.

Deletions of chromosomal region 13q14 have also been reported in a variety of human tumors, including other types of lymphoid tumors and myeloid leukemias, as well as prostate, head and neck, and non-small-cell lung cancers.

Expected Patterns

Normal Cell

Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell

Three green (3G), two orange (2O), and two blue (2B) signals.




Aberrant Cell

Two green (2G), one orange (1O), and two blue (2B) signals.



Aberrant Cell

Two green (2G), one orange (1O), and one blue (1B) signal.



v10.1

Literature

- Doehner et al (2000) N Engl J Med 34:1910-1916
- DeWald et al (2003) Brit J Haem 121:287-295
- Nelson et al (2007) Am J Clin Pathol 128:323-332

Order No:
D-5067-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL DLEU/TP53

XL DLEU/TP53 consists of an orange-labeled probe hybridizing to the DLEU1/MIR 15A/MIR 16-1 gene region at 13q14.2 including D13S319 and a green-labeled probe hybridizing to the TP53 gene region at 17p13.

The prognosis and clinical course of chronic lymphocytic leukemia (CLL) are heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent *in situ* hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH, abnormalities can be detected in more than 80% of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10% of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.

TP53 is a tumor suppressor gene which stops cell division when DNA damage is present. Loss of TP53 at 17p13 is a powerful predictor of resistance to therapy with purine analogues and alkylating agents and poor prognosis in CLL. The most frequently deleted region in B-CLL is located in 13q14.3 distal to RB1. The minimal deleted region (MDR) is 350kb in size and includes the gene loci for the mi-RNAs 15 and 16. CLL with 13q deletion as the sole cytogenetic abnormality (del13q-only) usually have a good prognosis.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal, indicating a deletion in 13q14.



Aberrant Cell (typical results)
One green (1G) and two orange (2O) signals, indicating a deletion in 17p13.

Literature

- Doehner et al (2000) N Engl J Med 34:1910-1916
- Stilgenbauer et al (2002) Leukemia 16:993-1007
- Gunn et al (2008) J Mol Diagn 10:442-451

XL TCRA/D

XL TCRA/D consists of an orange-labeled probe hybridizing proximal to the TCRA/D gene region at 14q11.2 and a green-labeled probe hybridizing distal to TCRA/D gene region at 14q11.2.

Chromosomal aberrations with breakpoints in T-cell receptor (TCR) gene loci are recurrent in several T-cell malignancies. The chromosomal alterations juxtapose oncogenes next to TCR regulatory sequences leading to deregulated expression of those oncogenes.

T-cell prolymphocytic leukemia (T-PLL) harbors frequent alterations of the TCRA/D locus, usually caused by an inv(14)(q11q32). By molecular cytogenetic studies, the incidence of TCRA/D rearrangements is about 24% of all T-cell acute lymphoblastic leukemia (T-ALL) cases.

Expected Patterns


Normal Cell

Two green-orange fusion signals (2GO).



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the TCRA/D locus.



Literature

- Gesk et al (2003) Leukemia 17:738-745
- Leich et al (2007) J Pathol 213:99-105
- Feldman et al (2009) Am J Clin Pathol 130:178-185

Order No:
D-5107-100-OG

Size: **100 µl**

XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL IGH BA

XL IGH BA consists of an orange-labeled probe partly covering the constant region of the IGH locus at 14q32.3 and a green-labeled probe hybridizing to the variable distal region of the IGH locus at 14q32.3.


Chromosomal translocations affecting the immunoglobulin heavy chain (IGH) locus at 14q32.3 are recurrent in many types of lymphomas and plasma cell neoplasms. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus.

Burkitt lymphoma (BL) is a rare but fast growing type of non-Hodgkin lymphoma (NHL). The translocation between the MYC gene locus at 8q24 and the immunoglobulin genes (IG) for the kappa light chain at 2p12 (IGK), for the heavy chain at 14q32 (IGH) or for the lambda light chain at 22q11 (IGL) juxtapose the MYC gene to an IG enhancer. About 80% of BL patients have the MYC rearrangement t(8;14) while approximately 10% show a translocation between the MYC gene region and IGK or IGL.


Follicular lymphoma (FL) is the most common indolent form of the NHL. The reciprocal translocation t(14;18) is observed in about 85% of patients with FL and results in overexpression of the BCL-2 protein which is involved in the regulation of apoptosis.

About 1% of all cancers and 10% of hematologic malignancies are caused by multiple myelomas (MM). Translocations affecting the IGH locus are observed in about 40% of MM cases.

Due to the telomeric position of the IGH locus, 14q32.3 translocations may be easily missed by conventional cytogenetics. FISH is therefore a valuable tool in the diagnostic of translocations affecting the IGH locus.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.

Literature

- Freedman (2014) Am J Hematol 89:429-436
- Rajan and Rajkumar (2015) Blood Canc J 5:1-7
- Nguyen et al (2017) Genes 8:1-23

XL t(14;16) IGH/MAF DF

XL t(14;16) IGH/MAF DF consists of a green-labeled probe hybridizing to the IGH gene region at 14q32.3 and an orange-labeled probe hybridizing to the WWOX/MAF gene region at 16q23.

The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunoglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. The consequence of these rearrangements is the dysregulation of genes juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk stratification strongly depend on the detection and interpretation of cytogenetic primary abnormalities. t(14;16) and t(14;20) are considered as high risk, t(4;14) as intermediate risk and t(6;14) and t(11;14) as standard risk cytogenetic aberrations in patients with MM based on FISH testing. Secondary aberrations are also influencing the outcome.

MAF overexpression caused by t(14;16)(q32;q23) increases gene expression levels of the downstream target genes cyclin D2 and integrin beta 7 and contributes to the pathogenesis of MM by at least two mechanisms. Cyclin D2 is a major player in cell cycle regulation and Cyclin D2 dysregulation promotes tumor development. Furthermore, overexpression of integrin beta 7 affects the interaction between myeloma cells and bone marrow stroma and thus promotes transformation of malignant plasma cells.

Expected Patterns


Normal Cell

Two green (2G) and two orange signals (2O).



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



Literature

- Chesi et al (1998) Blood 91:4457-4463
- Hurt et al (2004) Cancer Cell 5:191-199
- Rajan and Rajkumar (2015) Blood Cancer J 5:e365

Order No:
D-5113-100-OG


Size: 100 µl

XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe **XL**

XL t(14;18) IGH/BCL2 DF

XL t(14;18) IGH/BCL2 DF consists of a green-labeled probe hybridizing to the IGH gene region at 14q32.3 and an orange-labeled probe hybridizing to the BCL2 gene region at 18q21.3.

Rearrangements of the immunoglobulin heavy chain (IGH) gene locus are present in about 50% of all non-Hodgkin lymphomas (NHL) including follicular lymphomas (FL) and diffuse large B-cell lymphomas (DLBCL). FL is the most common indolent form of NHL and accounts for about 20-30% of all lymphoid tumors. The reciprocal translocation t(14;18) (q32;q21) can be detected in about 85% of FL patients and in up to 35% of patients with DLBCL. t(14;18) juxtaposes BCL2 to transcriptional enhancers in the IGH locus and results in overexpression of the BCL-2 protein in neoplastic follicles. BCL2 is involved in the regulation of programmed cell death and shows anti-apoptotic characteristics. Overexpression of BCL2 leads to a high number of B-cells having a prolonged lifespan in germinal centers. This increases the chance to acquire additional chromosomal alterations required for the neoplastic transformation of B-cells. Secondary aberrations promoting the transformation process are among others t(14;18) and deletion of the TP53 and CDKN2A genes.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.

Literature

- Bernicot et al (2005) Anticancer Res 25:3179-3182
- Ott and Rosenwald (2008) Haematologica 93:1773-1776
- Freedman (2014) Am J Hematol 89:429-436

XL t(14;18) IGH/MALT1 DF

XL t(14;18) IGH/MALT1 DF consists of a green-labeled probe hybridizing to the IGH gene region at 14q32.3 and an orange-labeled probe hybridizing to the MALT1 gene region at 18q21.3.

MALT (mucosa-associated lymphoid tissue) lymphomas occur at diverse anatomic sites and are closely linked to several distinct chronic inflammatory disorders. Up to 50% of the MALT lymphoma cases analyzed demonstrate MALT1 rearrangements. The MALT1 gene was originally identified by its involvement in the MALT lymphoma associated translocation t(11;18)(q21;q21). This rearrangement is detected in 30% of all cases of MALT lymphoma and leads to BIRC3-MALT1 fusions. It is restricted to MALT lymphomas and has not been detected in nodal or splenic marginal zone lymphomas, diffuse large B-cell lymphomas, or other non-Hodgkin lymphomas.

Approximately 20% of MALT lymphoma cases analyzed are characterized by t(14;18)(q32;q21) leading to a IGH-MALT1 fusion. This reciprocal translocation juxtaposes MALT1 to transcriptional enhancers in the IGH locus and results in overexpression of the MALT1 gene. The distinct breakpoints on both chromosomes are precisely defined. The oncogenic potential of MALT1 is linked to its participation in the activation of nuclear factor-kappa B (NF-κB). This important transcription factor mediates the expression of anti-apoptotic, cell survival- and proliferation-promoting genes. Furthermore, there is emerging evidence indicating an oncogenic cross-link between the above-mentioned genetic rearrangements and immunological stimulation occurring during the pathogenesis of MALT lymphoma.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.



v10.1

Literature

- Streubel et al (2003) Blood 101:2335-2339
- Bacon et al (2007) J Clin Pathol 60:361-372
- Du (2017) Best Pract Res Clin Haematol 30:13-23

Order No:
D-5146-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe

XL

XL IGH/MAFB DF

XL IGH/MAFB DF consists of a green-labeled probe hybridizing to the IGH gene region at 14q32.3 and an orange-labeled probe hybridizing to the MAFB gene region 20q12.

The most frequent primary abnormalities in multiple myeloma (MM) are trisomies of odd-numbered chromosomes or translocations involving the immunoglobulin heavy chain (IGH) gene locus. The most common MM-associated IGH translocations are t(11;14), t(4;14), t(6;14), t(14;16) and t(14;20) in the order of their occurrence. As a consequence, translocation partner genes of IGH are dysregulated, as they are juxtaposed to transcriptional enhancers in the IGH locus. Prognosis and risk classification are strongly associated with the detection and interpretation of cytogenetic primary abnormalities. According to the International Myeloma Working Group (IMWG), risk classification of MM by FISH based analysis of IgH locus involving translocations represents one column of the entire diagnostics. Secondary effects are also influencing the outcome. Even if associated with poor prognosis in MM, MGUS/SMM cases characterized by the presence of t(14;20) can be stable for years before progression occurs, whereas MGUS/SMM cases with t(4;14) and t(14;16) show a significantly faster progression rate. The recurrent translocation t(14;20) (q32;q12) results in ectopic expression of the basic leucine zipper transcription factor MAFB (Vmaf musculoaponeurotic fibrosarcoma oncogene homolog B) which plays an important role in lineage-specific hematopoiesis. Furthermore, t(14;20) is associated with poor prognosis by promoting high cyclin D2 activity, thereby dysregulating normally balanced cell cycle.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange (2GO) resulting from a reciprocal translocation between the relevant loci.

Literature

- Boersma-Vreugdenhil et al (2004) Brit J Haem 126:355-363
- Ross et al (2010) Haematologica 95:1221-1225
- Rajan and Rajkumar (2015) Blood Cancer J 5:e365

Order No:
D-5086-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Translocation/Dual Fusion Probe **XL**

XL t(15;17) DF

XL t(15;17) DF consists of an orange-labeled probe hybridizing to the PML gene region at 15q24 and a green-labeled probe hybridizing to the RARA gene region at 17q21.1-21.2.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

AML M3 and AML M3v are characterized by a reciprocal translocation between the long arm of chromosome 15 and the long arm of chromosome 17. This translocation leads to a rearrangement of the PML gene situated on chromosomal band 15q24 and the RARA gene situated on band 17q21. The PML-RARA rearrangement has gained major clinical importance because, in combination with all-trans retinoic acid (ATRA) and conventional anthracycline and cytarabine based chemotherapy, it leads to an improved prognosis in this subgroup of AML.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.

Literature

- Grimwade et al (2000) Blood 96:1297-1308
- Schoch et al (2002) Hematol J 3:259-263
- Campbell et al (2013) BioMed Res Int: Article ID 164501

XL CBFB

XL CBFB consists of an orange-labeled probe hybridizing proximal to the CBFB gene region at 16q21-22 and a green-labeled probe hybridizing distal to the CBFB gene region at 16q22.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myelogenous leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

The inv(16) and related t(16;16) are found in 10% of all cases of de novo AML. In these rearrangements, the core binding factor b (CBFB) gene on 16q22 is fused to the smooth muscle myosin heavy chain gene (MYH11) on 16p13. This cytogenetic group is usually associated with high complete remission rates and a relatively favorable outcome, especially when treated with repetitive cycles of high-dose cytarabine as consolidation therapy.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Literature

- Doehner et al (2010) Blood 115:453-474
- Froehling et al (2002) J Clin Oncol 20:2480-2485
- Arber et al (2016) Blood 127:2391-2405

Order No:
D-5126-100-OG

Size: 100 µl

XCytting Locus-Specific Probes
Translocation/Dual Fusion Probe


XL

XL CBFB/MYH11 plus

XL CBFB/MYH11 plus consists of a green-labeled probe hybridizing to the MYH11 gene region at 16p13.1 and an orange-labeled probe hybridizing to the CBFB gene region at 16q22.

Acute myeloid leukemia (AML) with $inv(16)(p13.1;q22)$ and $t(16;16)(p13.1;q22)$ is listed in the World Health Organization (WHO) classification of tumors of the haematopoietic and lymphoid tissues. These recurrent rearrangements are present in about 10% of young AML patients. In cases with $inv(16)/t(16;16)$, the core binding factor b (CBFB) gene on 16q22 is fused with the smooth muscle myosin heavy chain gene (MYH11) on 16p13.1. Patients carrying $inv(16)/t(16;16)$ usually have a good prognosis. Cryptic insertions with no indication in cytogenetic analyses have been published. In these cases, a partial insertion of MYH11 into CBFB or a partial insertion of CBFB into the MYH11 gene was observed.

FISH probes with a break apart design might overlook this cryptic rearrangement because no separation of flanking regions of CBFB occurs, whereas translocation/dual fusion FISH probes are indicating this kind of cryptic rearrangement. FISH is a complementary method for the detection of $inv(16)/t(16;16)$ increasing the sensitivity in combination with conventional cytogenetics. Furthermore, FISH is a valuable tool for cases without assessable metaphases.




Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.



Aberrant Cell (typical results)
Two green (2G), one orange (1O), and one green-orange colocalization/fusion signal (1GO) resulting from an insertion of parts of the green labeled chromosomal region into the orange labeled region.



Aberrant Cell (typical results)
One green (1G), two orange (2O), and one green-orange colocalization/fusion signal (1GO) resulting from an insertion of parts of the orange labeled chromosomal region into the green labeled region.

Literature

- Fröhling et al (2005) *Haematologica* 90:194-199
- Van Obbergh et al (2014) *Cancer Genetics* 207:231-232
- Zhang et al (2017) *Adv in Mod Onc Res* 3:12-14

XL FUS BA

XL FUS BA consists of an orange-labeled probe hybridizing proximal to the FUS gene region at 16p11.2 and a green-labeled probe hybridizing distal to the FUS gene region at 16p11.2.

Myxoid liposarcomas (MLS) are accounting for about 30% of liposarcomas and represent approximately 10% of adult soft tissue sarcomas. Patients with MLS showing progression to round-cell morphology have an inferior outcome. The most common aberration in MLS is the translocation $t(12;22)(q13;q12)$, in which FUS is not involved. These reciprocal translocations are resulting in the generation of FUS-DDIT3 and EWSR1-DDIT3 fusion genes, respectively. As FUS is also involved in the development of low-grade fibromyxoid sarcoma with the rearrangement $t(7;16)(q33;p11)$, FUS rearrangements are not highly specific for the detection of MLS. Human models of sarcomagenesis suggest that the FUS-DDIT3 fusion gene impedes with adipogenic differentiation of mesenchymal stem cells and thereby contributes to the development of liposarcoma.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.



Literature

- Knight et al (1995) Cancer Res 55:24-27
- Tanas et al (2009) Adv Anat Pathol 16:383-391
- Rodriguez et al (2013) Stem Cells 31:2061-2072

Order No:
D-6010-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Amplification Probe **XL**


XL ERBB2 (HER2/NEU) amp

XL ERBB2 (HER2/NEU) amp consists of an orange-labeled probe hybridizing to the ERBB2 (HER2/NEU) gene region at 17q12 and a green-labeled probe hybridizing to the centromere of chromosome 17.

Amplification or over-expression of the ERBB2 (HER2/NEU) gene occurs in approximately 15-30% of breast cancers. It is strongly associated with increased disease recurrence and a poor prognosis. Over-expression is also known to occur in ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.

ERBB2, located on the long arm of human chromosome 17 (17q12), is a member of the epidermal growth factor receptor (EGFR/ErbB) family which is composed of four plasma membrane-bound receptor tyrosine kinases. Signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis.

ERBB2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin®).




Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G), one orange (1O), and orange signal clusters, indicating amplification of ERBB2 (homogenous staining region = HSR).



Aberrant Cell (typical results)
Two green (2G) and multiple copies of orange signals, indicating amplification of ERBB2 (double minutes = dm).

Literature

- Isola et al (1999) Clin Cancer Res 5:4140-4145
- Blancato et al (2004) Br J Cancer 90:1612-1619
- Singhi et al (2012) Mod Pathol 25:378-387

XL RARA BA

XL RARA BA consists of an orange-labeled probe hybridizing proximal to the RARA gene region at 17q21.1-21.2 and a green-labeled probe hybridizing distal to the RARA gene region at 17q21.1-21.2.

Acute promyelocytic leukemia (APL) is considered as a subtype of acute myeloid leukemia (AML) and accounts for about 5-8% of all AML cases. The most frequent aberration in APL is t(15;17) which results in the formation of the promyelocytic leukemia (PML) - retinoic acid receptor alpha (RARA) fusion gene (PML-RARA). Around 98% of all APL cases are characterized by PML-RARA, whereas translocations affecting RARA and other genes have been identified in only 1-2% of APL cases. Known fusion genes are ZBTB16-RARA, NPM1-RARA, NUMA1-RARA, STAT5B-RARA, PRKAR1A-RARA, BCOR-RARA and FIP1L1-RARA. ZBTB16-RARA comprises about 0.8% of all APL cases, the other rare fusions occur with lower frequency. Cryptic rearrangements resulting in the PML-RARA fusion gene are observed regularly, but also insertions of RARA into other locations have been found in a minority of APL cases.

RARA is a nuclear hormone receptor which forms heterodimers with the retinoid X receptor alpha and is involved in the regulation of promyelocyte differentiation. RARA fusion genes interfere with myeloid differentiation and contribute to the development of APL. The majority of APL patients are responsive to therapeutic doses of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) associated with chemotherapeutic drug regimen. Patients with ZBTB16-RARA or STAT5B-RARA fusions are resistant to ATRA and ATO.

The FISH break apart assay is a valuable tool for the detection of RARA rearrangements independent of the translocation partner.

Expected Patterns


Normal Cell

Two green-orange fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.



Literature

- Grimwade et al (2000) Blood 15:1297-1308
- Schoch et al (2002) Hematol J 3:259-263
- Adams and Nassiri (2015) Arch Pathol Lab Med 139:1308-1313

Order No:
D-5048-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Amplification/Deletion Probe **XL**

XL Iso(17q)


XL Iso(17q) consists of a green-labeled probe hybridizing to the TP53 gene region at 17p13 and an orange-labeled probe hybridizing to the MPO gene region at 17q22.

An isochromosome of the long arm of chromosome 17, i(17q), is the most frequent genetic abnormality observed during the disease progression of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). The breakpoints are located in the short arm of chromosome 17 within the Smith-Magenis critical region at 17p11. In neuroblastoma and other hematologic malignancies, amplification of 17q is a significant predictive factor for adverse outcome.

Isochromosome 17q, or i(17q), is occurring in primitive neuroectodermal tumor/medulloblastoma (50%), chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS).



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical result)
One green (1G) and three orange (3O) signals, indicating the presence of i(17q).



Aberrant Cell (typical results)
Two green (2G) and three orange (3O) signals, indicating a gain of 17q.



Aberrant Cells (typical results)
One green (1G) and two orange (2O) signals, indicating a deletion of the TP53 locus.

Literature

- Fioretos et al (1999) Blood 94:225-232
- Barbouti et al (2004) Am J Hum Genet 74:1-10
- Carvalho et al (2008) Genome Res 18:1724-1732

XL TP53/17cen

XL TP53/17cen consists of an orange-labeled probe hybridizing to the TP53 gene region at 17p13 and a green-labeled probe hybridizing to the centromere of chromosome 17.

TP53 is a central tumor suppressor gene involved in DNA repair, differentiation, cell cycle arrest and apoptosis. It is regarded as the “guardian of the genome” because of its role in conserving genome stability. TP53 alteration due to mutation or deletion plays a crucial role in tumorigenesis and is generally associated with advanced stages of disease, insufficient response to therapy and poor prognosis.

TP53 is also the most frequently mutated gene in human cancer with a mutation frequency of up to 90% in solid tumors and an average of 10% alterations in hematologic malignancies. TP53 deletions are often associated with mutations of the second allele, supporting the “two-hit” hypothesis of cancer development. If both mutation and deletion of TP53 are present, there is a significant negative impact on overall survival in hematological malignancies. In multiple myeloma, 33.8% of newly diagnosed patients carry a TP53 deletion, with even higher frequencies at relapse (54.5%). In acute myeloid leukemia (AML), 13% of patients show TP53 alterations, including 5% with mutations and deletions and 1% with deletion only. Patients with myelodysplastic syndrome (MDS) show TP53 alterations in 7% of the cases, including 1% with mutations and deletions and 1% with deletion only. In AML and MDS, TP53 alterations and 17p deletion are associated with a complex karyotype, poor response to therapy, and reduced survival. In MDS, even TP53 deletion without mutation of the second allele has a significant negative impact on overall survival.

Deletions in TP53 frequently result from larger deletions of the short arm of chromosome 17. Interphase FISH for TP53 at 17p13 can be used to determine deletions of TP53 even in cells with a low proliferative capacity.

Expected Patterns


Normal Cell

Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Drach et al (1998) Blood 92:802-809
- Soenen et al (1998) Blood 91:1008-1015
- Stengel et al (2017) Leukemia 31:705-711

Order No:
D-5089-100-OG

Size: 100 µl


XCytting Locus-Specific Probes
Deletion Probe **XL**

XL TP53/NF1

XL TP53/NF1 consists of an orange-labeled probe hybridizing to the TP53 gene region at 17p13 and a green-labeled probe hybridizing to the NF1 gene region at 17q11.2.

TP53 is a tumor suppressor gene often described as the guardian of the genome. Deletions and/or mutations can be detected in a wide range of hematological neoplasms and are the most common genetic aberrations in human cancer. The neurofibromin 1 gene (NF1), located at 17q11.2, is a tumor suppressor gene negatively regulating the RAS signal transduction pathway. Germline-loss of function can cause neurofibromatosis type I, a congenital genetic disorder of the nervous system which usually appears during childhood. Somatic deletions of NF1 are detected in about 3.5-7% of de novo acute myeloid leukemia (AML) cases and are often associated with a complex aberrant karyotype. Mutations in the remaining NF1 allele are reported with varying frequency. NF1 deleted cells have a decreased sensitivity to Ara-C in cell culture studies.

FISH is a valuable tool for the detection of NF1 deletions which might be easily overlooked by conventional cytogenetics due to the small size of the aberration.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal, indicating a deletion of the TP53 locus.



Aberrant Cell (typical results)
One green (1G) and one orange (1O) signal indicating the deletion of the TP53 and NF1 locus.



Aberrant Cell (typical results)
Three green (3G) and one orange (1O) signal, indicating the presence of isochromosome 17q.

Literature

- Haferlach et al (2012) Leukemia 26:834-839
- Boudry-Labis et al (2013) Am J Hematol 88:306-311
- Tessoulin et al (2017) Blood Rev:doi.org/10.1016/j.blre.2017.03.001

XL BCL2 BA

XL BCL2 BA consists of an orange-labeled probe hybridizing proximal to the BCL2 gene region at 18q21.3 and a green-labeled probe hybridizing distal to the BCL2 gene region at 18q21.3.

The BCL2 gene rearrangement can be found in 50% of follicular lymphoma, 23.3% of B-cell lymphoma, and about 15% of diffuse large B-cell lymphoma. A consequence of this translocation is an overexpression of anti-apoptotic protein BCL2, which most likely represents the initial step of malignant transformation.

The majority of rearrangements in BCL2 occur at two distinct chromosomal regions, the major breakpoint cluster region (MBR) in 70% and the minor cluster region in 10% of patient's tumors.

FISH has been shown to be of higher sensitivity and of equivalent specificity when compared to PCR on paraffin-embedded tissue sections.

Expected Patterns


Normal Cell

Two green-orange (2GO) fusion signals representing the two normal BCL2 loci.



Aberrant Cell (typical results)

One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the BCL2 locus.



Literature

- Vaandrager et al (2000) Blood 96:1947-1952
- Godon et al (2003) Leukemia 17:255-259
- Weinberg et al (2007) J Mol Diagn 9:530-537

Order No:
D-6015-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL MALT1 BA


XL MALT1 BA consists of an orange-labeled probe hybridizing proximal to the MALT1 gene region at 18q21.3 and a green-labeled probe hybridizing distal to the MALT1 gene region at 18q21.3.

The MALT1 gene was identified through its involvement in t(11;18)(q21;q21), seen in 30% of cases of mucosa-associated lymphoid tissue (MALT) lymphoma. The t(11;18)(q21;q21) is restricted to MALT lymphomas and has not been detected in nodal or splenic marginal zone lymphomas, diffuse large B-cell lymphomas, or other non-Hodgkin lymphomas. The second most frequent translocation identified in MALT lymphoma is the t(14;18)(q32;q21) IGH/MALT1. The t(14;18)(q32;q21) IGH/MALT1 is found most often in MALT lymphomas arising at non-gastric sites and is identified in 5-25% of cases arising in the ocular adnexa, lung, salivary gland and skin.

The oncogenic activity of MALT1 is linked to its involvement of the CARMA1-BCL10-MALT1 (CBM) complex in antigen receptor-mediated activation of the transcription factor NF-κB, which controls the expression of numerous anti-apoptotic and proliferation-promoting genes.



Expected Patterns



Normal Cell
Two green-orange (2GO) fusion signals.



Aberrant Cell (typical results)
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the MALT1 locus.

Literature

- Streubel et al (2003) Blood 101:2335-2339
- Murga Penas et al (2003) Leukemia 17:2225-2229
- Bacon et al (2007) J Clin Pathol 60:361-372

XL SS18 BA


XL SS18 BA consists of an orange-labeled probe hybridizing proximal to the SS18 gene region at 18q11.2 and a green-labeled probe hybridizing distal to the SS18 gene region at 18q11.2.

Synovial sarcoma is a highly aggressive and relatively rare soft tissue sarcoma. It often develops in the limbs of adolescents and young adults and comprises about 10-20% of soft tissue sarcomas in this population. The disease is characterized by the balanced translocation t(X;18) resulting in an in-frame fusion of 'synovial sarcoma translocation, chromosome 18' (SS18) with members of the 'synovial sarcoma, X breakpoint' family (SSX), located on the X chromosome. The chimeric fusion protein consists of almost the complete SS18 protein, only eight amino acids are missing, with the carboxy terminus of SSX1 or SSX2 and in rare cases SSX4. Several studies have shown that the SS18-SSX chimeric protein is interacting with the ATP-dependent chromatin remodeling complex SWI/SNF, interfering with its proper function. The absence of the der(18) in some cases suggests that it is not mandatory for the maintenance of the tumor. Generally, synovial sarcoma shows a low genetic complexity, about 50% of the cases harbor t(X;18) as a sole aberration. Since cytogenetic analysis of solid tumors is challenging, FISH provides an alternative method for the characterization of the status of SS18-SSX rearrangements.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.



Literature

- Shipley et al (1996) Am J Pathol 148:559-567
- Surace et al (2004) Lab Invest 84:1185-1192
- Nielsen et al (2015) Cancer Discov 5:124-134

Order No:
D-6019-100-OG


Size: 100 µl

XCyting Locus-Specific Probes
Deletion Probe **XL**

XL 19p/19q del

XL 19p/19q del consists of a green-labeled probe hybridizing to the ZNF443 gene region at 19p13.2 and an orange-labeled probe hybridizing to the GLTSCR1/ GLTSCR2 gene region at 19q13.3.

The 2016 'World Health Organization Classification of Tumors of the Central Nervous System' (WHO 2016) combines, for the first time, histological features and molecular signatures for the definition of many tumor entities. Gliomas are a category of tumors of the brain and spinal cord originating in glia cells. Oligodendrogliomas are a subtype of gliomas accounting for up to 18% of all cases. According to the WHO 2016, the classification of an oligodendroglioma requires information about the isocitrate dehydrogenase mutation status and 1p/19q loss of heterozygosity (LOH). LOH of 19q can be detected in about 80% of oligodendroglial tumors and to a lower extent in mixed gliomas. Co-deletion of 1p/19q is a well-accepted prognostic biomarker in neuro-oncology. Patients suffering from anaplastic oligodendroglioma harboring 1p/19q deletion generally have a good prognosis. Co-deletion of 1p/19q also has a predictive character, the molecular status of 1p/19q is relevant for therapy decisions.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

- Reifenberger et al (1994) Am J Pathol 145:1175-1190
- Louis et al (2016) Acta Neuropathol 131:803-820
- Staedtke et al (2016) Trends Cancer 2:338-349

XL BCL3 BA

XL BCL3 BA consists of an orange-labeled probe hybridizing proximal to the BCL3 gene region at 19q13.3 and a green-labeled probe hybridizing distal to the BCL3 gene region at 19q13.3.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The clinical course is heterogeneous and ranges from good outcome to very aggressive and fast progressing disease. CLL is not characterized by a well-defined chromosomal translocation as many other lymphoid neoplasms. The most frequent aberrations are deletions on 6q21 (3-6%), 11q22-23 (5-20%), 13q14.3 (>50%) or 17q13.1 (3-8%) and trisomy 12 (10-20%).

The recurrent t(14;19)(q32.3;q13.3) is a rare event with an incidence of <0.1% in B-cell neoplasms and is often associated with trisomy 12 or a complex karyotype. It is also considered as a poor prognostic marker in CLL with inferior outcome. The translocation juxtaposes BCL3 with the immunoglobulin heavy chain gene region on chromosome 14, resulting in overexpression of BCL3. BCL3 is an oncogene involved in the regulation of NF-kappa-B target genes.

Since it is difficult to obtain metaphases from CLL patients, interphase FISH offers great advantage over conventional cytogenetics.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the relevant locus.



Literature

- Michaux et al (1996) Genes Chrom Can 15:38-47
- Huh et al (2011) Am J Clin Pathol 135:686-696
- Puiggros et al (2014) Biomed Res Int 2014:Article ID 435983

Order No:
D-5121-100-OG

Size: 100 µl


XCytting Locus-Specific Probes
Deletion Probe **XL**

XL 20q12/20qter plus

XL 20q12/20qter plus consists of an orange-labeled probe hybridizing to the PTPRT gene region at 20q12 and a green-labeled probe hybridizing to a region at 20q13.3.

Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders associated with ineffective hematopoiesis and peripheral blood cytopenias. Approximately 40% of MDS cases are progressing to acute myeloid leukemia. In about 50% of de novo MDS, cytogenetic aberrations are observed; deletions are predominant, translocations are rare. Recurrent abnormalities are del(5q), monosomy 7, del(7q), del(20q), del(17p) and del(11q).

A chromosome 20q deletion is seen in about 2% of MDS cases. Patients with a sole del(20q) have a favourable outcome compared to patients with additional abnormalities such as del(5q), del(7q), monosomy 7 and trisomy 8. The majority of patients with del(20q) have an interstitial deletion between 20q11.2 and 20q13.3. In rare cases, the 20q deletion can occur as an isoderivative chromosome ider(20q) with loss of the p-arm of chromosome 20 and partial trisomy of the remaining regions on the q-arm.



Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Aberrant Cell (typical results)
Three green (3G) and one orange (1O) signal resulting from the presence of ider(20q).

Literature

- Kurtin et al (1996) Am J Clin Pathol 106:680-688
- Douet-Gilbert et al (2008) Br J Haematol 143:716-720
- Bacher et al (2014) Br J Haematol 164:822-833

XL 20q12/20qter/8cen plus

XL 20q12/20qter/8cen plus consists of an aqua-labeled probe hybridizing to the centromere of chromosome 8, an orange-labeled probe hybridizing to the PTPRT gene region at 20q12 and a green-labeled probe hybridizing to a region at 20q13.3.

Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders associated with ineffective hematopoiesis and peripheral blood cytopenia. MDS patients have a high risk of progressing to acute leukemia. In about 50% of de novo MDS, cytogenetic aberrations are observed. A chromosome 20q deletion is seen in about 2% of MDS cases. Patients with a sole del(20q) have a favorable outcome. About 30% of all del(20q) patients are carrying additional recurrent chromosomal abnormalities such as del(5q), monosomy 7, del(7q) and trisomy 8. The presence of three or more additional aberrations is associated with an inferior outcome. In rare cases, the 20q deletion can occur as an isoderivative chromosome ider(20q) with loss of the p-arm of chromosome 20 and partial trisomy of the remaining regions on the q-arm. The knowledge of the cytogenetic status in MDS patients is of prognostic significance.

Expected Patterns

Normal Cell

Two blue (2B), two green (2G), and two orange (2O) signals.



Aberrant Cell (typical results)

Two blue (2B), two green (2G), and one orange (1O) signal resulting from the loss of one orange signal.




Aberrant Cell (typical results)

Three blue (3B), two green (2G), and one orange (1O) signal resulting from the loss of one orange signal and a trisomy of the blue labeled chromosome.



Aberrant Cell (typical results)

Two blue (2B), three green (3G), and one orange (1O) signal resulting from the presence of ider(20q).



Literature

- Solé et al (2005) Haematologica 90:1168-1178
- Douet-Gilbert et al (2008) Br J Haematol 143:716-720
- Bacher et al (2014) Br J Haematol 164:822-833

Order No:
D-5119-100-OG

Size: 100 µl


XCyting Locus-Specific Probes
Deletion Probe **XL**

XL del(20q) plus

XL del(20q) plus consists of an orange-labeled probe hybridizing to the PTPRT gene region at 20q12 and a green-labeled probe hybridizing to the MYBL2 gene region at 20q13.1.

Myelodysplastic syndromes (MDS) are a group of hematopoietic stem cell disorders associated with ineffective hematopoiesis and peripheral blood cytopenias. MDS patients have a significant risk of progression to acute myeloid leukemia. In about 50% of de novo MDS, cytogenetic aberrations are observed; deletions are predominant, translocations are rare. Recurrent abnormalities are del(5q), monosomy 7, del(7q), del(20q), del(17p) and del(11q).

Del(20q) is a recurrent but rare aberration and is present in about 3-7% of MDS patients. The majority of cases have an interstitial deletion which is flanked by the PTPRT gene and includes the MYBL2 gene. Sole del(20q) is associated with a more favorable outcome.




Expected Patterns



Normal Cell
Two green (2G) and two orange (2O) signals.



Aberrant Cell (typical results)
Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Aberrant Cell (typical results)
One green (1G) and two orange (2O) signals resulting from loss of one green signal.



Aberrant Cell (typical results)
One green (1G) and one orange (1O) signal resulting from loss of one green and one orange signal.

Literature

- Bench et al (2000) Oncogene 19:3902-3913
- Saunders et al (2005) Cancer Genet Cytogen 156:154-157
- Bacher et al (2013) Brit J Heamtol 164:822-833

XL RUNX1

XL RUNX1 consists of an orange-labeled probe hybridizing proximal to the RUNX1 gene region at 21q22.1 and a green-labeled probe hybridizing distal to the RUNX1 gene region at 21q22.1.

Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features if 20% or more blood or marrow blasts are present.

The RUNX1 gene, located on chromosome 21q22.1, is crucial for the establishment of definite hematopoiesis and the generation of hematopoietic stem cells in the embryo. The most common translocations involving RUNX1 are the t(8;21) RUNX1T1/RUNX1 in AML and t(12;21) ETV6/RUNX1 in acute lymphoblastic leukemia (ALL), both associated with a more favorable diagnosis. More than 40 different translocation partners have currently been identified making the RUNX1 break apart probe a valuable tool in molecular cytogenetics.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Literature

- Martinez-Ramirez et al (2001) Haematologica 86:1245-1253
- Zhang et al (2002) PNAS 99:3070-3075
- Harrison et al (2014) Leukemia 28:1015-1021

Order No:
D-5117-100-OG

Size: **100 µl**


XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL 22q11 IGL BA


XL 22q11 IGL BA consists of an orange-labeled probe hybridizing proximal to the IGL gene region at 22q11.2 and a green-labeled probe hybridizing distal to the IGL gene region at 22q11.2.

The immunoglobulin (IG) genes for the kappa light chain at 2p12 (IGK), the lambda light chain at 22q11 (IGL) and the heavy chain at 14q32 (IGH) are recurrently involved in the development of non-Hodgkin lymphomas (NHL). By far most frequently involved is IGH with more than 30 partner genes, less frequently IGK and IGL. IG-translocations are leading to juxtaposition of proto-oncogenes with IG enhancer sequences resulting in overexpression of the respective oncogene. Chromosomal translocations involving c-MYC at 8q24 and IG genes frequently occur in Burkitt lymphoma (BL). BL is a rare but fast growing type of NHL which is rapidly fatal if left untreated. About 75% of BL patients are carrying the MYC rearrangement t(8;14) while the remainder show a translocation between MYC and IGK or IGL. MYC-IG rearrangements are also involved in other B-cell malignancies such as atypical Burkitt/Burkitt-like lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and multiple myeloma. Besides 8q24 (MYC), other translocation partners for IGL, such as chromosomal regions 2p13-14, 3q27 (BCL6), 4q13, 6p25, 16p12, 17p11.2 and 17q21, are known.

FISH break apart assays are valuable tools for the detection of IG light chain rearrangements independent of the translocation partner. Furthermore, double translocations have been described which are difficult to detect by PCR-based methods.



Expected Patterns



Normal Cell
Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.

Literature

- Martin-Subero et al (2002) Int J Cancer 98:470-474
- Einerson et al (2006) Leukemia 10:1790-1799
- Fujimoto et al (2008) Eur J Haematol 80:143-150

XL EWSR1 BA


XL EWSR1 BA consists of an orange-labeled probe hybridizing proximal to the EWSR1 gene region at 22q12.1-12.2 and a green-labeled probe hybridizing distal to the EWSR1 gene region at 22q12.2.

Ewing sarcoma (EWS) is a rare and highly aggressive cancer with an incidence of about three in one million Caucasians. The incidence in Africans is significantly lower. EWS is more common among children and young adults than in adults and mostly arises in bones and to lower extent in soft tissue. EWS is typified by chromosomal translocations resulting in fusion genes between the EWS RNA Binding Protein 1 (EWSR1) and a member of the group of ETS transcription factors. t(11;22)(q24;q12) is the most common of these translocations represented by the EWSR1-FLI1 fusion gene with a frequency of about 85%. The EWSR1 part contributes a strong transcriptional domain while FLI1 is providing the ETS family DNA binding domain. The chimeric protein is dysregulating target genes leading to oncogenic transformation and is absolutely required for tumorigenesis in EWS. Other translocation partners are known, but no difference in survival has been observed between different fusion genes. Although complex karyotypes are rare in EWS, gain of chromosome 1q, 8, 12 and loss of 9p21 (CDKN2A) and 16q is observed. The EWSR gene is expressed in several tissues and is involved in other tumor diseases. EWSR1 has manifold functions and is involved in different control mechanisms in the cell. EWS is genetically stable and complex karyotypes are rare.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the respective locus.



Literature

- Delattre et al (1992) Nature 359:162-165
- Smith et al (2006) Cancer Cell 9:405-416
- Sannino et al (2017) Future Oncol 13:1207-1211

Order No:
D-5130-100-OG

Size: 100 µl

XCyting Locus-Specific Probes
Break Apart Probe **XL**

XL CRLF2 BA


XL CRLF2 BA consists of an orange-labeled probe hybridizing proximal to the CRLF2 gene region at Xp22.33 and Yp11.32 and a green-labeled probe hybridizing distal to the CRLF2 gene region at Xp22.33 and Yp11.32.

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children (prevalence of approximately 1:1500). Children with Down syndrome have a 10- to 20-fold increased risk of developing acute leukemia. B-Cell dependent BCR-ABL1-like ALL, also known as Philadelphia chromosome (Ph)-like ALL, is a high-risk subset with a gene expression profile which shares significant overlap with that of Ph-positive (Ph+) ALL, but lacking the BCR-ABL1 fusion. In 2017, the WHO recognized BCR-ABL1-like ALL as a new entity.


Chromosomal rearrangements resulting in the overexpression of cytokine receptor like factor 2 (CRLF2) can be found in up to 50% of BCR-ABL1-like ALL cases. The CRLF2 gene is located in the pseudoautosomal region 1 (PAR1) of the X and the Y chromosome. Three genetic key mechanisms regarding CRLF2 and ALL are known. Firstly, the CRLF2 gene is placed under the control of the IGH enhancer. Translocations of the type t(X;14) or t(Y;14) are the genetic basis for this aberration. Secondly, fusion of CRLF2 to CSF2RA, a further PAR1 gene, has been described. Thirdly, cryptic interstitial deletions juxtaposing the initial non-coding exon of the purinergic receptor P2Y8 (P2RY8) and CRLF2 have been shown. The resulting P2RY8-CRLF2 fusion under the control of the P2RY8 promoter is strongly transcribed in lymphoid cells. CRLF2 rearrangements result in increased protein levels, which initiate significantly enhanced JAK/STAT signaling, whereby disproportionate JAK and subsequent STAT5 activation induces strongly enhanced B-cell activation and proliferation.

XL CRLF2 BA detects chromosomal aberrations resulting from CRLF2 gene rearrangements (deletions and translocations).

XL P2RY8 del (D-5150-100-OG) can be used as an additional tool in order to detect the presence of the P2RY8-CRLF2 fusion gene.



Expected Patterns




Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange colocalization/fusion signal (1GO), one separate green (1G) and one separate orange (1O) signal each resulting from a chromosome break in the relevant locus.



Aberrant Cell (typical results)

One green-orange (1GO) colocalization/fusion signal and one green (1G) signal resulting from the loss of one orange signal.

v10.1

Literature

- Roll and Reuther (2010) Cancer Res 70:7347-7352
- Yoda et al (2010) Proc Natl Acad Sci 107:252-257
- Tasian et al (2017) Blood 130:2064-2072

Clinical Applications

ALL

Chromosome

X

Page

103

XL P2RY8 del

XL P2RY8 del consists of an orange-labeled probe hybridizing to P2RY8 and proximal to the P2RY8 gene region Xp22.33 and Yp11.32 and a green-labeled probe hybridizing distal to the P2RY8 gene region at Xp22.33 and Yp11.32.

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children (prevalence of approximately 1:1500). Children with Down syndrome have a 10- to 20-fold increased risk of developing acute leukemia. B-Cell dependent BCR-ABL1-like ALL, also known as Philadelphia chromosome (Ph)-like ALL, is a high-risk subset with a gene expression profile which shares significant overlap with that of Ph-positive (Ph+) ALL, but lacking the BCR-ABL1 fusion. In 2017, the WHO recognized BCR-ABL1-like ALL as new entity.

Chromosomal rearrangements resulting in the overexpression of cytokine receptor like factor 2 (CRLF2) can be found in up to 50% of BCR-ABL1-like ALL cases. The CRLF2 gene is located in the pseudoautosomal region 1 (PAR1) of the X and the Y chromosome. CRLF2 rearrangements result in increased protein levels, which initiate significantly enhanced JAK/STAT signaling, whereby disproportionate JAK and subsequent STAT5 activation induces strongly enhanced B-cell activation and proliferation. One of the genetic mechanisms leading to constitutive overexpression of CRLF2 is a gene fusion of CRLF2 with another PAR1 gene, purinergic receptor P2Y8 (P2RY8). The resulting P2RY8-CRLF2 fusion under the control of the P2RY8 promoter is strongly transcribed in lymphoid cells.

XL P2RY8 del can be used to detect the presence of the P2RY8-CRLF2 fusion gene.

Expected Patterns


Normal Cell

Two green-orange colocalization/fusion signals (2GO).



Aberrant Cell (typical results)

One green-orange (1GO) colocalization/fusion signal and one green (1G) signal resulting from the loss of one orange signal.



v10.1

Literature

- Mullighan et al (2009) Nat Genet 41:1243-1246
- Russell et al (2017) Genes Chromosomes Cancer 56:363-372
- Tasian et al (2017) Blood 130:2064-2072

Order No:
D-5441-050-OG

Size: **50 µl**

XCytting Locus-Specific Probes

XL


XL 21q22 / XCP 21

The XL 21q22/XCP 21 is a combination of a whole chromosome paint 21 in green with an orange labeled locus-specific probe for 21q22. This probe allows analysis of copy numbers and structural aberrations of chromosome 21 on metaphase chromosomes.

This probe is not intended for use in analysis of trisomy 21 in prenatal diagnosis.

XL 21q22/XCP 21 hybridized to normal human metaphase spreads will result in green signals along the entire length of chromosome 21 combined with orange signals at 21q22 (Down Syndrome Critical Region 4).


A translocation with involvement of chromosome 21 will result in a split of a green signal. In this case, the green signal will be partially visible on the der(21) and the respective partner chromosome of the translocation. Depending on the localization of the breakpoint on the der(21), the signal of the locus-specific probe remains on the der(21) or will be observed on the translocation partner.



XL Acro-p

The XL Acro-p probe contains sequences which specifically hybridize to the short (p) arm of all human acrocentric chromosomes. The XL Acro-p FISH probe may replace conventional silver staining used to stain the NOR regions.

Variations in length of stalks and satellites of human acrocentric chromosomes are considered as normal variable chromosome features. However, cryptic translocations can result in unbalanced karyotypes but might be misinterpreted as common acrocentric short arm polymorphisms.



Literature

- Benzacken et al (2001) Prenat Diagn 21:96-98





XL

XCyting Locus-Specific Probes
... for Hematology / Oncology

7



XA

XCyting Locus-Specific Probes
... for Aneuploidy Detection

109



Microdeletion Probes

XCyting Locus-Specific Probes
... for Detection of Microdeletions

121



XCE

XCyting Centromere
Enumeration Probes

129



XCP

XCyting Chromosome Paints

135



XCyte mFISH

XCyting Multicolor
FISH Probes

141



XCyte mBAND

XCyting Multicolor
Banding Probes

145



Non-Human

Paints and mFISH Kits
... for Mouse, Rat and CHO

149



XRNA

XCyting RNA FISH Probes

155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XA 13/21

The XA 13/21 mix of specific probes allows detecting copy number variations for chromosomes 13 and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Duplications of chromosome bands q22.13-q22.2 have been shown to define the smallest region implicated in the causation of Down syndrome. Trisomy 13 syndrome is a rare chromosomal disorder in which all or a portion of chromosome 13 appears three times (trisomy). Based on molecular results, a region ranging from 13q14-13qter has been found to be critically involved in Patau syndrome.

Expected Patterns

Normal Cell

Two green (2G) and two orange (2O) signals.




Aberrant Cell

Trisomy 13
Three green (3G) and two orange (2O) signals.



Aberrant Cell

Trisomy 21
Two green (2G) and three orange (3O) signals.



v20.1

Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

Order No:
D-5607-100-TC

Size: 100 µl

XCyting Aneusomy Probes

XA

XA 13/18/21

The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Duplications of chromosome bands 21q22.13-q22.2 have been shown to define the smallest region implicated in the causation of Down syndrome. Trisomy 13 syndrome is a rare chromosomal disorder in which all or a portion of chromosome 13 appears three times (trisomy). Based on molecular results, a region ranging from from 13q14-13qter has been found to be critically involved in Patau syndrome. Most of the features of Edwards syndrome have been shown to be associated with duplication of the region 18q12.3-q22.1. A locus-specific probe for 18q21 gives clearer signals and provides less ambiguous results compared to a centromeric probe for chromosome 18.

Expected Patterns



Normal Cell

Two green (2G), two orange (2O), and two blue (2B) signals.



Aberrant Cell

Trisomy 13
Three green (3G), two orange (2O), and two blue (2B) signals.




Aberrant Cell

Trisomy 21
Two green (2G), three orange (3O), and two blue (2B) signals.



Aberrant Cell

Trisomy 18
Two green (2G), two orange (2O), and three blue (3B) signals.



Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

XA AneuScore I

The XA AneuScore I Probe Kit contains different probe mix, provided in separate test vials, for assessing chromosomal aneuploidies for chromosomes 13, 18, 21, X, and Y.

XA 13/21 (D-5602-100-OG):

The XA 13/21 mix of specific probes allows detecting copy number variations for chromosomes 13 and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

XA X/Y/18 (D-5606-100-TC):

The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. Nowadays, it is widely accepted to provide preliminary results for the detection of anomalies in less than 12 hours.


Available in two package sizes:

D-5604-100-TC XA AneuScore I, 10 Tests

D-5604-500-TC XA AneuScore I, 50 Tests

Expected Patterns

For signal patterns please refer to:
XA 13/21 (D-5602-100-OG) and XA
X/Y/18 (D-5606-100-TC).



Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

Order No:
D-5609-100-TC

Size: **2x 100 µl**

XCyting Aneusomy Probes **XA**

XA AneuScore II

The XA AneuScore II Probe Kit contains different probe mix, provided in separate test vials, for assessing chromosomal aneuploidies for chromosomes 13, 18, 21, X, and Y.

XA 13/18/21 (D-5607-100-TC):

The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

XA X/Y (D-5608-100-OG):

The XA X/Y mix of specific probes allows detecting copy number variations for chromosomes X and Y. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green and Y in orange.

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations considerably faster than conventional chromosome analysis. Nowadays, it is widely accepted to provide preliminary results for the detection of anomalies in less than 12 hours.


Available in two package sizes:

D-5609-100-TC XA AneuScore II, 10 Tests

D-5609-500-TC XA AneuScore II, 50 Tests

Expected Patterns

For signal patterns please refer to:
XA 13/18/21 (D-5607-100-TC) and
XA X/Y (D-5608-100-OG).



Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

XA AneuScore III

The XA AneuScore III Probe Kit contains different probe mixes, provided in separate test vials, for assessing chromosomal aneuploidies for chromosomes 13, 18, 21, X, and Y.

XA 13/18/21 (D-5607-100-TC):

The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

XA X/Y/18 (D-5606-100-TC):

The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Duplications of chromosome bands 21q22.13-q22.2 have been shown to define the smallest region implicated in the causation of Down syndrome. Trisomy 13 syndrome is a rare chromosomal disorder in which all or a portion of chromosome 13 appears three times (trisomy). Based on molecular results, a region from 13q14-13qter has been found to be critically involved in Patau syndrome. Most of the features of Edwards syndrome have been shown to be associated with duplication of the region 18q12.3-q22.1. A locus-specific probe for 18q21 gives clearer signals and provides less ambiguous results compared to a centromeric probe for chromosome 18. Repetitive sequences around the centromeric regions of chromosomes X and Y can reliably identify Klinefelter syndrome (47,XXY), Triple-X syndrome (47,XXX), Turner syndrome (45,X0), and 47,XYY.


Available in two package sizes:

D-5613-100-TC XA AneuScore III, 10 Tests

D-5613-500-TC XA AneuScore III, 50 Tests

Expected Patterns

For signal patterns please refer to: XA X/Y/18 (D-5606-100-TC) and XA 13/18/21 (D-5607-100-TC).



Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

Order No:
D-5601-100-OR

Size: **100 µl**

XCyting Aneusomy Probes


XA

XA 21q22

The XA 21q22 specific probe allows detecting copy number variations for chromosomes 21. The orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Duplications of chromosome bands 21q22.13-q22.2 have been shown to define the smallest region implicated in the causation of Down syndrome.



Expected Patterns



Normal Cell
Two orange (2O) signals indicating a chromosome 21 each.



Aberrant Cell
Trisomy 21
Three orange (3O) signals.

Literature

- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Ronan et al (2007) J Med Genet 44:448-451
- Korbelt et al (2009) Proc Natl Acad Sci USA 106:12031-12036

XA X/Y

The XA X/Y mix of specific probes allows detecting copy number variations for chromosomes X and Y. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green and Y in orange.

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Repetitive sequences around the centromeric regions of chromosomes X and Y can reliably identify Klinefelter syndrome (47,XXY), Triple-X syndrome (47,XXX), Turner syndrome (45,X0), and 47,XYY.

Expected Patterns

Normal Cell Female:
Two green (2G) signals.



Normal Cell Male:
One green (1G) and one orange (1O) signal.




Aberrant Cell Female:
Turner (45,X0)
One green (1G) signal.



Aberrant Cell Male:
Klinefelter (47,XXY)
Two green (2G) and one orange (1O) signal.



Aberrant Cell Male:
47,XYY
One green (1G) and two orange (2O) signals. Additional X-Chromosomes are possible (e.g. 48,XXYY; 52,XXXXXXYY)



v10.1

Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

Order No:
D-5606-100-TC

Size: 100 µl


XCyting Aneusomy Probes **XA**

XA X/Y/18

The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Repetitive sequences around the centromeric region of chromosome 18 can reliably determine Edward's syndrome, while chromosome X and Y specifically detect Klinefelter syndrome (47,XXY), Triple-X syndrome (47,XXX), Turner syndrome (45,X0), and 47,XYY.




Expected Patterns



Normal Cell Male:

One green (1G), one orange (1O), and two blue (2B) signals.



Normal Cell Female:

Two green (2G) and two blue (2B) signals.



Aberrant Cell Male:

Trisomy 18
One green (1G), one orange (1O), and three blue (3B) signals.



Aberrant Cell Female:

Trisomy 18
Two green (2G) and three blue (3B) signals.



Aberrant Cell Male:

Klinefelter (47,XXY)
Two green (2G), one orange (1O), and two blue (2B) signals.



Aberrant Cell Female:

Turner (45,X0)
One green (1G) and two blue (2B) signals.

Literature

- Trepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

XA TriScore (X/Y/21)

The XA TriScore (X/Y/21) mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 21. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in blue (aqua) and Y in green. The orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. It has become a standard to provide preliminary results for the detection of anomalies in less than 12 hours.

Duplications of chromosome bands 21q22.13-q22.2 have been shown to define the smallest region implicated in the causation of Down syndrome. Repetitive sequences around the centromeric region of the X and Y chromosomes can reliably determine Klinefelter syndrome (47,XXY), Triple-X syndrome (47,XXX), Turner syndrome (45,X0), and 47,XYY. This probe also allows to differentiate male fetal cells from maternal cells in blood contaminated amniocyte samples.

Expected Patterns

Normal Cell Male:

One green (1G), two orange (2O), and one blue (1B) signal.



Normal Cell Female:

No green (0G), two orange (2O), and two blue (2B) signals.




Aberrant Cell Male:

Trisomy 21
One green (1G), three orange (3O), and one blue (1B) signal.



Aberrant Cell Female:

Trisomy 21
No green (0G), three orange (3O), and two blue (2B) signals.



v10.1










Literature

- Bryndorf et al (1996) Am J Hum Genet 59:918-926
- Tepperberg et al (2001) Prenat Diagn 21:293-301
- Stumm et al (2006) Cytogenet Genome Res 114:296-301

AneUScore-Table

Numerical aberrations of autosomes 13, 18, 21, and sex chromosomes X and Y account for 95% of birth defects in newborns. FISH applied to uncultured amniocytes provides a method to identify those aberrations much faster than conventional chromosome analysis. Nowadays, it is widely accepted to provide preliminary results for the detection of anomalies in less than 12 hours.

Product	Order No.	Package Size	Product Details
XA 21q22	D-5601-100-OR	100 µl	The XA 21q22 specific probe allows detecting copy number variations for chromosomes 21. The orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).
XA 13/21	D-5602-100-OG	100 µl	The XA 13/21 mix of specific probes allows detecting copy number variations for chromosomes 13 and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).
XA X/Y/21 TriScore	D-5603-100-TC	100 µl	The XA TriScore (X/Y/21) mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 21. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in blue (aqua) and Y in green. The orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).
XA X/Y/18	D-5606-100-TC	100 µl	The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).
XA 13/18/21	D-5607-100-TC	100 µl	The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4).
XA X/Y	D-5608-100-OG	100 µl	The XA X/Y mix of specific probes allows detecting copy number variations for chromosomes X and Y. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green and Y in orange.
XA AneUScore I (XA 13/21 + XA X/Y/18)	D-5604-100-TC D-5604-500-TC	2×100 µl 10×100 µl	The XA AneUScore I Probe Kit contains different probe mix, provided in separate test vials, for assessing chromosomal aneuploidies for Chromosomes 13, 18, 21, X, and Y. XA 13/21 (D-5602-100-OG): The XA 13/21 mix of specific probes allows detecting copy number variations for chromosomes 13 and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4). XA X/Y/18 (D-5606-100-TC): The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).
XA AneUScore II (XA 13/18/21 + XA X/Y)	D-5609-100-TC D-5609-500-TC	2×100 µl 10×100 µl	The XA AneUScore II Probe Kit contains different probe mix, provided in separate test vials, for assessing chromosomal aneuploidies for Chromosomes 13, 18, 21, X, and Y. XA 13/18/21 (D-5607-100-TC): The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4). XA X/Y (D-5608-100-OG): The XA X/Y mix of specific probes allows detecting copy number variations for chromosomes X and Y. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green and Y in orange.
XA AneUScore III (XA 13/18/21 + XA X/Y/18)	D-5613-100-TC D-5613-500-TC	2×100 µl 10×100 µl	The XA AneUScore III Probe Kit contains different probe mix, provided in separate test vials, for assessing chromosomal aneuploidies for chromosomes 13, 18, 21, X, and Y. XA 13/18/21 (D-5607-100-TC): The XA 13/18/21 mix of specific probes allows detecting copy number variations of chromosomes 13, 18, and 21. The green labeled probe hybridizes to a region at 13q14 including the RB1 locus, the blue (aqua) labeled probe hybridizes to a locus at 18q21, and the orange labeled probe hybridizes to a region at 21q22 including the DSCR4 (Down syndrome critical region 4). XA X/Y/18 (D-5606-100-TC): The XA X/Y/18 mix of specific probes allows detecting copy number variations for chromosomes X, Y, and 18. The probe mix is composed of repetitive sequences which hybridize to the centromeric region of chromosomes X in green, Y in orange, and 18 in blue (aqua).

	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XL Wolf-Hirschhorn

XL Wolf-Hirschhorn consists of an orange-labeled probe hybridizing to the NSD2/NELFA gene region at 4p16.3 and a green-labeled probe hybridizing to a region at 4q12.

Wolf-Hirschhorn syndrome (WHS) is a rare genetic disorder characterized by a range of problems including the minimal diagnostic criteria: distinctive facial features (Greek warrior helmet appearance), congenital hypotonia, intellectual disabilities, delayed development and seizures.

The association of partial 4p16 deletions with WHS was first described by Cooper and Hirschhorn in 1961. Most 4p16 deletions in WHS occur de novo, only in the minority of cases the rearranged chromosome is inherited. WHS is a contiguous gene syndrome associated with haploinsufficiency of several closely linked genes. The severity of clinical manifestation depends on the amount of genetic material affected.

Two WHS critical regions (WHSCR) have been identified. The classical WHSCR1, spanning 165 kb on chromosomal location 4p16.3, includes the genes NSD2 (nuclear receptor binding SET domain protein 2) and NELFA (negative elongation factor complex member A). WHSCR2 was defined based on the identification of patients with atypical forms of WHS, showing no deletion of WHSCR1. WHSCR2 is located distally to WHSCR1 partially including the gene NSD2, but excluding NELFA.

Expected Patterns


Normal Signal Pattern:

Two green (2G) and two orange (2O) signals.



Aberrant Signal Pattern:

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Wright et al (1997) Hum Mol Gen 6:317-324
- Zollino (2003) Am J Hum Genet 72:590-597
- Buggenhout (2004) J Med Genet 41:691-698

Order No:
D-5417-050-OG

Size: **50 µl**

XCyting Microdeletion Probes


XL

XL Cri-Du-Chat

XL Cri-Du-Chat consists of an orange-labeled probe hybridizing to a region at 5p15.2-15.3 including the markers D5S1976, D5S2064 and D5S1518E and a green-labeled probe hybridizing to a region at 5q31.2.

Cri-du-Chat syndrome (CdCS), or 5p-minus syndrome, was first described by Lejeune et al in 1963, a French pediatrician and geneticist. The name refers to the main clinical feature of the syndrome, a characteristic cat-like cry in early childhood. The severity of further symptoms as microcephaly, mental retardation, delayed development, craniofacial manifestations, and other anomalies may vary strongly among individuals.

CdCS is a rather frequent microdeletion syndrome with an incidence of about 1:15.000 to 1 :50.000 live births. The majority of patients carry a terminal deletion of the short arm of chromosome 5 with breakpoints ranging from 5p13 to 5p15.2 with a size of up to 40Mb. Most 5p deletions occur de novo, probably during spermatogenesis. Breakpoints are not well defined and differ between CdCS cases. Only a few patients have an interstitial deletion, translocations or other less common aberrations. Patient studies established a link between the size of the deleted region and the CdCS phenotype and identified regions 5p15.2 and 5p15.3 responsible for dysmorphism, mental retardation, and the cat-like cry.



Expected Patterns



Normal Signal Pattern:

Two green (2G) and two orange (2O) signals.



Aberrant Signal Pattern:

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

- Lejeune et al (1963) C R Hebd Seances Acad Sci 257:3098-3102
- Mainarid et al (2001) J Med Genet 38:151-158
- Nguyen et al (2015) Am J Med Genet C Semin Med Genet 169c:224-238

XL Williams-Beuren

XL Williams-Beuren consists of an orange-labeled probe hybridizing to the ELN/LIMK1 gene region at 7q11.23 and a green-labeled probe hybridizing to a region at 7p11.2.

Williams-Beuren syndrome (WBS) is a contiguous gene deletion syndrome with an estimated prevalence of 1:7.500 to 1:25.000 newborns. WBS phenotype is complex, age-dependent and varies between individuals. Newborns have characteristic ‘elfin-like’ facial features with full cheeks, small head, flat nasal bridge, broad forehead, prominent open mouth, broad nose and puffiness around eyes and lips. Patients have a wide spectrum of features affecting the cardiovascular system, development and cognition, teeth, endocrine system, gastrointestinal tract, acoustic perception, nose and throat. One of the most fatal and characteristic complications is supravalvular aortic stenosis (SVAS).

WBS is associated with a chromosomal microdeletion in region 7q11.23. The common critical region is about 1.6Mb in size and contains more than 20 genes, including ELN (elastin) and LIMK1 (LIM domain kinase 1). Haploinsufficiency of ELN correlates with cardiovascular problems and is responsible for the SVAS phenotype of WBS patients. Deletions in region 7q11.23 are a consequence of non-allelic homologous recombination between low copy repeat elements flanking the WBS deleted region. Most WBS cases are sporadic, only few cases are transmitted vertically.

Expected Patterns


Normal Signal Pattern:

Two green (2G) and two orange (2O) signals.



Aberrant Signal Pattern:

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Wu et al (1998) Am J Med Genet 78:82-89
- Bayés et al (2003) Am J Hum Genet 73:131-151
- Jurado (2003) Horm Res 59 (suppl 1):106-113

Order No:
D-5421-050-OG

Size: 50 µl


XCyting Microdeletion Probes

XL

XL Prader-Willi/Angelman

XL Prader-Willi/Angelman consists of an orange-labeled probe hybridizing to the SNRPN/PWAR5 gene region at 15q11.2 and a green-labeled probe hybridizing to the PML gene region at 15q24.

Prader-Willi syndrome (PWS), first described by Prader, Labhart and Willi in 1956, and Angelman syndrome (AS) initially reported by Angelman in 1963, are complex neurodevelopmental disorders caused by chromosomal deletion of genes in the 15q11-q13 region. In most cases, the corresponding genes are silenced on the sister chromosome via genetic imprinting. The deletion of the paternal segment 15q11-q13 leads to the development of PWS, while patients carrying the maternal deletion of this segment suffer from AS. The clinical manifestation of PWS is characterized by muscular hypotony (‘floppy infants’), hypogonadism, developmental and cognitive delays, hyperphagia and obesity. Furthermore, learning disabilities and obsessive-compulsive disorder can be observed. Typical AS indications observed are a small head, severe intellectual disability and developmental retardation. Speaking, sleep, balance and movement problems, as well as seizure disorder are further symptoms. The most common genetic cause for PWS is the deletion of the paternal 15q11-q13 copy. Maternal uniparental disomy of 15q11-q13 (genes are silenced via genetic imprinting) or translocations with breaks in the 15q11-q13 region are further mechanisms leading to PWS. Genes located in this region, especially SNRPN (small nuclear ribonucleoprotein polypeptide N) and NDN (necdin), are considered to be crucial for disease development. The absence of the maternal UBE3A (ubiquitin-protein ligase E3A) gene copy located in this segment is crucial for the development of AS.



Expected Patterns



Normal Signal Pattern:

Two green (2G) and two orange (2O) signals.



Aberrant Signal Pattern:

Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.

Literature

- Clayton-Smith and Pembrey (1992) Med Genet 29:412-415
- Butler (2011) Curr Genomics 12(3):204-215
- Kalsner and Chamberlain (2015) Pediatr Clin North Am 62(3):587-606

XL Smith-Magenis/ Miller-Dieker

XL Smith-Magenis/Miller-Dieker consists of a green-labeled probe hybridizing to the RAI1 gene region at 17p11.2 and an orange-labeled probe hybridizing to the PAFAH1B1 gene region at 17p13.

First described in 1982 by Ann C. M. Smith and her colleagues, Smith-Magenis syndrome (SMS) has an estimated prevalence of 1:25.000 newborns. While interstitial deletions in the segment 17p11.2 are the genetic basis of Smith-Magenis syndrome (SMS), deletions of the more distal part 17p13.3 lead to Miller-Dieker syndrome (MDS). SMS is characterized by relatively mild craniofacial and skeletal abnormalities, delay in psycho-motoric development, and specific behavioural disorders. In addition to neuro-behavioural problems, often including self-injurious pattern, SMS patients suffer from a disturbed sleep cycle, as the day and night melatonin secretion cycle is reversed.

MDS patients show a neuro-developmental and structural disorder of the brain, called lissencephaly. The typical walnut structure of the brain containing fissures and gyri is hardly recognizable. Craniofacial dysmorphism, decreased head circumference, delay in psychomotor development and seizures are further symptoms of this syndrome. The SMS inducing deletions of 17p11.2 have no preferential breakpoints, but most patients analyzed show deletions smaller than 4Mb. The key gene responsible for the manifestation of the clinical symptoms of SMS is RAI1 (retinoic acid induced 1), coding for a transcription factor. One of the crucial genes involved in the development of Miller-Dieker lissencephaly and craniofacial dysmorphism is the PAFAH1B1 gene encoding the regulatory subunit of the platelet activating factor acetylhydrolase 1b.

Expected Patterns


Normal Signal Pattern:

Two green (2G) and two orange (2O) signals.




Aberrant Signal Pattern:










Two green (2G) and one orange (1O) signal resulting from loss of one orange signal.



Literature

- Elsea (2008) Eur J Hum Genet 16:412-421
- Blazejewski et al (2018) Front Genet 9:8:doi:10.3389/fgene.2018.00080
- Falco et al (2017) Appl Clin Genet 10:85-94



	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XCE Table

The XCE DNA probes hybridize to human highly repetitive sequences (also called Satellite DNA) located at and around the centromeric region of chromosomes. The XCE probes produce sharp and bright signals allowing for rapid and precise identification and enumeration of human chromosomes in metaphase and interphase cells on various sample types.

XCE probes are provided premixed in hybridization buffer. They are directly labeled with either blue (aqua), green, or orange fluorochromes.

MetaSystems XCE probes are optimized for 1 hour hybridization.

Chromosome	Product	Package Size	Localization	D_Z	Order No. / Label		
					Green	Orange	Blue
1	XCE 1	50 µl	1q12	D1Z1	D-0801-050-FI	D-0801-050-OR	-
2	XCE 2	50 µl	2p11.1-q11.1	D2Z2	D-0802-050-FI	D-0802-050-OR	-
3	XCE 3	50 µl	3p11.1-q11.1	D3Z1	D-0803-050-FI	D-0803-050-OR	-
4	XCE 4	50 µl	4p11.1-q11.1	n.a. ¹	D-0804-050-FI	D-0804-050-OR	-
5/19	XCE 5/19	50 µl	5p11.1-q11.1 19p11.1-q11.1	D5Z1 D19Z2	D-0805-050-FI	D-0805-050-OR	-
6	XCE 6	50 µl	6p11.1-q11.1	D6Z1	D-0806-050-FI	D-0806-050-OR	D-0806-050-BL
7	XCE 7	50 µl	7p11.1-q11.1	n.a. ¹	D-0807-050-FI	D-0807-050-OR	D-0807-050-BL
8	XCE 8	50 µl	8p11.1-q11.1	n.a. ¹	D-0808-050-FI	D-0808-050-OR	D-0808-050-BL
9	XCE 9	50 µl	9p11.1-q11.1	D9Z4	D-0809-050-FI	D-0809-050-OR	-
10	XCE 10	50 µl	10p11.1-q11.1	D10Z1	D-0810-050-FI	D-0810-050-OR	-
11	XCE 11	50 µl	11p11.1-q11.1	D11Z1	D-0811-050-FI	D-0811-050-OR	D-0811-050-BL
12	XCE 12	50 µl	12p11.1-q11.1	D12Z3	D-0812-050-FI	D-0812-050-OR	D-0812-050-BL
15	XCE 15	50 µl	15p11.1-q11.1	D15Z4	D-0815-050-FI	D-0815-050-OR	-
17	XCE 17	50 µl	17p11.1-q11.1	n.a. ¹	D-0817-050-FI	D-0817-050-OR	-
18	XCE 18	50 µl	18p11.1-q11.1	D18Z1	D-0818-050-FI	D-0818-050-OR	D-0818-050-BL
20	XCE 20	50 µl	20p11.1-q11.1	D20Z1	D-0820-050-FI	D-0820-050-OR	-
X	XCE X	50 µl	Xp11.1-q11.1	DXZ1	D-0823-050-FI	D-0823-050-OR	-
Y	XCE Y	50 µl	Yp11.1-q11.1	DYZ3	D-0824-050-FI	D-0824-050-OR	D-0824-050-BL

1: No specific data available

Chromosomes	Product	Package Size	Order No. / Label
X/Y	XCE X/Y	50 µl	D-0825-050-OG Green / Orange
X/Y	XCE X/Y	4x50 µl	D-0825-200-OG Green / Orange
7/8	XCE 7/8	50 µl	D-0826-050-OG Orange / Green
3/7/17	XCE 3/7/17	50 µl	D-0829-050-TC Orange / Green / Blue
4/10/17	XCE 4/10/17	50 µl	D-0830-050-TC Orange / Green / Blue

For centromeric localization details of combined XCE products, see table above.
MetaSystems' XA and relevant XL products contain the same centromeric probes described in the table above.

Order No:
D-0832-050-OG

Size: 50 µl

XCyting Centromere
Enumeration Probes


XCE

XCE X/Yqh

The XCE X/Yqh DNA probe contains a mix of repetitive sequences specific for the chromosome X centromeric region in orange and chromosome Yqh in green which is located in the heterochromatic region at Yq12.

Following allogeneic bone marrow transplantation (BMT), careful monitoring of engraftment is important, as the presence of residual host cells can precede the reappearance of the abnormal hematopoietic clone. FISH allows rapid screening of a large number of cells and has become a powerful tool for monitoring engraftment with a high sensitivity and low false positivity rate in patients undergoing BMT from sex-mismatched donors.

FISH analysis of residual cells after sex-mismatched transplantations is based on simultaneous labeling of the centromeres of the X and Y chromosomes. Because the cytogenetic status of either donor or recipient is known, also a non-centromeric repeat at Yq12 can be chosen due to its more pronounced signals.



Expected Patterns



Normal Cell Female:
46, XX
Two orange (2O) signals.



Normal Cell Male:
46, XY
One green (1G) and one orange (1O) signal.



Aberrant Cell Female:
Turner (45,X0)
One orange (1O) signal.



Aberrant Cell Male:
Klinefelter (47,XXY)
One green (1G) and two orange (2O) signals.

Literature


- Dewald et al (1993) Bone Marrow Trans 12:149-154
- Najfeld et al (1997) Bone Marrow Trans 19:829-834

XCE pan-cen

XCE pan-cen is composed of green labeled repetitive sequences specific for human centromeres except for chromosome 1 which is identified by repetitive sequences specific for the heterochromatic region 1q12. The product is also available labeled in orange (D-0836-050-OR).

Please note that this product is not classified as an IVD product in the EU according to the In-Vitro Diagnostic Medical Device Directive 98/79/EC. It is marked as for 'Research Use Only' (RUO).


The centromeric region of chromosomes is essential for chromosomal inheritance and genome stability. XCE pan-cen probes target human highly repetitive sequences located at and around the centromeric region of each human chromosome. They can be used to determine the copy number of particular chromosomes in the cell, the detection of aneusomy and polyploidy and other genomic abnormalities. Fluorescence in situ hybridization of all centromeres is a powerful technique mainly used in radiobiology, but is also being applied in scientific research of chromosome organization and chromosome evolution.












v01.1

Literature

- Wojcik et al (2000) Genet Mol Biol 23:1083-1085
- Formian et al (2000) Int J Radiat Biol 76:807-813
- Lindberg et al (2008) Mutagenesis 23:371-376



	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XCP Green Table

XCyting Chromosome Paints are chromosome-specific and cover the entire chromosome. These XCPs are labeled in green.

Chromosomes	Product	Package Size / Order No.			
1	XCP 1 Green	50 µl	D-0301-050-FI	2×50 µl	D-0301-100-FI
2	XCP 2 Green	50 µl	D-0302-050-FI	2×50 µl	D-0302-100-FI
3	XCP 3 Green	50 µl	D-0303-050-FI	2×50 µl	D-0303-100-FI
4	XCP 4 Green	50 µl	D-0304-050-FI	2×50 µl	D-0304-100-FI
5	XCP 5 Green	50 µl	D-0305-050-FI	2×50 µl	D-0305-100-FI
6	XCP 6 Green	50 µl	D-0306-050-FI	2×50 µl	D-0306-100-FI
7	XCP 7 Green	50 µl	D-0307-050-FI	2×50 µl	D-0307-100-FI
8	XCP 8 Green	50 µl	D-0308-050-FI	2×50 µl	D-0308-100-FI
9	XCP 9 Green	50 µl	D-0309-050-FI	2×50 µl	D-0309-100-FI
10	XCP 10 Green	50 µl	D-0310-050-FI	2×50 µl	D-0310-100-FI
11	XCP 11 Green	50 µl	D-0311-050-FI	2×50 µl	D-0311-100-FI
12	XCP 12 Green	50 µl	D-0312-050-FI	2×50 µl	D-0312-100-FI
13	XCP 13 Green	50 µl	D-0313-050-FI	2×50 µl	D-0313-100-FI
14	XCP 14 Green	50 µl	D-0314-050-FI	2×50 µl	D-0314-100-FI
15	XCP 15 Green	50 µl	D-0315-050-FI	2×50 µl	D-0315-100-FI
16	XCP 16 Green	50 µl	D-0316-050-FI	2×50 µl	D-0316-100-FI
17	XCP 17 Green	50 µl	D-0317-050-FI	2×50 µl	D-0317-100-FI
18	XCP 18 Green	50 µl	D-0318-050-FI	2×50 µl	D-0318-100-FI
19	XCP 19 Green	50 µl	D-0319-050-FI	2×50 µl	D-0319-100-FI
20	XCP 20 Green	50 µl	D-0320-050-FI	2×50 µl	D-0320-100-FI
21	XCP 21 Green	50 µl	D-0321-050-FI	2×50 µl	D-0321-100-FI
22	XCP 22 Green	50 µl	D-0322-050-FI	2×50 µl	D-0322-100-FI
X	XCP X Green	50 µl	D-0323-050-FI	2×50 µl	D-0323-100-FI
Y	XCP Y Green	50 µl	D-0324-050-FI	2×50 µl	D-0324-100-FI

Chromosomes	Product	Package Size / Order No.	
1-22, X, Y	Kit with 24 XCPs Green	24×50µl	D-0325-050-FI
1-12	Kit with 12 XCPs Green	12×50µl	D-0326-050-FI
13-22, X, Y	Kit with 12 XCPs Green	12×50µl	D-0327-050-FI

XCP Orange Table

XCyting Chromosome Paints are chromosome-specific and cover the entire chromosome. These XCPs are labeled in orange.


Chromosomes	Product	Package Size / Order No.			
1	XCP 1 Orange	50 µl	D-0301-050-OR	2×50 µl	D-0301-100-OR
2	XCP 2 Orange	50 µl	D-0302-050-OR	2×50 µl	D-0302-100-OR
3	XCP 3 Orange	50 µl	D-0303-050-OR	2×50 µl	D-0303-100-OR
4	XCP 4 Orange	50 µl	D-0304-050-OR	2×50 µl	D-0304-100-OR
5	XCP 5 Orange	50 µl	D-0305-050-OR	2×50 µl	D-0305-100-OR
6	XCP 6 Orange	50 µl	D-0306-050-OR	2×50 µl	D-0306-100-OR
7	XCP 7 Orange	50 µl	D-0307-050-OR	2×50 µl	D-0307-100-OR
8	XCP 8 Orange	50 µl	D-0308-050-OR	2×50 µl	D-0308-100-OR
9	XCP 9 Orange	50 µl	D-0309-050-OR	2×50 µl	D-0309-100-OR
10	XCP 10 Orange	50 µl	D-0310-050-OR	2×50 µl	D-0310-100-OR
11	XCP 11 Orange	50 µl	D-0311-050-OR	2×50 µl	D-0311-100-OR
12	XCP 12 Orange	50 µl	D-0312-050-OR	2×50 µl	D-0312-100-OR
13	XCP 13 Orange	50 µl	D-0313-050-OR	2×50 µl	D-0313-100-OR
14	XCP 14 Orange	50 µl	D-0314-050-OR	2×50 µl	D-0314-100-OR
15	XCP 15 Orange	50 µl	D-0315-050-OR	2×50 µl	D-0315-100-OR
16	XCP 16 Orange	50 µl	D-0316-050-OR	2×50 µl	D-0316-100-OR
17	XCP 17 Orange	50 µl	D-0317-050-OR	2×50 µl	D-0317-100-OR
18	XCP 18 Orange	50 µl	D-0318-050-OR	2×50 µl	D-0318-100-OR
19	XCP 19 Orange	50 µl	D-0319-050-OR	2×50 µl	D-0319-100-OR
20	XCP 20 Orange	50 µl	D-0320-050-OR	2×50 µl	D-0320-100-OR
21	XCP 21 Orange	50 µl	D-0321-050-OR	2×50 µl	D-0321-100-OR
22	XCP 22 Orange	50 µl	D-0322-050-OR	2×50 µl	D-0322-100-OR
X	XCP X Orange	50 µl	D-0323-050-OR	2×50 µl	D-0323-100-OR
Y	XCP Y Orange	50 µl	D-0324-050-OR	2×50 µl	D-0324-100-OR

Chromosomes	Product	Package Size / Order No.	
1-22, X, Y	Kit with 24 XCPs Orange	24×50µl	D-0325-050-OR
1-12	Kit with 12 XCPs Orange	12×50µl	D-0326-050-OR
13-22, X, Y	Kit with 12 XCPs Orange	12×50µl	D-0327-050-OR

XCP-Mix #1O-#2G-#4GO

Probe mix containing whole chromosome paints (XCP) specific for chromosome 1 labeled with an orange emitting fluorophore, chromosome 2 with a green emitting fluorophore, and chromosome 4 with a combination of the 2 fluorophores.

Ionizing radiation exposure gives rise to a variety of lesions in DNA which result in genetic instability and potentially tumorigenesis or cell death. At present, a particular interest of biological dosimetry is establishing a methodology to indicate interindividual sensitivity of people to ionising radiation. Current dose and risk estimates derived using cytogenetic methods and adequate calibration curves, are based on the assumption that all individuals respond equally to radiation. However, this is not necessarily the case. Individual increased radiosensitivity has been highly associated with susceptibility to cancer; therefore it is of particular interest to elucidate the mechanisms leading to such genetic changes.




Literature










- Terzoudi et al (2006) *Radiat Prot Disom* 122:513-520
- Pouzoulet et al (2007) *J Radiat Res* 48:425-434
- Huber et al (2011) *Radiat Oncol* 6:doi:10.1186/1748-717X-6-32





Notes



	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

Order No:
D-0125-060-DI

Size: 60 µl

XCyting Multicolor FISH Probes
Human Multicolor FISH Probe

mFISH

24XCyte

24 painting probes specific for the 24 different human chromosomes, labeled with different fluorochromes. The excitation/emission spectra are comparable to the common aqua, green, orange, red and near infrared fluorochromes.

Also available as 120µl (2x60µl) D-0125-120-DI and as 600µl (10x60µl) D-0125-600-DI.

The principle of mFISH is based on combinatorial labeling of whole chromosome paints. For each chromosome the different fluorochromes are mixed resulting in a unique color combination (see labeling scheme). The analysis is carried out after capturing grey scale images of each fluorochrome. For best separation of the different colors, the filter sets used need to be highly selective, assuring that crosstalk is reduced to a minimum. Multicolor FISH Analysis with MetaSystems' Isis supports the analysis by applying appropriate algorithms which leads to pseudo coloring of the different chromosome classes (color combinations). Each chromosome class will be displayed in a unique color. Translocations show up as color changes on individual chromosomes.


		Labelling Scheme				
		Aqua	Green	Orange	Red	Near Infrared
Chromosomes	1					Yellow
	2	Aqua				
	3				Red	
	4		Green			
	5			Orange		
	6		Green			Yellow
	7	Aqua				Yellow
	8				Red	Yellow
	9			Orange		Yellow
	10	Aqua	Green			
	11		Green		Red	
	12		Green	Orange		
	13	Aqua			Red	
	14	Aqua		Orange		
	15			Orange	Red	
	16	Aqua	Green			Yellow
	17		Green		Red	Yellow
	18		Green	Orange		Yellow
	19	Aqua			Red	Yellow
	20	Aqua			Orange	Yellow
	21			Orange	Red	Yellow
	22	Aqua	Green		Red	
	X	Aqua	Green	Orange		
	Y	Aqua		Orange	Red	










Literature

- Speicher MR et al (1996) Nat Genet 12:368-375
- Fauth C and Speicher MR (2001) Cytogenet Cell Genet 93:1-10
- Schoch C et al (2002) Genes Chromosomes Cancer 35:20-29



Notes



	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XCyte mBAND Table

The mBAND technique is based on a series of partial chromosome paints for sequential partially overlapping chromosome regions of a single chromosome. For labeling the same 5 fluorochromes as in the 24XCyte probe are used. The characteristic multicolor banding pattern of mBAND is generated by quantifying the fluorescence intensity ratios along the chromosome. These ratios are unique and visualized as band-specific pseudo colors. mBAND provides information that allows for a precise analysis of even highly complex inter- and intrachromosomal aberrations.

The mBAND technique is protected by international patents (e.g. US 7,050,911, EP 0 957 176, EP 1 672 083).

Chromosome	Product	Package Size	Order No.
1	XCyte 1	30 µl	D-0201-030-DI
2	XCyte 2	30 µl	D-0202-030-DI
3	XCyte 3	30 µl	D-0203-030-DI
4	XCyte 4	30 µl	D-0204-030-DI
5	XCyte 5	30 µl	D-0205-030-DI
6	XCyte 6	30 µl	D-0206-030-DI
7	XCyte 7	30 µl	D-0207-030-DI
8	XCyte 8	30 µl	D-0208-030-DI
9	XCyte 9	30 µl	D-0209-030-DI
10	XCyte10	30 µl	D-0210-030-DI
11	XCyte 11	30 µl	D-0211-030-DI
12	XCyte 12	30 µl	D-0212-030-DI
13	XCyte 13	30 µl	D-0213-030-DI
14	XCyte 14	30 µl	D-0214-030-DI
15	XCyte 15	30 µl	D-0215-030-DI
16	XCyte 16	30 µl	D-0216-030-DI
17	XCyte 17	30 µl	D-0217-030-DI
18	XCyte 18	30 µl	D-0218-030-DI
19	XCyte 19	30 µl	D-0219-030-DI
20	XCyte 20	30 µl	D-0220-030-DI
21	XCyte 21	30 µl	D-0221-030-DI
22	XCyte 22	30 µl	D-0222-030-DI
X	XCyte X	30 µl	D-0223-030-DI
Y	XCyte Y	30 µl	D-0224-030-DI

Literature

- Chudoba I et al (1999) Cytogenet Cell Genet 84:156-160
- Johannes C et al (1999) Chromosome Res 7:625-633
- MacKinnon RN and Campbell LJ (2005) Cancer Genet Cytogenet 163:176-179



XL

XCyting Locus-Specific Probes
... for Hematology / Oncology

7



XA

XCyting Locus-Specific Probes
... for Aneuploidy Detection

109



Microdeletion Probes

XCyting Locus-Specific Probes
... for Detection of Microdeletions

121



XCE

XCyting Centromere
Enumeration Probes

129



XCP

XCyting Chromosome Paints

135



XCyte mFISH

XCyting Multicolor
FISH Probes

141



XCyte mBAND

XCyting Multicolor
Banding Probes

145



Non-Human

Paints and mFISH Kits
... for Mouse, Rat and CHO

149



XRNA

XCyting RNA FISH Probes

155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XMP Table

XMP are chromosome-specific and comprise mouse whole chromosome painting probes which are directly labeled with a green or orange emitting fluorochrome, respectively.

Mouse Chromosome	Product	Package Size	Order No. / Label	
			Green	Orange
1	XMP 1	50 µl	D-1401-050-FI	D-1401-050-OR
2	XMP 2	50 µl	D-1402-050-FI	D-1402-050-OR
3	XMP 3	50 µl	D-1403-050-FI	D-1403-050-OR
4	XMP 4	50 µl	D-1404-050-FI	D-1404-050-OR
5	XMP 5	50 µl	D-1405-050-FI	D-1405-050-OR
6	XMP 6	50 µl	D-1406-050-FI	D-1406-050-OR
7	XMP 7	50 µl	D-1407-050-FI	D-1407-050-OR
8	XMP 8	50 µl	D-1408-050-FI	D-1408-050-OR
9	XMP 9	50 µl	D-1409-050-FI	D-1409-050-OR
10	XMP 10	50 µl	D-1410-050-FI	D-1410-050-OR
11	XMP 11	50 µl	D-1411-050-FI	D-1411-050-OR
12	XMP 12	50 µl	D-1412-050-FI	D-1412-050-OR
13	XMP 13	50 µl	D-1413-050-FI	D-1413-050-OR
14	XMP 14	50 µl	D-1414-050-FI	D-1414-050-OR
15	XMP 15	50 µl	D-1415-050-FI	D-1415-050-OR
16	XMP 16	50 µl	D-1416-050-FI	D-1416-050-OR
17	XMP 17	50 µl	D-1417-050-FI	D-1417-050-OR
18	XMP 18	50 µl	D-1418-050-FI	D-1418-050-OR
19	XMP 19	50 µl	D-1419-050-FI	D-1419-050-OR
X	XMP X	50 µl	D-1420-050-FI	D-1420-050-OR
Y	XMP Y	50 µl	D-1421-050-FI	D-1421-050-OR

XRP Table

XRP are chromosome-specific and comprise rat whole chromosome painting probes which are directly labeled with a green or orange emitting fluorochrome, respectively.

Rat Chromosome	Product	Package Size	Order No. / Label	
			Green	Orange
1	XRP 1	50 µl	please inquire	
2	XRP 2	50 µl	please inquire	
3	XRP 3	50 µl	please inquire	
4	XRP 4	50 µl	please inquire	
5	XRP 5	50 µl	please inquire	
6	XRP 6	50 µl	please inquire	
7	XRP 7	50 µl	please inquire	
8	XRP 8	50 µl	please inquire	
9	XRP 9	50 µl	please inquire	
10	XRP 10	50 µl	please inquire	
12	XRP 12	50 µl	please inquire	
13	XRP 13	50 µl	please inquire	
16	XRP 16	50 µl	please inquire	
17	XRP 17	50 µl	please inquire	
18	XRP 18	50 µl	please inquire	
19	XRP 19	50 µl	please inquire	
20	XRP 20	50 µl	please inquire	
X	XRP X	50 µl	D-1521-050-FI	D-1521-050-OR
Y	XRP Y	50 µl	D-1522-050-FI	D-1522-050-OR


mFISH-Non-Human










mFISH probes are comprised of whole chromosome painting probes which are labeled with a total of five fluorochromes. The combinations of the fluorochromes for the different chromosomal paints result in an individual color signature for each chromosome class. The excitation/emission spectra are comparable to the common aqua, green, orange, red and near infrared fluorochromes.

Beside the human mFISH probes, MetaSystems offers additional specific mFISH probes for three different species: Mouse, Rat, and Chinese Hamster.

Probe Kit Family	Product		Package Size / Order No.		
Multicolor FISH Probe Kit for Mouse Chromosomes	21XMouse	60 µl	D-0425-060-DI	2×60 µl	D-0425-120-DI
Multicolor FISH Probe Kit for Rat Chromosomes	22XRat*	60 µl	D-1525-060-DI	2×60 µl	D-1525-120-DI
Multicolor FISH Probe Kit for Chinese Hamster Chromosomes	12XCHamster	60 µl	D-1526-060-DI	-	-

*Chromosomes 13 and 14 show an identical labeling scheme and are not distinguishable with 22XRat.



	XL XCyting Locus-Specific Probes ... for Hematology / Oncology	7
	XA XCyting Locus-Specific Probes ... for Aneuploidy Detection	109
	Microdeletion Probes XCyting Locus-Specific Probes ... for Detection of Microdeletions	121
	XCE XCyting Centromere Enumeration Probes	129
	XCP XCyting Chromosome Paints	135
	XCyte mFISH XCyting Multicolor FISH Probes	141
	XCyte mBAND XCyting Multicolor Banding Probes	145
	Non-Human Paints and mFISH Kits ... for Mouse, Rat and CHO	149
	XRNA XCyting RNA FISH Probes	155

General Reagents – 163

MetaSystems Imaging Systems – 169

Filters & Fluorochromes – 173

Index – 175

XRNA SARS-CoV-2, orange

The XRNA SARS-CoV-2 probe kit comprises 96 oligos detecting the spike glycoprotein mRNA of SARS-CoV-2 and a portion of the viral ORF1 mRNA. We are using the proprietary HuluFISH enzymatic multi fluorophore labeling technique enabling the detection of RNA at the single-cell, single-molecule level in cell and tissue samples. The probe kit is labeled in orange (Atto565).

For Research Use Only (RUO). Not for diagnostic procedures.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel human-pathogenic coronavirus causing coronavirus disease 2019 (COVID-19), was first reported in December 2019. The virus spread quickly, leading to the global COVID-19 pandemic. SARS-CoV-2 primarily causes respiratory infections but is also known to affect other organ systems. While most patients show mild clinical symptoms, severe COVID-19 is characterized by viral pneumonia and acute respiratory distress syndrome. In addition to respiratory symptoms, systemic inflammation and cytokine storm can lead to multiorgan failure and death.

Coronavirus particles consist of four structural proteins called spike (S), envelope (E), membrane (M) and nucleocapsid (N) protein. The SARS-CoV-2 genome is approximately 30kb in size and consists of a positive-sense, single-stranded RNA. It functions not only as viral genome but also as mRNA. The genome contains 10 open reading frames (ORFs) which encode 24-27 genes.

A well-studied cell entry mechanism of SARS-CoV-2 is mediated by the viral S protein, which uses angiotensin-converting-enzyme (ACE2) on the surface of host cells as an attachment receptor. After viral attachment, the S protein is cleaved by the host transmembrane serine protease TMPRSS2 leading to membrane fusion and the release of the viral genome into the cytoplasm. The first viral proteins translated are the polyproteins pp1a and pp1ab which are then cleaved into non-structural proteins by viral proteases. One of them is the RNA-dependent RNA polymerase (RdRP), which replicates the viral genome. After replication, the viral RNA and N proteins are assembled into nucleocapsids within the cytoplasm. Budding of new particles takes place at the membrane of the endoplasmic reticulum-Golgi intermediate compartment. Finally, the new viral particles are assembled and released via exocytosis.

The viral replication machinery uses the genomic positive-sense RNA as a template to synthesize a negative-sense antigenomic RNA. This negative-sense RNA then serves as a matrix for genomic RNA synthesis. Therefore, the presence of minus-strand RNA indicates viral RNA replication. RNA in situ hybridization and multiplex FISH analysis have shown differential distribution of the positive- and negative strand RNA within the cell. The positive-sense RNA showed distribution in the cytoplasm, while the negative-sense RNA was detected in perinuclear inclusion bodies, corresponding to the localization of the viral RNA replicase-transcriptase complex.

XRNA SARS-CoV-2 opens up manifold possibilities for COVID-19 research:

Semi-quantitative virus identification on a cellular level, application in pre-clinical studies for vaccines and therapeutics and analysis of cell-, tissue-, and organ-tropism are some examples of the possible applications. And the list goes on: analysis of the cell response to infection, analysis of sub-cellular RNA distribution, analysis of the end of infectivity and more!

Powered by HuluFISH technology from PixelBiotech

Literature

- Nishiga et al (2020) Nat Rev Cardiol 17:543-558
- Liu et al (2020) JCI Insight 5:e139042
- Khailany et al (2020) Gene Rep 19:100682

Order No:
R-0201-020-FI

Size: 200 µl

XCyting RNA Probes
Human RNA FISH

XRNA

XRNA ACE2, green

The XRNA ACE2 probe kit comprises 96 oligos detecting the human ACE2 mRNA. We are using the proprietary HuluFISH enzymatic multi fluorophore labeling technique enabling the detection of RNA at the single-cell, single-molecule level in cell and tissue samples. The probe kit is labeled in green (Atto488).

For Research Use Only (RUO). Not for diagnostic procedures.

Novel coronavirus SARS-CoV-2 primarily causes severe respiratory infections which can progress to diverse clinical manifestations affecting multiple organs. The broad tissue tropism of the virus is attributed to the cell entry mechanism employed by SARS-CoV-2:

The viral spike (S) protein binds to the cellular angiotensin-converting enzyme 2 (ACE2) receptor facilitating attachment of the virus to the host cell. In a second step, the viral S protein is primed by the cellular transmembrane serine protease TMPRSS2, enabling membrane fusion and thereby cell entry. Both ACE2 and TMPRSS2 are pleiotropically expressed, including but not limited to the lung, gastrointestinal tissue, testes, and kidneys. There is histological evidence of SARS-CoV-2 infecting respiratory- and non-respiratory organs such as the heart, brain, liver, and kidneys. Endothelial cells, which are an essential component of every organ system, show a high level of ACE2 expression. ACE2 is known to play an important regulatory role in the immune- and cardiovascular system and was shown to be involved in the development of hypertension, heart failure and diabetes.

SARS-CoV, the coronavirus responsible for the SARS outbreak in 2002, utilizes the same cell entry mechanism as SARS-CoV-2. Studies have shown that SARS-CoV entry into the cell is followed by downregulation of ACE2, a mechanism which is now being suspected to apply to SARS-CoV-2 as well. Given the cardio- and lung-protective role of ACE2, this could be a cause of cardiac dysfunction and exacerbated lung damage in COVID-19 patients. Within the cell, ACE2 is part of the renin-angiotensin-aldosterone system and inactivates angiotensin II by converting it to angiotensin (1-7).

Powered by HuluFISH technology from PixelBiotech

Literature

- Nishiga et al (2020) Nature Reviews Cardiology 17:543–558
- Baughn et al (2020) Mayo Clin Proc 95:1989–1999
- Hoffmann et al (2020) Cell 181:271–280

XRNA TMPRSS2, aqua

The XRNA TMPRSS2 probe kit comprises 96 oligos detecting the human TMPRSS2 mRNA. We are using the proprietary HuluFISH enzymatic multi fluorophore labeling technique enabling the detection of RNA at the single-cell, single-molecule level in cell and tissue samples. The probe kit is labeled in aqua (Atto425).

For Research Use Only (RUO). Not for diagnostic procedures.

Novel coronavirus SARS-CoV-2 causes severe respiratory infections which can progress to diverse clinical manifestations. The pleiotropic effects of SARS-CoV-2 infection are partly attributed to the two-step cell entry mechanism utilized by SARS-CoV-2, which is equal to the mechanism used by the related coronavirus SARS-CoV in its main features:

Binding of the viral spike (S) protein to the cellular angiotensin-converting enzyme 2 (ACE2) receptor facilitates attachment of the virus to the host cell. The cellular transmembrane protease serine 2 (TMPRSS2) then primes the viral S protein for entry, by cleavage of the S protein at the S1/S2 and S2 sites. S protein priming by TMPRSS2 is necessary for fusion of viral and cellular membranes, and therefore cell entry. Hence, TMPRSS2 activity is essential for viral spread and pathogenesis in the infected host. This makes TMPRSS2 expression and activity interesting candidates for targeted COVID-19 therapies. Inhibition of TMPRSS2 with a clinically proven inhibitor was already shown to be efficient against SARS-CoV-2 host cell entry in vitro.

Both ACE2 and TMPRSS2 are pleiotropically expressed, including but not limited to the lungs, gastrointestinal tract, testes, kidneys and skin. In a study analysing the tissue- and gender-specific expression level of TMPRSS2, it was found that the highest TMPRSS2 expression is located in the prostate. TMPRSS2 is a member of the type II transmembrane protease family and is positively regulated by androgen signalling. TMPRSS2 expression previously gained interest in cancer research, as it shows high expression in prostate cancers, as well as subcellular protein mislocalization in advanced prostate cancer and is associated with tumor cell differentiation.

Powered by HuluFISH technology from PixelBiotech

Literature

- Baughn et al (2020) Mayo Clin Proc 95:1989–1999
- Lucas et al (2008) J Pathol 215:118–125
- Hoffmann et al (2020) Cell 181:271–280

Order No:
R-0203-020-FI

Size: 200 µl

XCyting RNA Probes
Human RNA FISH

XRNA

XRNA PD-L1, green

The XRNA PD-L1 probe kit comprises 96 oligos detecting the human PD-L1 mRNA. We are using the proprietary HuluFISH enzymatic multi fluorophore labeling technique enabling the detection of RNA at the single-cell, single-molecule level in cell and tissue samples. The probe kit is labeled in green (Atto488).

For Research Use Only (RUO). Not for diagnostic procedures.

Programmed death ligand 1 (PD-L1) is the main ligand of the programmed cell death 1 (PD-1) receptor. PD-1 functions as coinhibitory receptor which can be constitutively expressed or induced on myeloid, lymphoid, normal epithelial and cancer cells. PD-L1 is encoded by the PDCDL1 gene located on chromosome 9p24.1. The resulting type I transmembrane protein is known to be constitutively expressed at low levels on resting lymphocytes and antigen-presenting cells, but also other cell types such as Langerhans' islet cells, where it plays a part in tissue homeostasis in proinflammatory response. Furthermore, the 'immune privileged' status of tissues such as testis, placenta and the anterior chamber of the eye is mediated by PD-L1, which prevents induction of the inflammatory response after exposure to exogenous antigens. In the course of infection and/or inflammation, PD-L1 plays a key role as suppressive signal on haematopoietic, epithelial, and endothelial cells. The expression of PD-L1 is influenced by multiple signalling pathways including toll-like receptor and IFN-γ receptor 1 and 2 mediated signal transduction.

In carcinogenesis, multiple oncogenic mechanisms lead to elevated PD-L1 expression levels via different dysregulated signalling pathways, causing the gain of an immune evasion mechanism in cancer cells. As a result, various types of cancer cells, including non-small cell lung cancer cells, show elevated PD-L1 levels on their surface. PD-1/PD-L1 is considered as an immune checkpoint, which can inhibit immune surveillance and promote tumor growth under oncogenic pathological conditions. Modern immunotherapy methods (immune checkpoint inhibitors) use monoclonal antibodies targeting PD-1 or PD-L1 to reestablish the anti-tumor immune response and suppress tumor growth. Meanwhile, several PD-1/PD-L1 immune checkpoint inhibitors have been approved or are currently being evaluated in clinical studies, as PD-L1 is a well-established immune-based biomarker in carcinogenesis.

Powered by HuluFISH technology from PixelBiotech

Literature

- Kythreotou et al (2018) Clin Pathol 71:189-194
- Pawelczyk et al (2019) J Mol Sci 20:824
- Davis and Patel (2019) J. Immunotherapy Cancer 7:278

XRNA PGK1, near infrared

The XRNA PGK1 probe kit comprises 96 oligos detecting the human PGK1 mRNA. We are using the proprietary HuluFISH enzymatic multi fluorophore labeling technique enabling the detection of RNA at the single-cell, single-molecule level in cell and tissue samples. The probe kit is labeled in near infrared (Atto647N).

For Research Use Only (RUO). Not for diagnostic procedures.


Phosphoglycerate kinase 1 (PGK1) is encoded by the X-chromosomal PGK1 gene and is ubiquitously expressed. The resulting polypeptide is a central enzyme of aerobic glycolysis and essential for the formation of adenosine triphosphate (ATP), which is referred to as the molecular unit of intracellular energy currency. Countless metabolic processes and enzymatic reactions are linked to the hydrolysis of ATP. PGK1 catalyzes the reversible formation of 3-phosphoglycerate and ATP by transferring a phosphate group from 1,3-bisphosphoglycerate to adenosine diphosphate (ADP). On top of maintaining cell metabolism, PGK1 has additional functions, depending also on its localization within the cell.

PGK1 is a commonly used housekeeping gene utilized in gene expression analyses, for example in real-time reverse transcription PCR assays. Housekeeping genes are used to normalize expression values of analyzed genes in gene expression assays. However, it has become clear that the expression levels of housekeeping genes can show considerable variation, depending on the experimental conditions and analyzed tissue. PGK1 has been shown to be a stably expressed housekeeping gene for performing expression studies of leukocytes.

Powered by HuluFISH technology from PixelBiotech

Literature

- Fu and Yu (2020) Life Sci 256:117863
- Vega-Sanchez et al (2015) Placenta 36:240-245
- Abruzzo et al (2005) Biotechniques 38:785-792



General Reagents



DAPI/Antifade – 164
TissueFISH Pretreatment Kit – 165
Liquillizer – 166

General Reagents


Order No:
D-0902-500-DA

Size: 500 µl

DAPI/Antifade

Chromosome counterstain in a buffer containing anti-photobleaching (antifade) reagent (250ng/ml, 500µl).

MetaSystems DAPI/Antifade contains a blue fluorescent stain with a concentration of 250ng/ml which intercalates into the minor groove of double stranded DNA. It is mixed with an anti-photobleaching, non-hardening solution. DAPI/Antifade is intended for use on cytogenetic preparations and on formalin-fixed paraffin embedded tissue sections suitable for FISH.



Order No:
D-0905-025-TF

General Reagents

TissueFISH Pretreatment Kit

The MetaSystems' TissueFISH Pretreatment Kit contains reagents and solutions to process formalin-fixed paraffin-embedded tissue sections for FISH assays. Reagents provided are: 5x 5ml 10x Pretreatment Buffer, 200ml Protease Buffer, 500µl Protease Stock Solution.

The MetaSystems' TissueFISH Pretreatment Kit provides reagents which help to unmask formalin-fixed paraffin-embedded tissue cells to allow FISH. The first step is permeabilization which is thought to reverse protein cross-linking caused by formalin fixation. In a second step cells are digested by a protease to facilitate penetration of the fluorescent probe. Processing tissue slides using the MetaSystems' TissueFISH Pretreatment Kit will take less than 90 minutes.

The kit comes in two parts:

Part 1: Pretreatment reagents, stored at room temperature

Part 2: Protease, to be stored at 2°C to 8°C upon arrival



Literature

- Fioretos et al (1999) Blood 94:225-232
- Srinivasan et al (2002) Am J Pathol 161:1961-1971
- Chin et al (2003) Mol Pathol 56:275-279

General Reagents

Order No:
P-7510-001-IG

Size: 125ml

Liquillizer

Liquillizer is intended for the liquefaction of viscous respiratory specimens such as sputa, tracheal secretions, bronchial secretions or bronchoalveolar lavage. The mucolytic Dithiothreitol (DTT)-free buffer reduces specimen viscosity for easier sample handling. The buffer is stable for 4 weeks after opening.

Respiratory samples from patients suffering from pneumonia, cystic fibrosis or tuberculosis are frequently highly viscous and are, without pretreatment, difficult to handle. These samples can be liquefied fast and highly effective with the ready-to-use Liquillizer, making them easy to handle in diagnostic workflows.

In contrast to DTT-containing reagents, Liquillizer is stable for four weeks after opening and therefore economic in use. Liquillizer is highly effective at room temperature, heating of samples during incubation is not necessary.


Available in two package sizes:

P-7510-001-IG Liquillizer 125ml


P-7510-002-IG Liquillizer 250ml

Liquillizer is manufactured by MetaSystems Indigo GmbH.

Liquillizer is an IVD product.








Neon
Metafer
RapidScore
TissueFISH

MetaSystems Automated Imaging Systems

Solutions for FISH Image Analysis by MetaSystems

For more than three decades, automated imaging devices from MetaSystems, the sister company of MetaSystems Probes are renowned for their outstanding quality and performance. MetaSystems' debut in 1986 was the launch of Metafer, the fastest and most reliable metaphase finder at this time. In the following decades, Metafer diversified to become an extremely versatile and flexible high-throughput scanning platform for microscope-based imaging. Dedicated workstations for FISH, karyotyping, and remote analysis complemented the product range. To date, MetaSystems creates entire solutions for laboratories working in cytogenetics, pathology, microbiology, toxicology, radiation biology and other fields. Our installations help users of more than 7,500 institutions in 94 countries to optimize and streamline their imaging work.

Neon



In modern laboratories, digital microscope-based workflows do not end with image acquisition. Every image relates to respective case data, external files, metadata and other sources of information. This is why we have invented Neon, the backbone for all MetaSystems imaging devices. Neon collects information from any given source, prepares data in a convenient and transparent manner, and manages all analysis workflows in the most effective way. Sensitive patient data are safely processed, and case information is selectively provided to users with the respective authorization. Every processing step is stored in the case history file, and powerful statistics engines allow for summarizing the activities in large case databases. Neon does not require changing existing routines; the software easily adapts to existing workflows and structures. Programmable gateways for automated import and export of case data and images allow for comprehensive integration in larger settings.

Metafer

Growing case numbers and limited resources are well-known obstacles in many clinical laboratories. Therefore, reliable automation is an important asset for every FISH-based analysis workflow. While automated systems usually score all cells irrespectively of the actual signal pattern, human scorers often are biased by certain expectations in the results. Therefore, labs often work with very low, abnormal cut off values for positivity. As a result of this discrepancy, technologists often spend significant time to correct and/or reject automated results of conventional scanning systems.






RapidScore

With Metafer, it is different: MetaSystems invented RapidScore (RS), a new method of analyzing FISH signals combining manual scoring strategies with the advantages of automated image analysis. Every Metafer system for FISH analysis comes with a complete package of parameter sets and report templates for every XL probe, and FISH signal patterns are analyzed automatically, precisely, and reproducibly. Analyzed cells are displayed in a gallery, and signal patterns are summarized in convenient graphs and tables. Immediately after automated analysis, the technicians can begin categorizing cells with doubtful results. Categories are assigned to each cell using the dynamic RapidScore keypad with key layouts that change with the probe analyzed. An enlarged original image of the current cell with single focus plane images facilitates evaluation of the signal pattern. New, unexpected categories can be added on the fly.








TissueFISH

Due to the interaction of sophisticated software tools and outstanding imaging and scanning hardware, RapidScore is the fastest way of analyzing FISH signal patterns. Together with Metafer's dedicated tools for imaging and analyzing FISH in tissue sections (TissueFISH), Metafer and RapidScore are the best solutions for high-throughput interpretation of FISH signals.









Filters and Fluorochromes





MetaSystems XCyting probes are directly labeled with bright fluorophores:

Label		Abs. max. [nm]	Em. max. [nm]
 AQUA	spectrally equivalent to DEAC/ SpectrumAqua™	426	480
 GREEN	spectrally equivalent to FITC/ SpectrumGreen™	505	530
 ORANGE	spectrally equivalent to TRITC/ SpectrumOrange™	552	576
 RED	spectrally equivalent to TexasRed®/ SpectrumRed™	595	615
 NEAR INFRARED	spectrally equivalent to Cy™5/ SpectrumFRed™	644	669

For appropriate analysis the following filter sets are recommended:

Label	Filter	Recommended for
 MetaSystems DAPI	Hard coated narrow-band filter set for DAPI Catalog No. C-3010-001-MS	XL, XA, XCE, XCP, 24XCyte, XCyte mBAND, XMP, XRP, 21XMouse, 22XRat, 12XCHamster
 MetaSystems AQUA	Hard coated narrow-band filter set for AQUA Catalog No. C-3010-004-MS	XL (tricolor probes), XA, XCE, 24XCyte, XCyte mBAND, 21XMouse, 22XRat, 12XCHamster, XRNA
 MetaSystems GREEN	Hard coated narrow-band filter set for GREEN Catalog No. C-3010-002-MS	XL, XA, XCE, XCP, 24XCyte, XCyte mBAND, XMP, XRP, 21XMouse, 22XRat, 12XCHamster, XRNA
 MetaSystems ORANGE	Hard coated narrow-band filter set for ORANGE Catalog No. C-3010-003-MS	XL, XA, XCE, XCP, 24XCyte, XCyte mBAND, XMP, XRP, 21XMouse, 22XRat, 12XCHamster, XRNA
 MetaSystems RED	Hard coated narrow-band filter set for RED Catalog No. C-3010-010-MS	24XCyte, XCyte mBAND, 21XMouse, 22XRat, 12XCHamster
 MetaSystems NEAR INFRARED	Hard coated narrow-band filter set for NEAR INFRARED Catalog No. C-3010-006-MS	24XCyte, XCyte mBAND, 21XMouse, 22XRat, 12XCHamster, XRNA

For viewing only the following multi-pass filter sets are recommended:

Label	Filter	Recommended for
 MetaSystems GO	Dual band filter set GREEN/ORANGE Catalog No. C-3010-007-MS	XL, XA, XCE, XCP, XMP, XRP
 MetaSystems DGO	Triple band filter set DAPI/GREEN/ORANGE Catalog No. C-3010-013-MS	XL, XA, XCE, XCP, XMP, XRP
 MetaSystems AGO	Triple band filter set AQUA/GREEN/ORANGE Catalog No. C-3010-008-MS	XL, XA, XCE
 MetaSystems DAGO	Quad band filter set DAPI/AQUA/GREEN/ORANGE Catalog No. C-3010-012-MS	XL, XA, XCE

Trademarks

Filters are distributed by MetaSystems.


Texas Red® is a registered trademark of Molecular Probes, Inc.

Cy™ is a trademark of Amersham Pharmacia Biotech UK Limited

SpectrumOrange™, SpectrumAqua™, SpectrumGreen™, SpectrumRed™ and SpectrumFRed™ are trademarks of Vysis, Inc.



Notes



Index

Index

- ... by Product Name – 175
- ... by Order Number – 180
- ... by Disease Entities – 184
- ... by Chromosomes – 190
- ... by Gene / Locus – 196

Index

By Product Name

Product	Order Number	Category	TissueFISH	Page
12XHamster	D-1526-060-DI	Multicolor FISH Probe Kit for Chinese Hamster Chromosomes	-	152
21XMouse	D-0425-NNN-DI	Multicolor FISH Probe Kit for Mouse Chromosomes	-	152
22XRat	D-1525-NNN-DI	Multicolor FISH Probe Kit for Rat Chromosomes	-	152
24XCyte	D-0125-060-DI	Human Multicolor FISH Probe	-	143
AneuScore-Table	D-56NN-NNN-NN	XCyting Aneusomy Probe	-	119
DAPI/Antifade	D-0902-500-DA	General Reagents	-	164
Liquillizer	P-7510-001-IG	General Reagents	-	166
TissueFISH Pretreatment Kit	D-0905-025-TF	General Reagents	•	165
XA 13/18/21	D-5607-100-TC	Aneusomy Probe	-	111
XA 13/21	D-5602-100-OG	Aneusomy Probe	-	110
XA 21q22	D-5601-100-OR	Aneusomy Probe	-	115
XA AneuScore I	D-5604-100-TC	Aneusomy Probe	-	112
XA AneuScore II	D-5609-100-TC	Aneusomy Probe	-	113
XA AneuScore III	D-5613-100-TC	Aneusomy Probe	-	114
XA TriScore (X/Y/21)	D-5603-100-TC	Aneusomy Probe	-	118
XA X/Y	D-5608-100-OG	Aneusomy Probe	-	116
XA X/Y/18	D-5606-100-TC	Aneusomy Probe	-	117
XCE pan-cen	D-0836-050-FI D-0836-050-OR	XCyting Centromere Enumeration Probe	-	132
XCE Table	D-08NN-NNN-NN	XCyting Centromere Enumeration Probe	-	130
XCE X/Yqh	D-0832-050-OG	XCyting Centromere Enumeration Probe	-	131
XCP Green Table	D-03NN-NNN-FI	XCyting Chromosome Paint	-	136
XCP Orange Table	D-03NN-NNN-OR	XCyting Chromosome Paint	-	137
XCP-Mix #10-#2G-#4GO	D-0328-200-MC	XCyting Chromosome Paint	-	138
XCyte mBAND Table	D-02NN-NNN-DI	Human mBAND Probe	-	147
XL 1p36/1q25 del	D-6021-100-OG	Deletion Probe	•	9
XL 2p11 IGK BA	D-5116-100-OG	Break Apart Probe	-	11
XL 4q12	D-5063-100-TC	Translocation/Deletion Probe	-	17
XL 4q12 DC	D-5123-100-OG	Translocation/Deletion Probe	-	18
XL 5p15/9q22/15q22 Hyperdiploidy	D-5095-100-TC	Enumeration Probe	-	29
XL 5q31/5q33	D-5042-100-OG	Deletion Probe	-	25
XL 5q31/5q33/5p15	D-5081-100-TC	Deletion Probe	-	28
XL 5q32 PDGFRB BA	D-5104-100-OG	Break Apart Probe	-	23
XL 6q21/6q23	D-5039-100-OG	Deletion Probe	-	30
XL 6q21/6q23/6cen	D-5088-100-TC	Deletion Probe	-	31
XL 7q22/7q36	D-5043-100-TC	Deletion Probe	-	37
XL 19p/19q del	D-6019-100-OG	Deletion Probe	•	95
XL 20q12/20qter plus	D-5121-100-OG	Deletion Probe	-	97
XL 20q12/20qter/8cen plus	D-5122-100-TC	Deletion Probe	-	98

Index

By Product Name

Product	Order Number	Category	TissueFISH	Page
XL 21q22 / XCP 21	D-5441-050-OG		-	105
XL 22q11 IGL BA	D-5117-100-OG	Break Apart Probe	-	101
XL ABL1 BA	D-5148-100-OG	Break Apart Probe	-	49
XL ABL2 BA	D-5138-100-OG	Break Apart Probe	-	8
XL Acro-p	D-5440-050-OR		-	106
XL ALK BA	D-6001-100-OG	Break Apart Probe	•	12
XL ATM/11cen	D-5102-100-OG	Deletion Probe	-	57
XL ATM/TP53	D-5046-100-OG	Deletion Probe	-	63
XL BCL2 BA	D-6018-100-OG	Break Apart Probe	•	92
XL BCL3 BA	D-5128-100-OG	Break Apart Probe	-	96
XL BCL6 BA	D-6016-100-OG	Break Apart Probe	•	14
XL BCR/ABL1 plus	D-5052-100-OG	Translocation/Dual Fusion Probe	-	54
XL BCR/ABL1/ASS	D-5082-100-TC	Deletion/Dual Fusion Probe	-	55
XL CBFβ	D-5092-100-OG	Break Apart Probe	-	84
XL CBFβ/MYH11 plus	D-5126-100-OG	Translocation/Dual Fusion Probe	-	85
XL CCND1	D-5071-100-OG	Break Apart Probe	-	58
XL CDKN2A	D-5053-100-OG	Deletion Probe	-	50
XL CDKN2A/9q22	D-5118-100-OG	Deletion Probe	-	51
XL CDKN2C/CKS1B	D-5099-100-OG	Amplification/Deletion Probe	-	10
XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	D-5044-100-TC	Deletion/Enumeration Probe	-	66
XL Cri-Du-Chat	D-5417-050-OG	Deletion Probe	-	123
XL CRLF2 BA	D-5130-100-OG	Break Apart Probe	-	103
XL DDIT3 BA	D-6032-100-OG	Break Apart Probe	•	67
XL del(5)(q31)	D-5085-100-OG	Deletion Probe	-	26
XL del(5)(q33)	D-5091-100-OG	Deletion Probe	-	27
XL del(7)(q22q31)	D-5068-100-TC	Deletion Probe	-	38
XL del(20q) plus	D-5119-100-OG	Deletion Probe	-	99
XL DLEU/LAMP	D-5054-100-OG	Deletion Probe	-	72
XL DLEU/LAMP/12cen	D-5055-100-TC	Deletion/Enumeration Probe	-	74
XL DLEU/TP53	D-5067-100-OG	Deletion Probe	-	75
XL EGFR amp	D-6005-100-OG	Amplification Probe	•	39
XL ERBB2 (HER2/NEU) amp	D-6010-100-OG	Amplification Probe	•	87
XL ETV6	D-5073-100-OG	Break Apart Probe	-	68
XL EWSR1 BA	D-6011-100-OG	Break Apart Probe	•	102
XL FGFR1	D-5041-100-OG	Break Apart Probe	-	41
XL FOXO1 BA	D-6034-100-OG	Break Apart Probe	•	71
XL FUS BA	D-6035-100-OG	Break Apart Probe	•	86
XL IGH BA	D-5107-100-OG	Break Apart Probe	-	77

Index

By Product Name

Product	Order Number	Category	TissueFISH	Page
XL IGH/MAFB DF	D-5146-100-OG	Translocation/Dual Fusion Probe	-	81
XL IRF4 BA	D-6040-100-OG	Break Apart Probe	•	32
XL Iso(17q)	D-5048-100-OG	Amplification/Deletion Probe	-	89
XL JAK2 BA	D-5098-100-OG	Break Apart Probe	-	52
XL KMT2A BA	D-5090-100-OG	Break Apart Probe	-	59
XL MALT1 BA	D-6015-100-OG	Break Apart Probe	•	93
XL MDM2	D-5047-100-OG	Amplification Probe	-	69
XL MECOM 3q26	D-5059-100-OG	Break Apart Probe	-	15
XL MLL plus	D-5060-100-OG	Break Apart Probe	-	60
XL MYC amp	D-6008-100-OG	Amplification Probe	•	42
XL MYC BA	D-6023-100-OG	Break Apart Probe	•	43
XL MYC BA triple-color	D-6030-100-TC	Break Apart Probe - Triple Color	•	44
XL MYCN amp	D-6031-100-OG	Amplification Probe	•	13
XL NUP98	D-5077-100-OG	Break Apart Probe	-	61
XL P2RY8 del	D-5150-100-OG	Deletion Probe	-	104
XL PDGFRA BA	D-5137-100-OG	Break Apart Probe	-	19
XL Prader-Willi/Angelman	D-5421-050-OG	Deletion Probe	-	125
XL RARA BA	D-5087-100-OG	Break Apart Probe	-	88
XL RB1/DLEU/LAMP	D-5070-100-TC	Deletion Probe	-	73
XL ROS1-GOPC BA	D-6029-100-OG	Break Apart Probe	•	33
XL RUNX1	D-5096-100-OG	Break Apart Probe	-	100
XL Smith-Magenis/Miller-Dieker	D-5422-050-OG	Deletion Probe	-	126
XL SS18 BA	D-6033-100-OG	Break Apart Probe	•	94
XL t(3;3) GATA2/MECOM DF	D-5124-100-OG	Translocation/Dual Fusion Probe	-	16
XL t(4;11) AFF1/KMT2A DF	D-5131-100-OG	Translocation/Dual Fusion Probe	-	21
XL t(4;14) FGFR3/IGH DF	D-5108-100-OG	Translocation/Dual Fusion Probe	-	22
XL t(6;9) DEK/NUP214	D-5097-100-OG	Translocation/Dual Fusion Probe	-	34
XL t(6;11) AFDN/KMT2A DF	D-5132-100-OG	Translocation/Dual Fusion Probe	-	35
XL t(6;14) CCND3/IGH DF	D-5109-100-OG	Translocation/Dual Fusion Probe	-	36
XL t(7;12) MNX1/ETV6	D-5101-100-OG	Translocation/Dual Fusion Probe	-	40
XL t(8;14) MYC/IGH DF	D-5110-100-OG	Translocation/Dual Fusion Probe	-	46
XL t(8;14) MYC/IGH DF 8cen	D-5125-100-TC	Translocation/Dual Fusion and Amplification Probe	-	47
XL t(8;21) plus	D-5114-100-OG	Translocation/Dual Fusion Probe	-	48
XL t(8;9) PCM1/JAK2 DF	D-5120-100-OG	Translocation/Dual Fusion Probe	-	45
XL t(9;11) MLLT3/KMT2A DF	D-5133-100-OG	Translocation/Dual Fusion Probe	-	53
XL t(10;11) MLLT10/KMT2A DF	D-5134-100-OG	Translocation/Dual Fusion Probe	-	56
XL t(11;14) MYEOV/IGH DF	D-5111-100-OG	Translocation/Dual Fusion Probe	-	62
XL t(11;19) KMT2A/ELL DF	D-5135-100-OG	Translocation/Dual Fusion Probe	-	64

Index

By Product Name

Product	Order Number	Category	TissueFISH	Page
XL t(11;19) KMT2A/MLLT1 DF	D-5136-100-OG	Translocation/Dual Fusion Probe	-	65
XL t(12;21) ETV6/RUNX1 DF	D-5115-100-OG	Translocation/Dual Fusion Probe	-	70
XL t(14;16) IGH/MAF DF	D-5112-100-OG	Translocation/Dual Fusion Probe	-	78
XL t(14;18) IGH/BCL2 DF	D-5113-100-OG	Translocation/Dual Fusion Probe	-	79
XL t(14;18) IGH/MALT1 DF	D-6020-100-OG	Translocation/Dual Fusion Probe	•	80
XL t(14;20) IGH/MAFB DF	D-5105-100-OG	Translocation/Dual Fusion Probe	-	82
XL t(15;17) DF	D-5086-100-OG	Translocation/Dual Fusion Probe	-	83
XL TCRA/D	D-5106-100-OG	Break Apart Probe	-	76
XL TET2	D-5038-100-OG	Deletion Probe	-	20
XL TLX3 BA	D-5129-100-OG	Break Apart Probe	-	24
XL TP53/17cen	D-5103-100-OG	Deletion Probe	-	90
XL TP53/NF1	D-5089-100-OG	Deletion Probe	-	91
XL Williams-Beuren	D-5418-050-OG	Deletion Probe	-	124
XL Wolf-Hirschhorn	D-5416-050-OG	Deletion Probe	-	122
XMP Table	D-14NN-NNN-NN	XCyting Mouse Chromosome Paint	-	150
XRNA ACE2, green	R-0201-020-FI	Human RNA FISH	-	157
XRNA PD-L1, green	R-0203-020-FI	Human RNA FISH	-	159
XRNA PGK1, near infrared	R-0204-020-IR	Human RNA FISH	-	160
XRNA SARS-CoV-2, orange	R-0101-020-OR	Virus RNA FISH	-	156
XRNA TMPRSS2, aqua	R-0202-020-BL	Human RNA FISH	-	158
XRP Table	D-15NN-NNN-NN	XCyting Rat Chromosome Paint	-	151

Index

By Order Number

Order Number	Product	Category	TissueFISH	Page
D-0125-060-DI	24XCyte	Human Multicolor FISH Probe	-	143
D-02NN-NNN-DI	XCyte mBAND Table	Human mBAND Probe	-	147
D-0328-200-MC	XCP-Mix #10-#2G-#4GO	XCyting Chromosome Paint	-	138
D-03NN-NNN-FI	XCP Green Table	XCyting Chromosome Paint	-	136
D-03NN-NNN-OR	XCP Orange Table	XCyting Chromosome Paint	-	137
D-0425-NNN-DI	21XMouse	Multicolor FISH Probe Kit for Mouse Chromosomes	-	152
D-0832-050-OG	XCE X/Yqh	XCyting Centromere Enumeration Probe	-	131
D-0836-050-FI D-0836-050-OR	XCE pan-cen	XCyting Centromere Enumeration Probe	-	132
D-08NN-NNN-NN	XCE Table	XCyting Centromere Enumeration Probe	-	130
D-0902-500-DA	DAPI/Antifade	General Reagents	-	164
D-0905-025-TF	TissueFISH Pretreatment Kit	General Reagents	•	165
D-14NN-NNN-NN	XMP Table	XCyting Mouse Chromosome Paint	-	150
D-1525-NNN-DI	22XRat	Multicolor FISH Probe Kit for Rat Chromosomes	-	152
D-1526-060-DI	12XCHamster	Multicolor FISH Probe Kit for Chinese Hamster Chromosomes	-	152
D-15NN-NNN-NN	XRP Table	XCyting Rat Chromosome Paint	-	151
D-5038-100-OG	XL TET2	Deletion Probe	-	20
D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
D-5041-100-OG	XL FGFR1	Break Apart Probe	-	41
D-5042-100-OG	XL 5q31/5q33	Deletion Probe	-	25
D-5043-100-TC	XL 7q22/7q36	Deletion Probe	-	37
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
D-5047-100-OG	XL MDM2	Amplification Probe	-	69
D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
D-5053-100-OG	XL CDKN2A	Deletion Probe	-	50
D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	-	72
D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	-	74
D-5059-100-OG	XL MECOM 3q26	Break Apart Probe	-	15
D-5060-100-OG	XL MLL plus	Break Apart Probe	-	60
D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	-	17
D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	-	38
D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	-	73
D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
D-5073-100-OG	XL ETV6	Break Apart Probe	-	68

Index

By Order Number

Order Number	Product	Category	TissueFISH	Page
D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	-	28
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5085-100-OG	XL del(5)(q31)	Deletion Probe	-	26
D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
D-5087-100-OG	XL RARA BA	Break Apart Probe	-	88
D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
D-5090-100-OG	XL KMT2A BA	Break Apart Probe	-	59
D-5091-100-OG	XL del(5)(q33)	Deletion Probe	-	27
D-5092-100-OG	XL CBF3	Break Apart Probe	-	84
D-5095-100-TC	XL 5p15/9q22/15q22 Hyperdiploidy	Enumeration Probe	-	29
D-5096-100-OG	XL RUNX1	Break Apart Probe	-	100
D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	-	34
D-5098-100-OG	XL JAK2 BA	Break Apart Probe	-	52
D-5099-100-OG	XL CDKN2C/CKS1B	Amplification/Deletion Probe	-	10
D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
D-5102-100-OG	XL ATM/11cen	Deletion Probe	-	57
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5104-100-OG	XL 5q32 PDGFRB BA	Break Apart Probe	-	23
D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	-	82
D-5106-100-OG	XL TCRA/D	Break Apart Probe	-	76
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78
D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
D-5116-100-OG	XL 2p11 IGK BA	Break Apart Probe	-	11
D-5117-100-OG	XL 22q11 IGL BA	Break Apart Probe	-	101
D-5118-100-OG	XL CDKN2A/9q22	Deletion Probe	-	51
D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	-	45
D-5121-100-OG	XL 20q12/20qter plus	Deletion Probe	-	97
D-5122-100-TC	XL 20q12/20qter/8cen plus	Deletion Probe	-	98

Index

By Order Number

Order Number	Product	Category	TissueFISH	Page
D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	-	18
D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16
D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
D-5126-100-OG	XL CBFβ/MYH11 plus	Translocation/Dual Fusion Probe	-	85
D-5128-100-OG	XL BCL3 BA	Break Apart Probe	-	96
D-5129-100-OG	XL TLX3 BA	Break Apart Probe	-	24
D-5130-100-OG	XL CRLF2 BA	Break Apart Probe	-	103
D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	-	21
D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	-	64
D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
D-5138-100-OG	XL ABL2 BA	Break Apart Probe	-	8
D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	-	81
D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49
D-5150-100-OG	XL P2RY8 del	Deletion Probe	-	104
D-5416-050-OG	XL Wolf-Hirschhorn	Deletion Probe	-	122
D-5417-050-OG	XL Cri-Du-Chat	Deletion Probe	-	123
D-5418-050-OG	XL Williams-Beuren	Deletion Probe	-	124
D-5421-050-OG	XL Prader-Willi/Angelman	Deletion Probe	-	125
D-5422-050-OG	XL Smith-Magenis/Miller-Dieker	Deletion Probe	-	126
D-5440-050-OR	XL Acro-p		-	106
D-5441-050-OG	XL 21q22 / XCP 21		-	105
D-5601-100-OR	XA 21q22	Aneusomy Probe	-	115
D-5602-100-OG	XA 13/21	Aneusomy Probe	-	110
D-5603-100-TC	XA TriScore (X/Y/21)	Aneusomy Probe	-	118
D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
D-5606-100-TC	XA X/Y/18	Aneusomy Probe	-	117
D-5607-100-TC	XA 13/18/21	Aneusomy Probe	-	111
D-5608-100-OG	XA X/Y	Aneusomy Probe	-	116
D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113
D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114
D-56NN-NNN-NN	AneuScore-Table	XCyting Aneusomy Probe	-	119
D-6001-100-OG	XL ALK BA	Break Apart Probe	•	12
D-6005-100-OG	XL EGFR amp	Amplification Probe	•	39
D-6008-100-OG	XL MYC amp	Amplification Probe	•	42

Index

By Order Number

Order Number	Product	Category	TissueFISH	Page
D-6010-100-OG	XL ERBB2 (HER2/NEU) amp	Amplification Probe	•	87
D-6011-100-OG	XL EWSR1 BA	Break Apart Probe	•	102
D-6015-100-OG	XL MALT1 BA	Break Apart Probe	•	93
D-6016-100-OG	XL BCL6 BA	Break Apart Probe	•	14
D-6018-100-OG	XL BCL2 BA	Break Apart Probe	•	92
D-6019-100-OG	XL 19p/19q del	Deletion Probe	•	95
D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	•	80
D-6021-100-OG	XL 1p36/1q25 del	Deletion Probe	•	9
D-6023-100-OG	XL MYC BA	Break Apart Probe	•	43
D-6029-100-OG	XL ROS1-GOPC BA	Break Apart Probe	•	33
D-6030-100-TC	XL MYC BA triple-color	Break Apart Probe - Triple Color	•	44
D-6031-100-OG	XL MYCN amp	Amplification Probe	•	13
D-6032-100-OG	XL DDIT3 BA	Break Apart Probe	•	67
D-6033-100-OG	XL SS18 BA	Break Apart Probe	•	94
D-6034-100-OG	XL FOXO1 BA	Break Apart Probe	•	71
D-6035-100-OG	XL FUS BA	Break Apart Probe	•	86
D-6040-100-OG	XL IRF4 BA	Break Apart Probe	•	32
P-7510-001-IG	Liquillizer	General Reagents	–	166
R-0101-020-OR	XRNA SARS-CoV-2, orange	Virus RNA FISH	–	156
R-0201-020-FI	XRNA ACE2, green	Human RNA FISH	–	157
R-0202-020-BL	XRNA TMPRSS2, aqua	Human RNA FISH	–	158
R-0203-020-FI	XRNA PD-L1, green	Human RNA FISH	–	159
R-0204-020-IR	XRNA PGK1, near infrared	Human RNA FISH	–	160

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
Acute Lymphoblastic Leukemia				
D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
D-5053-100-OG	XL CDKN2A	Deletion Probe	-	50
D-5060-100-OG	XL MLL plus	Break Apart Probe	-	60
D-5073-100-OG	XL ETV6	Break Apart Probe	-	68
D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
D-5090-100-OG	XL KMT2A BA	Break Apart Probe	-	59
D-5096-100-OG	XL RUNX1	Break Apart Probe	-	100
D-5098-100-OG	XL JAK2 BA	Break Apart Probe	-	52
D-5106-100-OG	XL TCRA/D	Break Apart Probe	-	76
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
D-5118-100-OG	XL CDKN2A/9q22	Deletion Probe	-	51
D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
D-5129-100-OG	XL TLX3 BA	Break Apart Probe	-	24
D-5130-100-OG	XL CRLF2 BA	Break Apart Probe	-	103
D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	-	21
D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	-	64
D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
D-5138-100-OG	XL ABL2 BA	Break Apart Probe	-	8
D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49
D-5150-100-OG	XL P2RY8 del	Deletion Probe	-	104
Acute Myelogenous Leukemia				
D-5038-100-OG	XL TET2	Deletion Probe	-	20
D-5042-100-OG	XL 5q31/5q33	Deletion Probe	-	25
D-5043-100-TC	XL 7q22/7q36	Deletion Probe	-	37
D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
D-5059-100-OG	XL MECOM 3q26	Break Apart Probe	-	15
D-5060-100-OG	XL MLL plus	Break Apart Probe	-	60
D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	-	38
D-5073-100-OG	XL ETV6	Break Apart Probe	-	68
D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	-	28
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5085-100-OG	XL del(5)(q31)	Deletion Probe	-	26
D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
D-5087-100-OG	XL RARA BA	Break Apart Probe	-	88
D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
D-5090-100-OG	XL KMT2A BA	Break Apart Probe	-	59
D-5091-100-OG	XL del(5)(q33)	Deletion Probe	-	27
D-5092-100-OG	XL CBFB	Break Apart Probe	-	84
D-5096-100-OG	XL RUNX1	Break Apart Probe	-	100
D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	-	34
D-5098-100-OG	XL JAK2 BA	Break Apart Probe	-	52
D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
D-5121-100-OG	XL 20q12/20qter plus	Deletion Probe	-	97
D-5122-100-TC	XL 20q12/20qter/8cen plus	Deletion Probe	-	98
D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16
D-5126-100-OG	XL CBFB/MYH11 plus	Translocation/Dual Fusion Probe	-	85
D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	-	64
D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49

Chronic Eosinophilic Leukemia

D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
---------------	--------------	-------------------	---	----

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
Chronic Lymphocytic Leukemia				
D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
D-5047-100-OG	XL MDM2	Amplification Probe	-	69
D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	-	72
D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	-	74
D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	-	73
D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
D-5102-100-OG	XL ATM/11cen	Deletion Probe	-	57
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5128-100-OG	XL BCL3 BA	Break Apart Probe	-	96
Chronic Myelogenous Leukemia				
D-5038-100-OG	XL TET2	Deletion Probe	-	20
D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
Chronic Myelogenous Leukemia and Myeloproliferative Neoplasms				
D-5041-100-OG	XL FGFR1	Break Apart Probe	-	41
D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
D-5073-100-OG	XL ETV6	Break Apart Probe	-	68
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5098-100-OG	XL JAK2 BA	Break Apart Probe	-	52
D-5104-100-OG	XL 5q32 PDGFRB BA	Break Apart Probe	-	23
D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	-	45
D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49
Complex Chromosomal Aberrations				
D-0125-060-DI	24XCyte	Human Multicolor FISH Probe	-	143

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
Microdeletion Syndrome				
D-5416-050-OG	XL Wolf-Hirschhorn	Deletion Probe	-	122
D-5417-050-OG	XL Cri-Du-Chat	Deletion Probe	-	123
D-5418-050-OG	XL Williams-Beuren	Deletion Probe	-	124
D-5421-050-OG	XL Prader-Willi/Angelman	Deletion Probe	-	125
D-5422-050-OG	XL Smith-Magenis/Miller-Dieker	Deletion Probe	-	126
Multiple Myeloma and Plasma Cell Neoplasms				
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	-	72
D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	-	73
D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
D-5099-100-OG	XL CDKN2C/CKS1B	Amplification/Deletion Probe	-	10
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	-	82
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78
D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	-	81
Myelodysplastic Syndrome				
D-5038-100-OG	XL TET2	Deletion Probe	-	20
D-5042-100-OG	XL 5q31/5q33	Deletion Probe	-	25
D-5043-100-TC	XL 7q22/7q36	Deletion Probe	-	37
D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
D-5059-100-OG	XL MECOM 3q26	Break Apart Probe	-	15
D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	-	38
D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	-	28
D-5085-100-OG	XL del(5)(q31)	Deletion Probe	-	26
D-5091-100-OG	XL del(5)(q33)	Deletion Probe	-	27

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
D-5121-100-OG	XL 20q12/20qter plus	Deletion Probe	-	97
D-5122-100-TC	XL 20q12/20qter/8cen plus	Deletion Probe	-	98
D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16

Myeloproliferative Neoplasm

D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	-	17
D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	-	18

Non-Hodgkin Lymphomas

D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
D-5106-100-OG	XL TCRA/D	Break Apart Probe	-	76
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
D-5116-100-OG	XL 2p11 IGK BA	Break Apart Probe	-	11
D-5117-100-OG	XL 22q11 IGL BA	Break Apart Probe	-	101
D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
D-6015-100-OG	XL MALT1 BA	Break Apart Probe	•	93
D-6016-100-OG	XL BCL6 BA	Break Apart Probe	•	14
D-6018-100-OG	XL BCL2 BA	Break Apart Probe	•	92
D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	•	80
D-6023-100-OG	XL MYC BA	Break Apart Probe	•	43
D-6030-100-TC	XL MYC BA triple-color	Break Apart Probe - Triple Color	•	44
D-6040-100-OG	XL IRF4 BA	Break Apart Probe	•	32

Solid Tumors

D-6005-100-OG	XL EGFR amp	Amplification Probe	•	39
D-6008-100-OG	XL MYC amp	Amplification Probe	•	42
D-6010-100-OG	XL ERBB2 (HER2/NEU) amp	Amplification Probe	•	87
D-6011-100-OG	XL EWSR1 BA	Break Apart Probe	•	102
D-6015-100-OG	XL MALT1 BA	Break Apart Probe	•	93
D-6016-100-OG	XL BCL6 BA	Break Apart Probe	•	14

Index

By Disease Entities

Order Number	Product	Category	TissueFISH	Page
D-6018-100-OG	XL BCL2 BA	Break Apart Probe	•	92
D-6019-100-OG	XL 19p/19q del	Deletion Probe	•	95
D-6021-100-OG	XL 1p36/1q25 del	Deletion Probe	•	9
D-6023-100-OG	XL MYC BA	Break Apart Probe	•	43
D-6029-100-OG	XL ROS1-GOPC BA	Break Apart Probe	•	33
D-6030-100-TC	XL MYC BA triple-color	Break Apart Probe - Triple Color	•	44
D-6031-100-OG	XL MYCN amp	Amplification Probe	•	13
D-6032-100-OG	XL DDIT3 BA	Break Apart Probe	•	67
D-6033-100-OG	XL SS18 BA	Break Apart Probe	•	94
D-6034-100-OG	XL FOXO1 BA	Break Apart Probe	•	71
D-6035-100-OG	XL FUS BA	Break Apart Probe	•	86

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
Chromosome 1				
D-5099-100-OG	XL CDKN2C/CKS1B	Amplification/Deletion Probe	-	10
D-5138-100-OG	XL ABL2 BA	Break Apart Probe	-	8
D-6021-100-OG	XL 1p36/1q25 del	Deletion Probe	•	9
Chromosome 2				
D-5116-100-OG	XL 2p11 IGK BA	Break Apart Probe	-	11
D-6001-100-OG	XL ALK BA	Break Apart Probe	•	12
D-6031-100-OG	XL MYCN amp	Amplification Probe	•	13
Chromosome 3				
D-5059-100-OG	XL MECOM 3q26	Break Apart Probe	-	15
D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16
D-6016-100-OG	XL BCL6 BA	Break Apart Probe	•	14
Chromosome 4				
D-5038-100-OG	XL TET2	Deletion Probe	-	20
D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	-	17
D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	-	18
D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	-	21
D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
D-5416-050-OG	XL Wolf-Hirschhorn	Deletion Probe	-	122
Chromosome 5				
D-5042-100-OG	XL 5q31/5q33	Deletion Probe	-	25
D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	-	28
D-5085-100-OG	XL del(5)(q31)	Deletion Probe	-	26
D-5091-100-OG	XL del(5)(q33)	Deletion Probe	-	27
D-5095-100-TC	XL 5p15/9q22/15q22 Hyperdiploidy	Enumeration Probe	-	29
D-5104-100-OG	XL 5q32 PDGFRB BA	Break Apart Probe	-	23
D-5129-100-OG	XL TLX3 BA	Break Apart Probe	-	24
D-5417-050-OG	XL Cri-Du-Chat	Deletion Probe	-	123
Chromosome 6				
D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	-	34
D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
D-6029-100-OG	XL ROS1-GOPC BA	Break Apart Probe	•	33
D-6040-100-OG	XL IRF4 BA	Break Apart Probe	•	32

Chromosome 7

D-5043-100-TC	XL 7q22/7q36	Deletion Probe	-	37
D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	-	38
D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
D-5418-050-OG	XL Williams-Beuren	Deletion Probe	-	124
D-6005-100-OG	XL EGFR amp	Amplification Probe	•	39

Chromosome 8

D-5041-100-OG	XL FGFR1	Break Apart Probe	-	41
D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	-	45
D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
D-6008-100-OG	XL MYC amp	Amplification Probe	•	42
D-6023-100-OG	XL MYC BA	Break Apart Probe	•	43
D-6030-100-TC	XL MYC BA triple-color	Break Apart Probe - Triple Color	•	44

Chromosome 9

D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
D-5053-100-OG	XL CDKN2A	Deletion Probe	-	50
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5095-100-TC	XL 5p15/9q22/15q22 Hyperdiploidy	Enumeration Probe	-	29
D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	-	34
D-5098-100-OG	XL JAK2 BA	Break Apart Probe	-	52
D-5118-100-OG	XL CDKN2A/9q22	Deletion Probe	-	51
D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	-	45
D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49

Chromosome 10

D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
---------------	-----------------------------	---------------------------------	---	----

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
Chromosome 11				
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
D-5060-100-OG	XL MLL plus	Break Apart Probe	-	60
D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
D-5090-100-OG	XL KMT2A BA	Break Apart Probe	-	59
D-5102-100-OG	XL ATM/11cen	Deletion Probe	-	57
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	-	21
D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	-	64
D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
Chromosome 12				
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5047-100-OG	XL MDM2	Amplification Probe	-	69
D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	-	74
D-5073-100-OG	XL ETV6	Break Apart Probe	-	68
D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
D-6032-100-OG	XL DDIT3 BA	Break Apart Probe	•	67
Chromosome 13				
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	-	72
D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	-	74
D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	-	73
D-5440-050-OR	XL Acro-p		-	106
D-5602-100-OG	XA 13/21	Aneusomy Probe	-	110
D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
D-5607-100-TC	XA 13/18/21	Aneusomy Probe	-	111
D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114
D-6034-100-OG	XL FOXO1 BA	Break Apart Probe	•	71
Chromosome 14				
D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	-	82
D-5106-100-OG	XL TCRA/D	Break Apart Probe	-	76
D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78
D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	-	81
D-5440-050-OR	XL Acro-p		-	106
D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	•	80
Chromosome 15				
D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
D-5095-100-TC	XL 5p15/9q22/15q22 Hyperdiploidy	Enumeration Probe	-	29
D-5421-050-OG	XL Prader-Willi/Angelman	Deletion Probe	-	125
D-5440-050-OR	XL Acro-p		-	106
Chromosome 16				
D-5092-100-OG	XL CBFβ	Break Apart Probe	-	84
D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78
D-5126-100-OG	XL CBFβ/MYH11 plus	Translocation/Dual Fusion Probe	-	85
D-6035-100-OG	XL FUS BA	Break Apart Probe	•	86
Chromosome 17				
D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
D-5087-100-OG	XL RARA BA	Break Apart Probe	-	88

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
D-5422-050-OG	XL Smith-Magenis/Miller-Dieker	Deletion Probe	-	126
D-6010-100-OG	XL ERBB2 (HER2/NEU) amp	Amplification Probe	•	87
Chromosome 18				
D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
D-5606-100-TC	XA X/Y/18	Aneusomy Probe	-	117
D-5607-100-TC	XA 13/18/21	Aneusomy Probe	-	111
D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113
D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114
D-6015-100-OG	XL MALT1 BA	Break Apart Probe	•	93
D-6018-100-OG	XL BCL2 BA	Break Apart Probe	•	92
D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	•	80
D-6033-100-OG	XL SS18 BA	Break Apart Probe	•	94
Chromosome 19				
D-5128-100-OG	XL BCL3 BA	Break Apart Probe	-	96
D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	-	64
D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
D-6019-100-OG	XL 19p/19q del	Deletion Probe	•	95
Chromosome 20				
D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	-	82
D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
D-5121-100-OG	XL 20q12/20qter plus	Deletion Probe	-	97
D-5122-100-TC	XL 20q12/20qter/8cen plus	Deletion Probe	-	98
D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	-	81
Chromosome 21				
D-5096-100-OG	XL RUNX1	Break Apart Probe	-	100
D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
D-5440-050-OR	XL Acro-p		-	106
D-5441-050-OG	XL 21q22 / XCP 21		-	105
D-5601-100-OR	XA 21q22	Aneusomy Probe	-	115

Index

By Chromosomes

Order Number	Product	Category	TissueFISH	Page
D-5602-100-OG	XA 13/21	Aneusomy Probe	-	110
D-5603-100-TC	XA TriScore (X/Y/21)	Aneusomy Probe	-	118
D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
D-5607-100-TC	XA 13/18/21	Aneusomy Probe	-	111
D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113
D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114

Chromosome 22

D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
D-5117-100-OG	XL 22q11 IGL BA	Break Apart Probe	-	101
D-5440-050-OR	XL Acro-p		-	106
D-6011-100-OG	XL EWSR1 BA	Break Apart Probe	•	102

Chromosome X/Y

D-5130-100-OG	XL CRLF2 BA	Break Apart Probe	-	103
D-5150-100-OG	XL P2RY8 del	Deletion Probe	-	104
D-5603-100-TC	XA TriScore (X/Y/21)	Aneusomy Probe	-	118
D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
D-5606-100-TC	XA X/Y/18	Aneusomy Probe	-	117
D-5608-100-OG	XA X/Y	Aneusomy Probe	-	116
D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113
D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
ABL1	9q34.1	D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
	9q34.1	D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
	9q34.1	D-5148-100-OG	XL ABL1 BA	Break Apart Probe	-	49
ABL2	1q25.2	D-5138-100-OG	XL ABL2 BA	Break Apart Probe	-	8
AFDN	6q27	D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	-	35
AFF1	4q21.3-22	D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	-	21
ALK	2p23	D-6001-100-OG	XL ALK BA	Break Apart Probe	•	12
ASS	9q34.1	D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
ATM	11q22.3	D-5044-100-TC	XL CLL Probe Kit (XL DLEU/ LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
	11q22.3	D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
	11q22.3	D-5102-100-OG	XL ATM/11cen	Deletion Probe	-	57
BCL2	18q21.3	D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
	18q21.3	D-6018-100-OG	XL BCL2 BA	Break Apart Probe	•	92
BCL3	19q13.3	D-5128-100-OG	XL BCL3 BA	Break Apart Probe	-	96
BCL6	3q27	D-6016-100-OG	XL BCL6 BA	Break Apart Probe	•	14
BCR	22q11.2	D-5052-100-OG	XL BCR/ABL1 plus	Translocation/Dual Fusion Probe	-	54
	22q11.2	D-5082-100-TC	XL BCR/ABL1/ASS	Deletion/Dual Fusion Probe	-	55
CBFB	16q22	D-5092-100-OG	XL CBFB	Break Apart Probe	-	84
	16q22	D-5126-100-OG	XL CBFB/MYH11 plus	Translocation/Dual Fusion Probe	-	85
CCND1 (BCL1)	11q13.3	D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
	11q13.3	D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
CCND3	6p21.1	D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
CDKN2A	9p21	D-5053-100-OG	XL CDKN2A	Deletion Probe	-	50
	9p21	D-5118-100-OG	XL CDKN2A/9q22	Deletion Probe	-	51

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
CDKN2C	1p32.3	D-5099-100-OG	XL CDKN2C/CKS1B	Amplification/Deletion Probe	–	10
CENPP	9q22.3	D-5118-100-OG	XL CDKN2A/9q22	Deletion Probe	–	51
CHIC2	4q12	D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	–	17
	4q12	D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	–	18
CKS1B	1q21-22	D-5099-100-OG	XL CDKN2C/CKS1B	Amplification/Deletion Probe	–	10
CRLF2	Xp22.33	D-5130-100-OG	XL CRLF2 BA	Break Apart Probe	–	103
	Yp11.32	D-5130-100-OG	XL CRLF2 BA	Break Apart Probe	–	103
DDIT3	12q13.3	D-6032-100-OG	XL DDIT3 BA	Break Apart Probe	•	67
DEK	6p22.3	D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	–	34
DLEU1	13q14.2	D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	–	66
	13q14.2	D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	–	72
	13q14.2	D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	–	74
	13q14.2	D-5067-100-OG	XL DLEU/TP53	Deletion Probe	–	75
	13q14.2	D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	–	73
DSCR4	21q22	D-5441-050-OG	XL 21q22 / XCP 21		–	105
	21q22	D-5601-100-OR	XA 21q22	Aneusomy Probe	–	115
	21q22	D-5602-100-OG	XA 13/21	Aneusomy Probe	–	110
	21q22	D-5603-100-TC	XA TriScore (X/Y/21)	Aneusomy Probe	–	118
	21q22	D-5604-100-TC	XA AneuScore I	Aneusomy Probe	–	112
	21q22	D-5607-100-TC	XA 13/18/21	Aneusomy Probe	–	111
	21q22	D-5609-100-TC	XA AneuScore II	Aneusomy Probe	–	113
	21q22	D-5613-100-TC	XA AneuScore III	Aneusomy Probe	–	114
EGFR	7p11.2	D-6005-100-OG	XL EGFR amp	Amplification Probe	•	39
EGR1	5q31.2	D-5042-100-OG	XL 5q31/5q33	Deletion Probe	–	25
	5q31.2	D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	–	28
	5q31.2	D-5085-100-OG	XL del(5)(q31)	Deletion Probe	–	26
ELL	19p13.1	D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	–	64

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
ELN	7q11.23	D-5418-050-OG	XL Williams-Beuren	Deletion Probe	-	124
ERBB2 (HER2/NEU)	17q12	D-6010-100-OG	XL ERBB2 (HER2/NEU) amp	Amplification Probe	•	87
ETV6 (TEL)	12p13.2	D-5073-100-OG	XL ETV6	Break Apart Probe	-	68
	12p13.2	D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
	12p13.2	D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
EWSR1	22q12.2	D-6011-100-OG	XL EWSR1 BA	Break Apart Probe	•	102
EZH2	7q36	D-5043-100-TC	XL 7q22/7q36	Deletion Probe	-	37
FGFR1	8p11.2	D-5041-100-OG	XL FGFR1	Break Apart Probe	-	41
FGFR3	4p16.3	D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
FIP1L1	4q12	D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	-	17
	4q12	D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	-	18
FOXO1	13q14.1	D-6034-100-OG	XL FOXO1 BA	Break Apart Probe	•	71
FUS	16p11.2	D-6035-100-OG	XL FUS BA	Break Apart Probe	•	86
GATA2	3q21	D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16
GOPC	6q22.1	D-6029-100-OG	XL ROS1-GOPC BA	Break Apart Probe	-	33
IGH	14q32.3	D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	-	82
	14q32.3	D-5107-100-OG	XL IGH BA	Break Apart Probe	-	77
	14q32.3	D-5108-100-OG	XL t(4;14) FGFR3/IGH DF	Translocation/Dual Fusion Probe	-	22
	14q32.3	D-5109-100-OG	XL t(6;14) CCND3/IGH DF	Translocation/Dual Fusion Probe	-	36
	14q32.3	D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
	14q32.3	D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
	14q32.3	D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78
	14q32.3	D-5113-100-OG	XL t(14;18) IGH/BCL2 DF	Translocation/Dual Fusion Probe	-	79
	14q32.3	D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
	14q32.3	D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	-	81
14q32.3	D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	•	80	

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
IGK	2p11.2	D-5116-100-OG	XL 2p11 IGK BA	Break Apart Probe	–	11
IGLV	22q11.2	D-5117-100-OG	XL 22q11 IGL BA	Break Apart Probe	–	101
IRF4	6p25	D-6040-100-OG	XL IRF4 BA	Break Apart Probe	•	32
JAK2	9p24	D-5098-100-OG	XL JAK2 BA	Break Apart Probe	–	52
	9p24	D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	–	45
KMT2A (MLL)	11q23.3	D-5060-100-OG	XL MLL plus	Break Apart Probe	–	60
	11q23.3	D-5090-100-OG	XL KMT2A BA	Break Apart Probe	–	59
	11q23.3	D-5131-100-OG	XL t(4;11) AFF1/KMT2A DF	Translocation/Dual Fusion Probe	–	21
	11q23.3	D-5132-100-OG	XL t(6;11) AFDN/KMT2A DF	Translocation/Dual Fusion Probe	–	35
	11q23.3	D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	–	53
	11q23.3	D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	–	56
	11q23.3	D-5135-100-OG	XL t(11;19) KMT2A/ELL DF	Translocation/Dual Fusion Probe	–	64
	11q23.3	D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	–	65
KMT2E (MLL5)	7q22	D-5043-100-TC	XL 7q22/7q36	Deletion Probe	–	37
	7q22	D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	–	38
LAMP1	13q34	D-5044-100-TC	XL CLL Probe Kit (XL DLEU/ LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	–	66
	13q34	D-5054-100-OG	XL DLEU/LAMP	Deletion Probe	–	72
	13q34	D-5055-100-TC	XL DLEU/LAMP/12cen	Deletion/Enumeration Probe	–	74
	13q34	D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	–	73
MAF	16q23	D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	–	78
MAFB	20q12	D-5105-100-OG	XL t(14;20) IGH/MAFB DF	Translocation/Dual Fusion Probe	–	82
	20q12	D-5146-100-OG	XL IGH/MAFB DF	Translocation/Dual Fusion Probe	–	81
MALT1	18q21.3	D-5607-100-TC	XA 13/18/21	Aneusomy Probe	–	111
	18q21.3	D-5609-100-TC	XA AneuScore II	Aneusomy Probe	–	113
	18q21.3	D-5613-100-TC	XA AneuScore III	Aneusomy Probe	–	114
	18q21.3	D-6015-100-OG	XL MALT1 BA	Break Apart Probe	•	93
	18q21.3	D-6020-100-OG	XL t(14;18) IGH/MALT1 DF	Translocation/Dual Fusion Probe	–	80
MDM2	12q15	D-5047-100-OG	XL MDM2	Amplification Probe	–	69

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
MECOM	3q26.2	D-5059-100-OG	XL MECOM 3q26	Break Apart Probe	-	15
	3q26.2	D-5124-100-OG	XL t(3;3) GATA2/MECOM DF	Translocation/Dual Fusion Probe	-	16
MET	7q31.2	D-5068-100-TC	XL del(7)(q22q31)	Deletion Probe	-	38
MLLT1	19p13.3	D-5136-100-OG	XL t(11;19) KMT2A/MLLT1 DF	Translocation/Dual Fusion Probe	-	65
MLLT3	9p21	D-5133-100-OG	XL t(9;11) MLLT3/KMT2A DF	Translocation/Dual Fusion Probe	-	53
MLLT10	10p12.3	D-5134-100-OG	XL t(10;11) MLLT10/KMT2A DF	Translocation/Dual Fusion Probe	-	56
MNX1	7q36	D-5101-100-OG	XL t(7;12) MNX1/ETV6	Translocation/Dual Fusion Probe	-	40
MPO	17q22	D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
MYB	6q23.3	D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
	6q23.3	D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
MYBL2	20q12-13.1	D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
MYC	8q24.21	D-5110-100-OG	XL t(8;14) MYC/IGH DF	Translocation/Dual Fusion Probe	-	46
	8q24.21	D-5125-100-TC	XL t(8;14) MYC/IGH DF 8cen	Translocation/Dual Fusion and Amplification Probe	-	47
	8q24.21	D-6008-100-OG	XL MYC amp	Amplification Probe	•	42
	8q24.21	D-6023-100-OG	XL MYC BA	Break Apart Probe	•	43
	8q24.21	D-6030-100-TC	XL MYC BA triple-color	Break Apart Probe - Triple Color	•	44
MYCN	2p24	D-6031-100-OG	XL MYCN amp	Amplification Probe	•	13
MYEOV	11q13.3	D-5071-100-OG	XL CCND1	Break Apart Probe	-	58
	11q13.3	D-5111-100-OG	XL t(11;14) MYEOV/IGH DF	Translocation/Dual Fusion Probe	-	62
MYH11	16p13.1	D-5126-100-OG	XL CFBF/MYH11 plus	Translocation/Dual Fusion Probe	-	85
NF1	17q11.2	D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
NR4A3	9q22.3-31	D-5095-100-TC	XL 5p15/9q22/15q22 Hyper-diploidy	Enumeration Probe	-	29

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
NSD2	4p16.3	D-5416-050-OG	XL Wolf-Hirschhorn	Deletion Probe	-	122
NUP214	9q34.1	D-5097-100-OG	XL t(6;9) DEK/NUP214	Translocation/Dual Fusion Probe	-	34
NUP98	11p15.4	D-5077-100-OG	XL NUP98	Break Apart Probe	-	61
P2RY8	Xp22.33	D-5150-100-OG	XL P2RY8 del	Deletion Probe	-	104
	Yp11.32	D-5150-100-OG	XL P2RY8 del	Deletion Probe	-	104
PAFAH1B1	17p13	D-5422-050-OG	XL Smith-Magenis/Miller-Dieker	Deletion Probe	-	126
PCM1	8p22	D-5120-100-OG	XL t(8;9) PCM1/JAK2 DF	Translocation/Dual Fusion Probe	-	45
PDGFRA	4q12	D-5063-100-TC	XL 4q12	Translocation/Deletion Probe	-	17
	4q12	D-5123-100-OG	XL 4q12 DC	Translocation/Deletion Probe	-	18
	4q12	D-5137-100-OG	XL PDGFRA BA	Break Apart Probe	-	19
PDGFRB	5q32-33.1	D-5104-100-OG	XL 5q32 PDGFRB BA	Break Apart Probe	-	23
PML	15q24	D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
PTPRT	20q12	D-5119-100-OG	XL del(20q) plus	Deletion Probe	-	99
	20q12	D-5121-100-OG	XL 20q12/20qter plus	Deletion Probe	-	97
	20q12	D-5122-100-TC	XL 20q12/20qter/8cen plus	Deletion Probe	-	98
RARA	17q21.1-21.2	D-5086-100-OG	XL t(15;17) DF	Translocation/Dual Fusion Probe	-	83
	17q21.1-21.2	D-5087-100-OG	XL RARA BA	Break Apart Probe	-	88
RB1	13q14.2	D-5070-100-TC	XL RB1/DLEU/LAMP	Deletion Probe	-	73
	13q14.2	D-5602-100-OG	XA 13/21	Aneusomy Probe	-	110
	13q14.2	D-5604-100-TC	XA AneuScore I	Aneusomy Probe	-	112
	13q14.2	D-5607-100-TC	XA 13/18/21	Aneusomy Probe	-	111
	13q14.2	D-5609-100-TC	XA AneuScore II	Aneusomy Probe	-	113
	13q14.2	D-5613-100-TC	XA AneuScore III	Aneusomy Probe	-	114
ROS1	6q22.1	D-6029-100-OG	XL ROS1-GOPC BA	Break Apart Probe	•	33

Index

By Gene / Locus

Gene / Locus	Chromosome Region	Order Number	Product	Category	TissueFISH	Page
RPS14	5q32-33.1	D-5042-100-OG	XL 5q31/5q33	Deletion Probe	-	25
	5q32-33.1	D-5081-100-TC	XL 5q31/5q33/5p15	Deletion Probe	-	28
	5q32-33.1	D-5091-100-OG	XL del(5)(q33)	Deletion Probe	-	27
RUNX1 (AML1)	21q22.1	D-5096-100-OG	XL RUNX1	Break Apart Probe	-	100
	21q22.1	D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
	21q22.1	D-5115-100-OG	XL t(12;21) ETV6/RUNX1 DF	Translocation/Dual Fusion Probe	-	70
RUNX1T1 (ETO)	8q21.3-22.1	D-5114-100-OG	XL t(8;21) plus	Translocation/Dual Fusion Probe	-	48
SEC63	6q21	D-5039-100-OG	XL 6q21/6q23	Deletion Probe	-	30
	6q21	D-5088-100-TC	XL 6q21/6q23/6cen	Deletion Probe	-	31
SMAD6	15q22.3	D-5095-100-TC	XL 5p15/9q22/15q22 Hyperdiploidy	Enumeration Probe	-	29
SNRPN	15q11.2	D-5421-050-OG	XL Prader-Willi/Angelman	Deletion Probe	-	125
SS18	18q11.2	D-6033-100-OG	XL SS18 BA	Break Apart Probe	•	94
TCR A/D	14q11.2	D-5106-100-OG	XL TCRA/D	Break Apart Probe	-	76
TET2	4q24	D-5038-100-OG	XL TET2	Deletion Probe	-	20
TLX3	5q35.1	D-5129-100-OG	XL TLX3 BA	Break Apart Probe	-	24
TP53	17p13	D-5044-100-TC	XL CLL Probe Kit (XL DLEU/LAMP/12cen + XL ATM/TP53)	Deletion/Enumeration Probe	-	66
	17p13	D-5046-100-OG	XL ATM/TP53	Deletion Probe	-	63
	17p13	D-5048-100-OG	XL Iso(17q)	Amplification/Deletion Probe	-	89
	17p13	D-5067-100-OG	XL DLEU/TP53	Deletion Probe	-	75
	17p13	D-5089-100-OG	XL TP53/NF1	Deletion Probe	-	91
	17p13	D-5103-100-OG	XL TP53/17cen	Deletion Probe	-	90
WVOX	16q23	D-5112-100-OG	XL t(14;16) IGH/MAF DF	Translocation/Dual Fusion Probe	-	78

MetaSystems Probes

XCyting FISH Probes

EUROPE & RUSSIA

Germany, Altlussheim
info@metasystems-probes.com

Italy, Milan
info@metasystems-italy.com

Russia, Moscow
info@metasystems.su

AMERICAS

USA, Medford
info@metasystems.org


Argentina, Buenos Aires
info@metasystems-latam.com

ASIA

China, Hong Kong
info@metasystems-asia.com

China, Taizhou
info@metasystems-china.com

India, Bangalore
info@metasystems-india.com



Document No. BRO-ProbesINT-2020-12-01-P
© 2020 by MetaSystems Probes

CONTACT



info@metasystems-probes.com
www.metasystems-probes.com

